Document:

Exhibit 10.02

 

CONFIDENTIAL

 

 

 

 

 

 

 

      SECOND AMENDED AND RESTATED OPERATING AGREEMENT OF

 

Novvi LLC

 

by and among

 

Amyris, Inc.,

 

Cosan US, Inc.,

 

American Refining Group, Inc.

 

and   Novvi LLC

 

 

 

 

dated as of July 19, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

TABLE OF CONTENTS

 

CONTENTS

 

	Article I Defined terms	2
	 	 	 	 
	Section 1.01.	 	Certain Defined Terms.	2
	 	 	 	 
	Article II Formation, term, purpose and powers	11
	 	 	 	 
	Section 2.01.	 	Formation.	11
	Section 2.02.	 	Name.	11
	Section 2.03.	 	Term.	11
	Section 2.04.	 	Principal Place of Business.	12
	Section 2.05.	 	Title to Company Property.	12
	Section 2.06.	 	Agent for Service of Process.	12
	Section 2.07.	 	Purpose.	12
	Section 2.08.	 	Powers of the Company.	12
	Section 2.09.	 	Maintenance of Separate Existence.	12
	Section 2.10.	 	Strategic Decisions.	13
	Section 2.11.	 	Related Party Transaction.	13
	Section 2.12.	 	Management Goals.	13
	Section 2.13.	 	Conduct of Company Business.	13
	Section 2.14.	 	No Personal Liability.	13
	Section 2.15.	 	Admission of New Members.	13
	Section 2.16.	 	Waiver of Fiduciary Duties; Corporate Opportunities.	14
	 	 	 	 
	Article III Representations and warranties of the members	15
	 	 	 	 
	Section 3.01.	 	Organization and Authority.	15
	Section 3.02.	 	No Conflict.	15
	Section 3.03.	 	Governmental Consents and Approvals.	15
	 	 	 	 
	Article IV Capital contributions and capital accounts	15
	 	 	 	 
	Section 4.01.	 	Capital Contributions.	15
	Section 4.02.	 	Membership Units.	16
	Section 4.03.	 	Additional Membership Units.	16
	Section 4.04.	 	Funding Requirements; Additional Funding.	16
	Section 4.05.	 	Status of Capital Contributions.	18
	Section 4.06.	 	Capital Accounts.	19
	 	 	 	 
	Article V Board of managers; managers and officers	19
	 	 	 	 
	Section 5.01.	 	Management of the Company.	19
	Section 5.02.	 	Board of Managers; Quorum Requirements.	19
	Section 5.03.	 	Removal of Managers; Vacancies.	21
	Section 5.04.	 	Frequency of Meetings; Notice of Meetings; Agenda.	21
	Section 5.05.	 	Board of Managers Voting; Approval Matters.	22
	Section 5.06.	 	Members’ Meetings; Notice; Agenda; Voting; Member Approval Matters.	23
	Section 5.07.	 	Action by Written Consent.	25
	Section 5.08.	 	Telephonic Meetings.	25
	Section 5.09.	 	Company Minutes.	25

 

    	 	 i	 

     

    

	Section 5.10.	 	Manager Compensation and Reimbursement.	25
	Section 5.11.	 	Audit Committee.	25
	Section 5.12.	 	Officers.	25
	Section 5.13.	 	Language.	28
	Section 5.14.	 	D&O Insurance.	28
	Section 5.15.	 	Subsidiaries.	28
	Section 5.16.	 	Deadlock of Members or Managers.	28
	 	 	 	 
	Article VI Change of control event	31
	 	 	 	 
	Section 6.01.	 	Change of Control Event.	31
	Section 6.02.	 	Change of Control Event Consequence.	31
	 	 	 	 
	Article VII Allocations; tax matters	31
	 	 	 	 
	Section 7.01.	 	Allocations.	31
	Section 7.02.	 	Special Allocations.	32
	Section 7.03.	 	Curative Allocations.	33
	Section 7.04.	 	Tax Allocations.	33
	Section 7.05.	 	Tax Matters.	34
	 	 	 	 
	Article VIII Distribution	35
	 	 	 	 
	Section 8.01.	 	Distribution.	35
	Section 8.02.	 	Liquidation Distribution.	35
	Section 8.03.	 	Distribution Rules.	35
	Section 8.04.	 	Limitations on Distribution.	36
	 	 	 	 
	Article IX Books and records; financial statements	36
	 	 	 	 
	Section 9.01.	 	Books and Records; Financial Statements.	36
	Section 9.02.	 	Reporting Requirements.	37
	Section 9.03.	 	Access; Due Diligence.	38
	Section 9.04.	 	Semi-Annual Updates to Members regarding Company BioFene Transformation Technology.	38
	 	 	 	 
	Article X Restrictions on transfer	38
	 	 	 	 
	Section 10.01.	 	Legends.	38
	Section 10.02.	 	Restrictions on Transfer; Required Transfers.	39
	Section 10.03.	 	Improper Transfer or Encumbrance.	42
	Section 10.04.	 	Transferees to Execute Agreement.	42
	 	 	 	 
	Article XI dissolution, liquidation and termination	43
	 	 	 	 
	Section 11.01.	 	No Dissolution.	43
	Section 11.02.	 	Events Causing Dissolution.	43
	Section 11.03.	 	Notice of Dissolution.	43
	Section 11.04.	 	Liquidation.	44
	Section 11.05.	 	Termination of the Company.	45
	Section 11.06.	 	Claims of the Members.	45

 

    	 	 ii	 

     

    

	Article XII Liability and indemnification	45
	 	 	 	 
	Section 12.01.	 	Liability of Members.	45
	Section 12.02.	 	Indemnification of Covered Person.	45
	Section 12.03.	 	Indemnification by the Company.	45
	Section 12.04.	 	Advancement of Expenses.	47
	 	 	 	 
	Article XIII Exclusivity	47
	 	 	 	 
	Section 13.01.	 	Exclusivity.	47
	Section 13.02.	 	Non-Solicitation.	48
	 	 	 	 
	Article XIV Miscellaneous	48
	 	 	 	 
	Section 14.01.	 	Confidential Information.	48
	Section 14.02.	 	Notices.	49
	Section 14.03.	 	Public Announcements.	50
	Section 14.04.	 	Interpretation.	50
	Section 14.05.	 	Severability.	50
	Section 14.06.	 	Counterparts.	51
	Section 14.07.	 	Entire Agreement.	51
	Section 14.08.	 	Governing Law; Submission to Jurisdiction; Arbitration.	51
	Section 14.09.	 	Specific Performance.	54
	Section 14.10.	 	Expenses.	54
	Section 14.11.	 	Amendments and Waivers; Assignment.	54
	Section 14.12.	 	No Third Party Beneficiaries.	54
	Section 14.13.	 	Headings.	55
	Section 14.14.	 	Construction.	55
	Section 14.15.	 	Further Assurances.	55

 

	Schedule 2.01	List of Members and Addresses
	Schedule 4.01(a)	Prior Capital Contributions
	Schedule 4.01(b)	Holders of Membership Units
	Exhibit A	Member Certificate
	Exhibit B	Fair Market Value Methodology

 

 

    	 	 iii	 

     

    

SECOND AMENDED AND RESTATED OPERATING AGREEMENT

 

OF

 

NOVVI LLC

 

This SECOND AMENDED AND RESTATED OPERATING
AGREEMENT of Novvi LLC, a Delaware limited liability company (the “Company”), is made and effective as of July
19, 2016 (the “Effective Date”), among Amyris, Inc., a Delaware corporation (“Amyris”), Cosan
US, Inc., a Delaware corporation (“Cosan US”), and American Refining Group, Inc., a Pennsylvania corporation
(“ARG” and together with Amyris and Cosan US, each, a “Member” and collectively, the “Members”)
and the Company (the “Agreement”).

 

WITNESSETH:

 

WHEREAS, Amyris and Cosan US formed the Company
pursuant to and in accordance with the Delaware Limited Company Act, 6 Del. C. § 18-101, et seq. (as the same may be
amended from time to time, the “Act”) and entered into an Agreement of Limited Liability Company of Novvi LLC
on September 6, 2011, as the same was amended in October of 2011 (the “Original Operating Agreement”);

 

WHEREAS, Amyris, Cosan US and the Company
executed and delivered an Amended and Restated Operating Agreement of the Company dated March 26, 2013 (the “First Amended
and Restated Agreement”);

 

WHEREAS, in connection with formation of the
Company, Amyris and Cosan US agreed to collaborate, through the Company, on the development, production, marketing and distribution
of Base Oils, Additives, and Lubricants derived from BioFene (and possibly from other molecules and technologies) for use in the
Lubricant Market (“Company Business”), all as further defined and described below;

 

WHEREAS, in pursuit of the Company Business,
the Company and Amyris are parties to (i) that certain Amended and Restated IP License Agreement (as the same may be amended from
time to time, the “IP License Agreement”), entered into on July 19, 2016 under which Amyris granted the Company
certain rights under its intellectual property, including (a) the Expanded License and Rights under Amyris Base Technology and
(b) a right of first offer with regard to Amyris’ Alternative Technology, to develop, make and sell Base Oils, Additives
and Lubricants for the Lubricant Market, all as further described in the IP License Agreement; and (ii) that certain Farnesene
Strain Escrow Agreement, entered into on July 19, 2016 under which Amyris has agreed to deposit into escrow intellectual property
relating to the Amyris Base Technology, in accordance with the IP License Agreement.

 

WHEREAS, in pursuit of the Company Business,
the Company and Cosan US are parties to that certain Cosan US Alternative Technology License Agreement, entered into on August
23, 2013 (as the same may be amended from time to time, the “Cosan US License Agreement”), under which Cosan
US granted the Company a right of first offer with regard to Cosan US’s Alternative Technology to develop, make and sell
Base Oils, Additives and Lubricants for the Lubricant Market, all as further described in the Cosan US License Agreement;

 

WHEREAS, in pursuit of the Company Business,
effective on the Effective Date, the Company and ARG have entered into an Equity Purchase Agreement (the “Purchase Agreement”),
pursuant to which ARG purchased that number of Membership Units specified therein, initially

 

representing a thirty-three and one-third percent (33 1/3%) interest
in the Company as of the Effective Date, upon the terms and subject to the conditions set forth therein;

 

    	 	1	 

     

    

 

WHEREAS, as contemplated by the Purchase Agreement
and Section 2.15 of the First Amended and Restated Agreement, the Members and the Company now desire to enter into this Agreement
to amend and restate in its entirety the First Amended and Restated Agreement and to memorialize the admission of ARG as a Member;
and

 

WHEREAS, by executing and delivering this
Agreement, the Company and each of the Members hereby (i) agree to amend and restate the terms of the First Amended and Restated
Agreement as set forth herein, and that upon the effectiveness of this Agreement, the First Amended and Restated Agreement shall
be superseded entirely by this Agreement and (ii) declare this Agreement to be the operating agreement of the Company for the purposes
and upon the terms and conditions set forth herein;

 

NOW, THEREFORE, in consideration of the agreements
and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Members hereby agree as follows:

 

Article
I

Defined terms

 

Section 1.01.       
Certain Defined Terms. (a) Each of the following terms shall have the following meanings:

 

 

 

“Additive” means
any material added to a Base Oil to change its properties, characteristics, or performance (e.g., anti-foam, anti-wear, corrosion
inhibitor, detergent, dispersant, pour point depressant, anti-oxidant, viscosity index improver, or friction modifier).

 

“Adjusted Capital Account”
means, with respect to each Member, the balance in such Member’s Capital Account as of the end of the relevant Fiscal Year,
after giving effect to the following adjustments:

 

(i)                  
Credit to such Capital Account any amounts which such Member is obligated to restore pursuant to any provision of this Agreement
or is deemed to be obligated to restore pursuant to the penultimate sentences of each of Sections 1.704-2(g)(1) and 1.704-2(i)(5)
of the Regulations); and

 

(ii)                
Debit to such Capital Account the items described in Sections 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) and 1.704-1(b)(2)(ii)(d)(6)
of the Regulations.

 

“Adjusted Capital Account
Deficit” means, with respect to each Member, the deficit balance, if any, in such Member’s Adjusted Capital Account
as of the end of the relevant Fiscal Year.

 

“Affiliate” means,
as regards to a certain Person (a “First Person”), any Person who, directly or indirectly, through one or more
intermediates, Controls the First Person, is Controlled by the First Person, or is under common Control with the First Person.
Notwithstanding the preceding definition, for purposes of this Agreement, the Company is not considered an Affiliate of Amyris,
Cosan US or ARG (or their respective Affiliates) nor are Amyris, Cosan US or ARG (or their respective Affiliates) considered Affiliates
of the Company.

 

    	 	2	 

     

    

“Agreement” means
this Second Amended and Restated Operating Agreement of Novvi LLC, as amended, modified, supplemented or restated from time to
time.

 

“Alternative Technology”
means a technology (other than a BioFene-related technology) from a renewable source or a molecule (other than a BioFene-derived
molecule) from a renewable source from which Base Oils or Additives, in each case, for the Lubricants Market could reasonably be
expected to be developed or made.

 

“Amyris BioFene Manufacturing
Technology” means the Patents and Know-How that (i) are Controlled by Amyris and (ii) are necessary or reasonably
useful for the development, making (and having made), offering for sale, sale, and importing of BioFene itself, including, but
not limited to, BioFene Production Strains and any Patents and Know-How related to the genetic engineering of such BioFene Production
Strains, the fermentation methods for making BioFene, the methods of recovery of BioFene from fermentation broth, the processes
of isolating BioFene directly from fermentation broth, and the methods of purifying BioFene. The term “Amyris BioFene Manufacturing
Technology” also includes any and all Joint BioFene Manufacturing Improvements (as defined in the IP License Agreement) and
Novvi LLC BioFene Manufacturing Improvements (as defined in the IP License Agreement), but expressly excludes any Company BioFene
Transformation Technology.

 

“Asset Value”
means, with respect to any asset, the asset’s adjusted basis for United States federal income tax purposes, except as follows:

 

(i)                  
The initial Asset Value of any asset (other than cash) contributed by a Member to the Company shall be the gross fair market
value of such asset (A) as set forth in Section 4.01(a)(i), or (B) if such asset is not listed in Section 4.01(a)(i), as agreed
to by all of the Members;

 

(ii)                
The Asset Values of all Company assets shall be adjusted to equal their respective gross fair market values as determined
by agreement among all of the Members as of the following times: (a) the acquisition of an additional interest in the Company by
any new or existing Member in exchange for more than a de minimis Capital Contribution; (b) the distribution by the Company
to a Member of more than a de minimis amount of property as consideration for an interest in the Company; or (c) the liquidation
of the Company within the meaning of Section 1.704-1(b)(2)(ii)(g) of the Regulations, provided however, that adjustments
pursuant to clauses (a) and (b) above shall be made only if all of the Members agree that such adjustments are necessary or appropriate
to reflect the relative economic interests of the Members in the Company; and

 

(iii)              
The Asset Value of any Company asset distributed to any Member shall be the gross fair market value of such asset on the
date of distribution, as determined by the agreement among all the Members.

 

If the Asset Value of an asset has been determined or
adjusted pursuant to subparagraph (i) or (ii), such Asset Value shall thereafter be adjusted by the Depreciation taken into account
with respect to such asset.

 

“Base Oil” means
a fluid base compound to which other oils, Additives, or components are added to produce a Lubricant.

 

    	 	3	 

     

    

“Beneficial Owner”
or “Beneficially Own” has the meaning given such term in Rule 13d-3 (or any successor provision) under the United
States Securities Exchange Act of 1934, as amended.

 

“BioFene” means
farnesene produced through Amyris BioFene Manufacturing Technology.

 

“Business Day”
means any day, except a Saturday, Sunday or other day on which commercial banking institutions in the State of California in the
United States of America and in the State of São Paulo in Brazil are authorized or directed by applicable Law or executive
order to close.

 

“Capital Account”
means, with respect to any Member, the account maintained for such Member in accordance with the provisions of Section 4.06.

 

“Capital Contribution”
means, with respect to any Member, the aggregate amount of cash contributed to the Company and the Asset Value of any property
(other than cash) contributed to the Company pursuant to Article IV. In the case of a Member that acquires an interest in the Company
by virtue of an assignment or transfer in accordance with the terms of this Agreement, “Capital Contribution” means
the Capital Contribution of such Member’s predecessor to the extent relating to the acquired interest.

 

“Certificate”
means the Certificate of Formation of the Company and any and all amendments thereto and restatements thereof filed on behalf of
the Company with the Office of the Secretary of State of the State of Delaware pursuant to the Act.

 

“Change of Control of Amyris”
means any transaction (or a series of related transactions), as a result of which a Competitor of the Company becomes, direct or
indirectly, the Controlling Person of Amyris.

 

“Change of Control of Cosan
US” means any transaction (or a series of related transactions) as a result of which a Competitor of the Company becomes,
direct or indirectly, the Controlling Person of Cosan US.

 

“Change of Control of ARG”
means any transaction (or a series of related transactions), as a result of which a Competitor of the Company becomes, direct or
indirectly, the Controlling Person of ARG.

 

“Code” means
the Internal Revenue Code of 1986, as amended from time to time, or any corresponding United States federal tax statute enacted
after the date of this Agreement. The reference to a specific section of the Code refers not only to such specific section but
also to any corresponding provision of any United States federal tax statute enacted after the date of this Agreement, as such
specific section or corresponding provision is in effect on the date of application of the provisions of this Agreement containing
such reference.

 

“Company BioFene Transformation
Technology” means the Patents and Know-How in each case that (i) are Controlled by the Company as of March 26, 2013 or
become Controlled by the Company during the term of Amyris’s license under Section 2.2 of the IP License Agreement (in each
case other than Patents and Know-How licensed from Amyris) and (ii) are related to the chemical transformation of BioFene or a
BioFene-derivative into another compound. For clarity, the term “Company BioFene Transformation Technology” does not
include Novvi LLC Breach Inventions (as defined in the IP License Agreement).

 

    	 	4	 

     

    

“Competitor of the Company”
means any Person that is engaged in the development, production, marketing and distribution of Base Oils, Additives or Lubricants
for the Lubricants Market.

 

“Control” means,
when used with respect to any Person (“Controlled Person”), (i) the power, held by another Person, alone or
together with other Persons bound by a voting or similar agreement (each a “Controlling Person”), to elect,
directly or indirectly, the majority of the senior management and to establish and conduct the policies and management of the relevant
Controlled Person; or (ii) the direct or indirect ownership by a Controlling Person and its Affiliates, alone or together with
another Controlling Person and its Affiliates, of at least fifty percent (50%) plus one (1) share/quota representing the voting
stock of the Controlled Person. In the context of Patents and Know-How, Control means rights under and to such Patents and Know-How
held by a party, whether by ownership or license, sufficient to grant the applicable license or rights under the IP License Agreement
without violating the terms of any arrangement with any Third Party. Terms derived from Control, such as “Controlled”,
“Controlling” and “under common Control” shall have a similar meaning to Control.

 

“Controlled Group Liability”
means any and all liabilities (i) under Title IV of ERISA, (ii) under Section 302 of ERISA, (iii) under Sections 412 and 4971
of the Code, (iv) as a result of a failure to comply with the continuation coverage requirements of Section 601 et seq. of ERISA
and Section 4980B of the Code, or (v) under corresponding or similar provisions of foreign Laws under any employee benefit plan
of the Company or its Affiliates.

 

“Controlling Member”
means a Member who owns more than fifty percent (50%) of the Membership Units of the Company.

 

“Copyrights”
means all copyrights, whether in published or unpublished works; databases, data collections and rights therein, mask work rights,
software, web site content; rights to compilations, collective works and derivative works of any of the foregoing and moral rights
in any of the foregoing; registrations and applications for registration for any of the foregoing and any renewals or extensions
thereof; and moral rights and economic rights of others in any of the foregoing.

 

“Covered Person”
means a Member, any Affiliate of a Member, any officers, directors, Managers, shareholders, employees or partners or members of
a Member, or its respective Affiliates or any Managers or Officers of the Company.

 

“Deadlock Issue”
means an issue or a matter with respect to which a decision is required to be made in order to (a) prevent the occurrence of an
event that would reasonably be expected to have a Material Adverse Effect on the Company, (b) alleviate the effect on the business,
assets, operations, results of operations or financial condition of the Company caused by such event such as to, to the extent
possible, restore the Company to the state of affairs enjoyed by the Company immediately prior to the occurrence of such event,
(c) avoid a material change in the state of affairs, business, corporate governance, assets, operations, results of operations
or financial condition of the Company caused by such event, or (d) approve a Member Approval Matter, as set forth in Section 5.06(e)
below, or a Board of Managers Approval Matter, as set forth in Section 5.05(a) below.

 

“Depreciation”
means, for each Fiscal Year or other period, an amount equal to the depreciation, amortization or other cost recovery deduction
allowable for United States federal income tax purposes with respect to an asset for such Fiscal Year or other period; provided
however, that if the Asset Value of an asset differs from its adjusted basis for

 

United States federal income tax
purposes at the beginning of such Fiscal Year or other period, Depreciation shall be an amount that bears the same ratio to such
beginning Asset Value as the United States federal income tax depreciation, amortization or other cost recovery deduction with
respect to such asset for such Fiscal Year or other period bears to such beginning adjusted tax basis; and provided further
that, if the United States federal income tax depreciation, amortization or other cost recovery deduction for such Fiscal Year
or other period is zero, Depreciation shall be determined with reference to such beginning Asset Value using any reasonable method
selected by the Members.

 

    	 	5	 

     

    

“Encumbrance”
means any security interest, pledge, mortgage, lien, charge, adverse claim of ownership or use, or other encumbrance of any kind.

 

“Expanded Licenses and
Rights under Amyris Base Technology” means the licenses and related rights granted by Amyris to the Company in the IP
License Agreement.

 

“Fair Market Value”
means the fair market value of the Company’s Membership Units, as calculated using the methodology set forth in Exhibit
B to this Agreement.

 

“Fiscal Year”
means (i) the period commencing upon the formation of the Company and ending on December 31, 2011, (ii) any subsequent twelve-month
period commencing on January 1 and ending on December 31, or (iii) any portion of the period described in clause (ii) of this
sentence for which the Company is required to allocate Net Profits, Net Losses and other items of Company income, gain, loss or
deduction pursuant to Article VII hereof.

 

“GAAP” means
United States generally accepted accounting principles as in effect from time to time.

 

“Insolvency Event”
means (i) an involuntary petition under any bankruptcy or insolvency law or under the reorganization provisions of any such law
is filed with respect to a Member or a receiver of, or for, the property of a Member is appointed without the consent of such Member,
which petition or appointment remains undischarged or unstayed for an aggregate period of ninety (90) days (whether or not consecutive);
or (ii) a Member consents to the entry of an order for relief against it in an involuntary case under any bankruptcy or insolvency
law or under the reorganization provisions of any such law; or (iii) a voluntary petition under any bankruptcy or insolvency law
or under the reorganization provisions of any such law is filed by a Member, a voluntary assignment of a Member’s property
for the benefit of creditors is made, or a receiver of, or for, the property of a Member is appointed by, or consented to, by such
Member.

 

“Know-How” means
any non-patented information and tangible materials, including: (i) technical and non-technical data, specifications, formulae,
compounds, formulations, assays, designs, results, information, conclusions, interpretations, inventions, developments, discoveries,
ideas, improvements, and trade secrets, (ii) methods, databases, tests, procedures, processes, and techniques, (iii) Production
Strains (if applicable), and (iv) other know-how and technology including Copyrights.

 

“Law” means any
statute, law, ordinance, regulation, rule, code, executive order, injunction, judgment, decree or other order issued or promulgated
by any national, supranational, state, United States federal, provincial, local or municipal government or any administrative or
regulatory body with authority therefrom with jurisdiction over Company or the Members, as the case may be.

 

    	 	6	 

     

    

“Lubricant” means
all substances introduced between two moving surfaces to reduce the friction between them, improving efficiency and reducing wear,
or dissolving or transporting foreign particles, or distributing heat, in each case comprising a formulation of at least one Base
Oil combined or blended with Additives, sold as a finished product for automotive and industrial applications, for use in, by way
of example only: automotive, 2-cycle, marine and other engines, ship lubrication, hydraulic equipment, food processing equipment
and machinery, and wind turbines, However, the term “Lubricants” expressly excludes drilling oils, fluids and muds,
in accordance with the standards set by American Petroleum Institute.

 

“Lubricants Market”
means the worldwide market for automotive, commercial, and industrial Lubricants. For the avoidance of doubt, the following markets,
but not limited to the following markets, are expressly excluded from the term “Lubricants Market”: the markets for
flavors and fragrances, food additives, cosmetics and personal care, drilling oils, fluids and muds, fuels, cleaners, paints, coatings,
ink, consumer-packaged goods, pesticides, and pharmaceuticals.

 

“Majority Vote”
means, with respect to any matter to be voted on, the written approval of, or the affirmative vote by, a majority of the Managers
serving on the Board of Managers entitled to vote on such matter.

 

“Material Adverse Effect”
means any event, condition, change or effect that materially and adversely affect the business, assets, operations, results of
operations or financial condition of the Company, taken as a whole.

 

“Member” means
any Person named as a member of the Company on Schedule 2.01 hereto and any Person admitted as an additional Member pursuant to
the provisions of this Agreement, in each case, in such Person’s capacity as a member of the Company.

 

“Membership Unit”
means a limited liability company interest in the Company (not including any right to the return of Capital Contributions and any
interest thereon) representing such fractional part of the interest of all unit holders pursuant to this Agreement as is equal
to the quotient of one divided by the total number of Membership Units as evidenced by a certificate in the form of Exhibit
A to this Agreement.

 

“Net Profits”
and “Net Losses” mean, for each Fiscal Year, an amount equal to the Company’s taxable income or loss for
such Fiscal Year, determined in accordance with Section 703(a) of the Code (but including in taxable income or loss, for this
purpose, all items of income, gain, loss or deduction required to be stated separately pursuant to Section 703(a)(1) of the Code),
with the following adjustments:

 

(i)                  
any income of the Company exempt from United States federal income tax and not otherwise taken into account in computing
Net Profits or Net Losses pursuant to this definition shall be added to such taxable income or loss;

 

(ii)                
any expenditures of the Company described in Section 705(a)(2)(B) of the Code (or treated as expenditures described in Section
705(a)(2)(B) of the Code pursuant to Regulation Section 1.704-1(b)(2)(iv)(i)) and not otherwise taken into account in computing
Net Profits or Net Losses pursuant to this definition shall be subtracted from such taxable income or loss;

 

(iii)              
in the event the Asset Value of any asset of the Company is adjusted in accordance with paragraph (ii) or paragraph (iii)
of the definition of “Asset Value” above, the amount of such adjustment shall be taken into account as gain or loss
from the disposition of such asset for purposes of computing Net Profits or Net Losses;

 

    	 	7	 

     

    

(iv)              
gain or loss resulting from any disposition of any asset of the Company with respect to which gain or loss is recognized
for United States federal income tax purposes shall be computed by reference to the Asset Value of the asset disposed of, notwithstanding
that the adjusted tax basis of such asset differs from its Asset Value;

 

(v)                
in lieu of the depreciation, amortization and other cost recovery deductions taken into account in computing such taxable
income or loss, there shall be taken into account Depreciation for such Fiscal Year or other period, computed in accordance with
the definition of “Depreciation” above; and

 

(vi)              
any items which are specially allocated pursuant to Sections 7.02 and 7.03 shall not be taken into account in computing
Net Profits or Net Losses.

 

The amounts of the items of Company income, gain, loss
or deduction available to be specially allocated pursuant to Sections 6.02 and 6.03 shall be determined by applying rules analogous
to those set forth in subparagraphs (i) through (v) above.

 

“Patents” means
any patents, patent applications, or certificates of invention, together with all additions, divisions, continuations, continuations-in-part,
provisionals, converted provisionals, substitutions, reissues, re-examinations, revalidations, extensions, registrations, patent
term extensions, supplemental protection certificates, renewals, and the like with respect to any of the foregoing.

 

“Percentage Interest”
means a fraction, the numerator of which shall be the aggregate number of Membership Units owned by such Member and the denominator
of which shall be the total number of outstanding Membership Units of the Company.

 

“Person” means
any individual, corporation, partnership, limited partnership, limited partnership with share capital, limited liability company,
Brazilian limited liability company (sociedade limitada), association, joint-stock company (sociedade por ações),
joint venture, other legal entity, trust, unincorporated or governmental organization or any agency or political subdivision thereof.

 

“Production Strain”
means recombinant yeast or some other microbial agent that has been genetically engineered to make a desired compound or product
by means of a fermentation process.

 

“Regulations”
means the income tax regulations, including temporary regulations, promulgated under the Code, as such regulations may be amended
from time to time (including corresponding provisions of succeeding regulations).

 

“Related Party Transaction”
means any deal, operation, transaction and/or business relationship between, on one side, the Company or a Person Controlled by
the Company and, on the other side, a Member or any Affiliate of such Member, or their respective officers, directors, managers
or relatives up to three degrees of relationship separation.

 

“Restricted Membership
Units” means all Membership Units other than (a) Membership Units that have been registered under a registration statement
pursuant to the Securities Act, (b) Membership Units with respect to which a Transfer has been made in reliance on and in
accordance with Rule 144 or (c) Membership Units with respect to which the holder thereof shall

 

    	 	8	 

     

    

have delivered to the Company either
(i) an opinion, in form and substance reasonably satisfactory to the Company, of counsel, who shall be reasonably satisfactory
to the Company, or (ii) a “no action” letter from the staff of the United States Securities and Exchange Commission,
to the effect that subsequent transfers of such Membership Units may be effected without registration under the Securities Act
or in compliance with Rule 144.

 

“Revised Partnership Audit
Procedures” means the provisions of Subchapter C of Subtitle A, Chapter 63 of the Code, as amended by P.L. 114 74, the
Bipartisan Budget Act of 2015 (together with any subsequent amendments thereto, treasury regulations promulgated thereunder, published
administrative interpretations thereof, any guidance issued thereunder and any successor provisions) or any similar procedures
established by a state, local, or non-U.S. taxing authority.

 

“Rule 144” means
Rule 144 (or any successor provision) under the Securities Act.

 

“Securities Act”
means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
or “Subsidiaries” of any Person means any corporation, partnership, limited partnership, limited partnership
with share capital, limited liability company, Brazilian limited liability company (sociedade limitada), association, joint-stock
company (sociedade por ações), joint venture or other legal entity of which such Person (either alone or through
or together with any other Subsidiary), owns, directly or indirectly, more than fifty percent (50%) of the stock or other equity
interests, the holders of which are generally entitled to vote for the election of the board of directors or other governing body
of such corporation or other legal entity.

 

“Transfer” means,
in respect of any Membership Unit, property or other asset, any direct or indirect transfer, sale, assignment, exchange, donation,
lease, abandonment or other disposition of any kind, voluntary or involuntary, contingent or non-contingent, including any direct
or indirect transfer, sale, assignment, exchange, donation, lease, abandonment or other disposition of any kind that results from
the foreclosure of any Encumbrance.

 

“Transferee”
means any Person that is a transferee of a Member’s interest in the Company, or part thereof.

 

“Third Party”
means any Person, except for the Company, the Members and their respective Affiliates or their respective permitted successors
and assigns.

 

“Trigger Event”
means the Company’s delivery to ARG, following a payment default by ARG under the terms of Section 1.3 of the Purchase Agreement
and with approval by a Majority Vote of only the Amyris Managers and Cosan Managers, of written notice that the Company elects
to declare an uncured Unpaid Contribution (as defined in the Purchase Agreement) by ARG as no longer curable, in which event ARG
shall be subject to the consequences set forth in Section 2.17 below.

 

(b)               
The following terms have the meanings set forth in the Section set forth opposite such term:

 

	Term	Section
	Act	Recitals
	Amyris	Preamble
	Amyris Managers	5.02(a)

 

    	 	9	 

     

    

 

	Term	Section
	Applicable Deadlock Issue	5.16(d)
	Appraisers	Exhibit B
	Arbitration Chamber	14.08(b)
	Arbitration Rules	14.08(b)
	Arbitration Tribunal	14.08(c)
	ARG	Preamble
	ARG Initial Capital Contribution	4.01(b)
	ARG Managers	5.02(a)
	Board of Managers Approval Matter	5.05(a)
	Capital Call	4.04(c)
	Chair	5.02(a)
	Change of Control Event	6.01(a)
	Company	Preamble
	Company Business	Recitals
	Confidential Information	14.01(a)
	Corporate Opportunities Group	2.16(a)(i)
	Cosan US	Preamble
	Cosan US License Agreement	Recitals
	Cosan US Managers	5.02(a)
	Deadlock	5.16(a)
	Deadlock Mediation Period	5.16(e)
	Deadlock Notice	5.16(a)
	Deadlock Question	5.16(c)
	Declaration	5.16(d)
	Declaring Member	5.16(c)
	Deciding Members	5.16(f)
	Disclosing Party	14.01(a)
	Effective Date	Preamble
	Employee Units	4.02(b)
	Exercise Date	11.01(a)
	First Amended and Restated Agreement	Recitals
	Former Member	11.04(a)
	Initiating Member	5.16(f)
	IP License Agreement	Recitals
	Liquidating Trustee	11.05
	Losses	12.02
	Manager	5.02(a)
	Mediator	5.16(e)
	Member Approval Matter	5.06(e)
	Negotiation Period	5.16(d)
	Non Cash Consideration	10.02(c)(ii)
	Officers	5.12(a)
	Offer Notice	5.16(f)
	Original Operating Agreement	Recitals
	President	5.12(a)
	Prior Capital Contributions	4.01(a)
	Prospective Transferee	10.04
	Purchase Agreement	Recitals

 

    	 	10	 

     

    

 

	Term	Section
	Receiving Party	14.01(a)
	Regulatory Allocations	7.03
	Representatives	14.01(a)
	Response Notice	5.16(f)
	Right of First Refusal	10.02(c)
	ROFR Notice	10.02(c)
	Sale Notice	10.02(c)
	Selected Arbitration	14.08(h)
	Selling Member	10.02(c)
	Sole Appraiser	Exhibit B
	Tag Along Notice	10.02(c)
	Tag Along Right	10.02(c)
	Tax Matters Partner	7.05(c)
	Termination Date	5.16(f)
	Third Appraiser	Exhibit B

 

 

Article
II

Formation, term, purpose and powers

 

Section 2.01.       
Formation. (a) The Members hereby confirm the formation of the Company as a Delaware limited liability company under
and pursuant to the provisions of the Act and all other pertinent Laws of the State of Delaware for the purposes and upon the terms
and conditions hereinafter set forth. The parties hereto agree that their rights, duties and liabilities and the rights, duties
and liabilities of any additional Member admitted to the Company in accordance with the terms hereof, shall be as provided in the
Act, except as otherwise provided herein.

 

(b)               
The name and mailing address of each Member shall be listed on Schedule 2.01 attached hereto. Each of the Members is hereby
admitted as a Member of the Company. Additional Members shall be admitted as Members of the Company in accordance with Section
2.11. The President, or a designee of the President, shall be required to update Schedule 2.01 from time to time, as necessary
to reflect accurately the information therein as known by the President, but no such update shall modify Schedule 2.01 in any manner
inconsistent with this Agreement or the Act. Any amendment or revision to Schedule 2.01 made in accordance with this Agreement
shall not be deemed an amendment to this Agreement for purposes of Section 13.13. Any reference in this Agreement to Schedule 2.01
shall be deemed to be a reference to Schedule 2.01, as amended and in effect from time to time.

 

(c)                
The President, together with at least one other Officer of the Company, shall be designated as authorized persons, within
the meaning of the Act, to execute, deliver and file, or to cause the execution, delivery and filing of, any amendments or restatements
of the Certificate and any other certificates, notices, statements or other instruments (and any amendments or restatements thereof)
necessary or advisable for the formation of the Company or the operation of the Company in all jurisdictions where the Company
may elect to do business, but no such amendment, restatement or other instrument may be executed, delivered or filed unless adopted
by the Members in a manner authorized by Section 5.06(e) this Agreement.

 

Section 2.02.       
Name. The name of the Company is Novvi LLC. The Company Business may not be conducted under any other name unless
the Members expressly agree in writing.

 

    	 	11	 

     

    

Section 2.03.       
Term. The term of the Company commenced, and the Certificate was filed in the Office of the Secretary of State of
the State of Delaware, on September 6, 2011, and the Company shall continue for any term set forth from time to time in the Certificate,
subject to the provisions set forth in Article XI and applicable Law. The existence of the Company as a separate legal entity shall
continue until cancellation of the Certificate in the manner required by the Act.

 

Section 2.04.       
Principal Place of Business. The principal place of business of the Company shall be located at 5885 Hollis Street,
Emeryville, CA 94608, or such other place as the Board of Managers may determine from time to time per Section 5.05, and the Company
shall have other regional offices and operations as the Board of Managers may determine from time to time per Section 5.05.

 

Section 2.05.       
Title to Company Property. Any property of the Company, whether real, personal or mixed, tangible or intangible,
shall be deemed to be owned by the Company as an entity, and no Member, individually, shall have any direct ownership interest
in such property.

 

Section 2.06.       
Agent for Service of Process. The Company’s registered agent for service of process in the State of Delaware
shall be as set forth in the Certificate, as the same may be amended by the Members from time to time per Section 5.06(e).

 

Section 2.07.       
Purpose. The purpose of the Company is to engage in the Company Business.

 

Section 2.08.       
Powers of the Company. Subject to the limitations set forth in this Agreement, the Company will possess and may exercise
all of the powers and privileges granted to it by the Act, by any other applicable Law or this Agreement, together with all powers
incidental thereto, so far as such powers are necessary or convenient to the conduct, promotion or attainment of the purpose of
the Company set forth in Section 2.07.

 

Section 2.09.       
Maintenance of Separate Existence. (a) The Company shall do all things necessary to maintain its limited liability
company existence separate and apart from each Member and any Affiliate of any Member, including holding regular meetings of the
Members and maintaining its books and records on a current basis separate from that of any Affiliate of the Company or any other
Person, and shall not commingle the Company’s assets with those of any Affiliate of the Company or any other Person. In furtherance,
and not in limitation, of the foregoing, the Company shall not:

 

(i)                  
Authorize or permit any Person other than the Board of Managers and the Officers as provided herein, to act on its own behalf
with respect to matters (other than matters customarily delegated to others under powers of attorney) for which a limited liability
company’s members or managing member would customarily be responsible;

 

(ii)                
Fail (A) to maintain or cause to be maintained by an agent under the Company’s control physical possession of all
its books and records, (B) to maintain capitalization adequate for the conduct of its business, (C) to account for and manage all
of its liabilities separately from those of any other Person, including payment by it of administrative expenses and taxes, other
than income taxes, from its own assets, or (d) to identify or cause to be identified separately all of its assets from those of
any other Person;

 

(iii)              
Commingle, or permit the commingling of, its funds with the funds of any Member or any Affiliate of any Member or use its
funds for other than the Company’s uses; or

 

    	 	12	 

     

    

(iv)              
Maintain, or permit the maintenance of, joint bank accounts or other depository accounts to which any Member would have
independent access.

 

Section 2.10.       
Strategic Decisions. The Company’s strategic decisions shall always take into account the Company’s best
interests, with the purpose of (a) providing the Members with the best possible sustainable return on their investments and (b)
achieving the goals and objectives set forth in any approved business plan.

 

Section 2.11.       
Related Party Transaction. Any Related Party Transaction shall be carried out on an arms’ length basis under
terms and conditions consistent to those that such parties would be offered in case such transaction were carried out with Third
Parties, without conflict of interest and in the best interests of the Company and its Subsidiaries. Notwithstanding any provision
in this Agreement to the contrary, if the Board of Managers has been called upon to consider a Related Party Transaction, any Manager
may request that the Manager(s) appointed by any Member with an interest in such Related Party Transaction recuse himself or herself
from all Board of Managers’ discussions, activities, and voting relating to such Related Party Transaction. All approvals,
modifications, or terminations of a Related Party Transaction must be approved by a majority vote of all of the unconflicted Managers
before the Company may proceed.

 

Section 2.12.       
Management Goals. The Managers and Officers of the Company and its Subsidiaries shall be instructed, subject to any
applicable fiduciary duties of Officers under applicable Delaware Law, to use their best efforts in pursuing return over capital
employed, efficiency, productivity, safety and competitiveness with respect to the activities of the Company and its Subsidiaries.

 

Section 2.13.       
Conduct of Company Business. The Company, its Subsidiaries, and its and their respective Managers, directors, Officers,
agents, employees and any other Person acting on behalf of the Company or any of its Subsidiaries shall not, under any circumstances
and for any reason whatsoever, engage in any illegal or unlawful business conduct, and the Company shall use its reasonable best
efforts — and cause its Subsidiaries to use their reasonable best efforts − to maintain good labor, social and environmental
standards, in the conduct of the Company Business.

 

Section 2.14.       
No Personal Liability. Except as provided by the Act, no Member or any Manager shall be personally liable for any
obligations of the Company and except as specifically provided in Article IV, no Member shall have any obligation or be required
to make any Capital Contribution or loan or otherwise advance any funds to the Company.

 

Section 2.15.       
Admission of New Members. (a) New Members shall be admitted to the Company, subject to the terms of this Section
2.15, only with the approval of Members representing at least seventy-five percent (75%) of the Membership Units and on terms and
conditions which are consistent with this Agreement (including without limitation any applicable restrictions on transfer set forth
in Article X), the Certificate, the Act and any applicable Law. Any such new Members shall execute and deliver to the Company a
joinder agreement in a form to be supplied by the Company (a “Joinder Agreement”), and shall obtain Membership
Units and shall participate in the management, profits, losses, and distributions of the Company on such terms and with such amendments
to this Agreement as are approved by the affirmative vote of the existing Members representing at least seventy-five percent (75%)
of the Voting Membership Units. Any such new Member shall be deemed a “Member” for purposes of this Agreement and shall
have the rights and be subject to the obligations of a Member under this Agreement with respect to the Membership Units owned by
such new Member.

 

(b)               
A Transferee will be admitted as a substitute Member only if the Transfer to the Transferee is made in compliance with all
the requirements of Article X (including, but not limited to, the

 

    	 	13	 

     

    

requirement that such Transferee becomes a party
to this Agreement) and the Transferee complies with all of the terms of this Agreement applicable to it.

 

Section 2.16.       
Waiver of Fiduciary Duties; Corporate Opportunities. (a) This Agreement is not intended to, and does not, create
or impose any fiduciary duty on any of the Members hereto or their respective Affiliates or designated Managers. Further, the Members
hereby waive any and all fiduciary duties that, absent such waiver, may be implied by applicable Law, and in doing so, recognize,
acknowledge and agree that their duties and obligations to one another and to the Company are only as expressly set forth in this
Agreement. Additionally, each Member acknowledges that the other Members and the Affiliates of such Members own and/or manage other
businesses, including businesses that may compete with the Company, the other Members or the Affiliates of such other Members.
Without any accountability to the Company or any Member by virtue of this Agreement (other than obligations in Section 14.01):

 

(i)                  
Each Member and its Affiliates, and their respective officers, directors, shareholders, partners, members, agents and employees,
and each Manager designated by such Member (collectively, a “Corporate Opportunities Group”), shall not in any
way be prohibited or restricted from engaging or investing in, independently or with others, any business opportunity of any type
or description, including, without limitation, those business opportunities that might be the same or similar to the Company Business;

 

(ii)                
Neither the Company nor any Member or such Member’s Corporate Opportunities Group shall have any right in or to such
other business opportunities of any other Member or such Member’s Corporate Opportunities Group or to the income or proceeds
derived therefrom;

 

(iii)              
No Member or its Corporate Opportunities Group shall be obligated to present any business opportunity to the Company or
any other Member or such other Member’s Corporate Opportunities Group, even if the opportunity is of the character that,
if presented to the Company, could be taken by the Company, or if presented to any other Member or other Member’s Corporate
Opportunities Group, could be taken by such Persons; and

 

(iv)              
Each Member and its Corporate Opportunities Group shall have the right to hold any such business opportunity for its own
account or to recommend such opportunity to Persons other than the Company, any other Member, or any Person in such other Member’s
Corporate Opportunities Group.

 

(b)               
Notwithstanding the foregoing, nothing in this Section 2.16 shall alter or amend the rights and obligations of the Company,
Amyris and its Affiliates, or Cosan US and its Affiliates under Article 3 of the IP License Agreement (including with respect to
the Company’s right of first offer regarding Amyris’ Alternative Technology), the Cosan US License Agreement (including
with respect to the Company’s right of first offer to Cosan US’s Alternative Technology), or in Section 13.1 of this
Agreement (with respect to Exclusivity).

 

2.17       Trigger
Event Consequence. If, following a Trigger Event, ARG continues to hold at least twenty-eight percent (28%) of the Membership
Units, the Parties agree that, following a Trigger Event, ARG shall be accorded the same status, solely for purposes of Sections
5.02(a), 5.02(d), 5.02(e), 5.05, 5.06(c) and 5.16(f) of this Agreement, as a Member holding less than twenty-eight percent (28%)
of the Membership Interests. In addition, in such event this Agreement shall be deemed automatically amended, without further action
of the Members (who by execution of this Agreement hereby consent to such amendment), to substitute “sixty-eight percent
(68%)” in place of each reference

 

    	 	14	 

     

    

herein to “seventy-five percent (75%)”
as it relates to the affirmative vote of Members required to approve certain matters as provided in Sections 2.15(a), 5.06(e) and
7.05(c) of this Agreement. The Trigger Event consequences described herein are in addition to any Trigger Event consequences set
forth in the Purchase Agreement.

 

Article
III

Representations and warranties of the members

 

Each Member severally, but not jointly, represents
and warrants to the Company and each other Member as follows:

 

Section 3.01.       
Organization and Authority. To the extent such Member is not a natural person, it is duly incorporated or organized,
validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary
power and authority to enter into this Agreement, to carry out its obligations hereunder and to perform the actions contemplated
hereby. Such Member is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties
owned or leased by it or the operation of its business makes such licensing or qualification necessary, except to the extent that
the failure to be so licensed or qualified would not prevent or materially hinder the performance of the actions contemplated by
this Agreement. The execution and delivery of this Agreement by such Member, the performance by it of its obligations hereunder
and the performance by it of the actions contemplated hereby have been duly authorized by all requisite action on its part. This
Agreement has been duly executed and delivered by such Member, and (assuming due authorization, execution and delivery by the other
Persons signatory hereto) this Agreement constitutes a legal, valid and binding obligation of such Member enforceable against it
in accordance with its terms.

 

Section 3.02.       
No Conflict. The execution, delivery and performance of this Agreement by such Member do not and will not (a) violate,
conflict with or result in the breach of any provision of its charter or by-laws (or similar organizational documents), to the
extent it has such, (b) conflict with or violate any Law, governmental regulation or governmental order applicable to such party
or any of its assets, properties or businesses or (c) conflict with, result in any breach of, constitute a default (or event which
with the giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others
any rights pursuant to, any contract, agreement or arrangement, whether among the Members or otherwise, by which such party is
bound, except to the extent that any conflict under (b) or (c) above would not prevent or materially hinder the performance of
the actions contemplated by this Agreement.

 

Section 3.03.       
Governmental Consents and Approvals. The execution, delivery and performance of this Agreement by such party do not
and will not require any consent, approval, authorization or other order of, action by, filing with or notification to, any governmental
authority.

 

Article
IV

Capital contributions and capital accounts

 

Section 4.01.       
Capital Contributions.

 

(a)                
Schedule 4.01(a) sets forth the Capital Contributions made to the Company by each of Amyris and Cosan US as of the Effective
Date, which (i) with respect to Amyris, shall include the unpaid principal and interest accrued under the notes and the deferred
payables converted into Units pursuant to the Loan Conversion Agreement by and between Amyris and the Company, dated July 19, 2016;
and (ii) with respect to Cosan US, shall include the unpaid principal and interest under the notes converted into Units pursuant
to the Loan Conversion Agreement by and between Cosan US and the Company, dated July 19, 2016 (the “Prior Capital Contributions”).

 

    	 	15	 

     

    

(b)               
Concurrently with the execution of this Agreement and in accordance with the Purchase Agreement, ARG will contribute to
the Company as its initial Capital Contribution the amount set forth in the Purchase Agreement, subject to the terms and conditions
of the Purchase Agreement (the “ARG Initial Capital Contribution”). As a result of the Prior Capital Contributions
and the ARG Initial Capital Contribution, as of the Effective Date the Members will hold an interest in the Company represented
by the Membership Units set forth opposite such Member’s name on Schedule 4.01(b).

 

Section 4.02.       
Membership Units. All Membership Units shall have identical rights in all respects as all other Membership Units
except as otherwise specified in this Agreement. Each Member hereby agrees that its interest in the Company and in its Membership
Units shall for all purposes be personal property. The Members agree that, within ninety (90) days after the Effective Date, to
discuss, agree upon, and implement a performance incentive plan for Company employees involving granting a non-voting, economic
interest in the Company in an aggregate amount equivalent to up to seven percent (7%) of the Company’s outstanding Membership
Units.

 

Section 4.03.       
Additional Membership Units. In the event (i) additional Membership Units shall be issued to a Member or to any other
Person or (ii) Membership Units are sold or Transferred to another Member or any other Person (subject to the restrictions and
provisions of this Agreement) and such Person shall be admitted as a Member in accordance with Section 2.15, the President shall
amend Schedule 2.01 accordingly. Any Capital Contribution to be made by such Person in exchange for Membership Units shall be subject
to the restrictions and provisions of this Agreement and in the form and amount determined by the Members per Section 5.06(e),
and the amount of such Capital Contribution, if any, shall be credited to such Person’s Capital Account.

 

Section 4.04.       
Funding Requirements; Additional Funding.

 

(a)                
In the event that the Board of Managers determines, at any time, that additional capital is required to support the operations
of the Company, such capital will be obtained through any one or a combination of the following means (in no particular order),
at the election of the Board of Managers, in each case subject to any applicable approval requirement set forth in this Agreement
including without limitation the approval of the Members with respect to financing obtained through (i), (ii), and (iii) below
as required under Section 5.06(e)(i):

 

(i)                  
cash advances or other credit or loan facilities provided by the Members or their Affiliates;

 

(ii)                
additional cash Capital Contributions by the Members; or

 

(iii)              
revolving credit or other loan facilities provided by unrelated Persons (such as banks).

 

(b)               
In the event that such additional Member approved capital raise under Section 4.04(a) is to be obtained in the form of cash
advances or other credit or loan facilities provided by a Member, the Company shall notify the Members of the advances to be made
or other credit or loan facilities to be provided pursuant to Section 4.04(a) by delivering a written notice to the Members in
accordance with Section 14.02 specifying (i) the aggregate amount of cash advances or other credit or loan facilities required
at such time and (ii) the amount of cash advances to be made or loan or credit facilities to be provided by the Member, which amount
shall be the product of (A) the aggregate amount of cash advances or other credit or loan facilities to be made and (B) such Member’s
Percentage Interest. The cash advances to be made by each Member shall be made in immediately available funds by wire transfer
or other similar means to a bank account designated by the Company in such notice prior to the close of business on the tenth Business
Day following the date of delivery of such notice.

 

    	 	16	 

     

    

Notwithstanding anything in this Agreement to
the contrary, neither Amyris nor Cosan nor ARG shall be required to make a cash advance or other credit or loan facility absent
its written consent thereto.

 

(c)                
In the event that such additional Member approved funding pursuant to Section 4.04(a) is to be made in the form of additional
Capital Contributions by the Members (a “Capital Call”), the Members satisfying such Capital Call shall receive
additional Membership Units at a price per Membership Unit equal to the Fair Market Value of the Membership Units. The Company
shall notify each Member of the Capital Call to be made pursuant to Section 4.04(a) by delivering written notice to each Member
in accordance with Section 14.02 specifying (i) the aggregate amount of the Capital Call required at such time and (ii) the amount
of the Capital Call to be provided by such Member, which amount shall be the product of (A) the aggregate amount of the Capital
Call to be made and (B) such Member’s Percentage Interest. In the event a Member is authorized by the Capital Call to satisfy
its share of such Capital Call in the form of assets (instead of cash), the value of such additional Capital Contribution shall
be deemed to be the fair market value of such assets as determined per clause (i) of the definition of Asset Value. Notwithstanding
anything in this Agreement to the contrary, neither Amyris nor Cosan nor ARG (except, with regard to ARG, as required by the Purchase
Agreement) shall be required to make a Capital Contribution absent its written consent thereto.

 

(d)               
Any written notice delivered by the Company to the Members pursuant to this Section 4.04 shall specify, in addition
to the information otherwise required, the date on which any advance, other credit support or Capital Call is due, account numbers
for the wire transfer of cash amounts and any other information the Company determines.

 

(e)                
Notwithstanding anything to the contrary set forth herein, any (i) cash advances or other credit or loan facilities provided
by the Members or their Affiliates or (ii) additional cash or non-cash Capital Contributions by the Members contemplated herein
in connection with the funding of the Company shall be made by each Member at the same time, on the same terms, in the same manner
and in the same proportion as each other Member, based on such Member’s Percentage Interest as contemplated in this Section 4.04.

 

(f)                
Amyris and the Company entered into a Renewable Farnesene Supply Agreement, dated July 19, 2016 (as amended from time-to-time,
the “Supply Agreement”), under which the Company can purchase farnesene from Amyris.  The Members and the
Company agree that the Sales Losses (as defined in Section 2.2(b) of the Supply Agreement) incurred by Amyris under the Supply
Agreement will be credited, at Amyris’s election, either to Amyris’s Capital Account or against any Member cash advance,
credit or loan facility, or other Capital Contribution obligation Amyris may have under this Agreement; provided that, if Amyris
elects to credit Sales Losses to its Capital Account such credit will not result in the issuance of additional Membership Units
to Amyris or otherwise increase its Percentage Interest and will not trigger any obligation by the other Members to match this
credit by making a Capital Contribution under Section 4.04(e) hereof. 

 

(g)                
The Members and the Company contemplate that ARG and ARG personnel will provide services to the Company from time to time,
subject to a written services agreement(s) between ARG and the Company that has been approved by the Board of Managers per Section
2.11, and in connection therewith will incur unreimbursed direct costs and out-of-pocket expenses described and authorized in such
approved agreements creditable under this subsection (“ARG Costs”). Within fifteen (15) days following the end
of each calendar quarter, ARG will provide the Board of Managers with a detailed, itemized report of ARG Costs incurred during
the preceding quarter per each service agreement. Absent objection by any Manager within thirty (30) days following receipt of
a report, the ARG Costs set forth in such report shall be deemed approved. The Members and the Company further agree that the approved
ARG Costs will be credited, at ARG’s election, either to ARG’s Capital Account or against any

 

    	 	17	 

     

    

Member cash advance, credit or loan facility,
or other Capital Contribution obligation ARG may have under this Agreement; provided that, if ARG elects to credit ARG Costs to
its Capital Account such credit will not result in the issuance of additional Membership Units to ARG or otherwise increase its
Percentage Interest and will not trigger any obligation by the other Members to match this credit by making a Capital Contribution
Section 4.04(e) hereof.  The maximum aggregate ARG Costs creditable under this subsection is $1,000,000.

 

(h)               
The Members and the Company contemplate that Cosan and Cosan personnel will provide services to the Company from time to
time, subject to a written services agreement(s) between Cosan and the Company that has been approved by the Board of Managers
per Section 2.11, and in connection therewith will incur unreimbursed direct costs and out-of-pocket expenses described and authorized
in such approved agreements creditable under this subsection (“Cosan Costs”). Within fifteen (15) days following
the end of each calendar quarter, ARG will provide the Board of Managers with a detailed, itemized report of Cosan Costs incurred
during the preceding quarter per each service agreement. Absent objection by any Manager within thirty (30) days following receipt
of a report, the Cosan Costs set forth in such report shall be deemed approved. The Members and the Company further agree that
the approved Cosan Costs will be credited, at Cosan’s election, either to Cosan’s Capital Account or against any Member
cash advance, credit or loan facility, or other Capital Contribution obligation Cosan may have under this Agreement; provided that,
if Cosan elects to credit Cosan Costs to its Capital Account such credit will not result in the issuance of additional Membership
Units to Cosan or otherwise increase its Percentage Interest and will not trigger any obligation by the other Members to match
this credit by making a Capital Contribution Section 4.04(e) hereof.  The maximum aggregate Cosan Costs creditable under this
subsection is $1,000,000.

 

(i)                 
The Members and the Company contemplate that Amyris and Amyris personnel will provide services to the Company from time
to time, subject to a written services agreement(s) between Amyris and the Company that has been approved by the Board of Managers
per Section 2.11, and in connection therewith will incur unreimbursed direct costs and out-of-pocket expenses described and authorized
in such approved agreements creditable under this subsection (“Amyris Costs”). Within fifteen (15) days following
the end of each calendar quarter, Amyris will provide the Board of Managers with a detailed, itemized report of Amyris Costs incurred
during the preceding quarter per each service agreement. Absent objection by any Manager within thirty (30) days following receipt
of a report, the Amyris Costs set forth in such report shall be deemed approved. The Members and the Company further agree that
the approved Amyris Costs will be credited, at Amyris’s election, either to Amyris’s Capital Account or against any
Member cash advance, credit or loan facility, or other Capital Contribution obligation Amyris may have under this Agreement; provided
that, if Amyris elects to credit Amyris Costs to its Capital Account such credit will not result in the issuance of additional
Membership Units to Amyris or otherwise increase its Percentage Interest and will not trigger any obligation by the other Members
to match this credit by making a Capital Contribution Section 4.04(e) hereof.  The maximum aggregate Amyris Costs creditable
under this subsection is $1,000,000. For clarity, this subsection (i) does not apply to either the IP License Agreement or to the
Supply Agreement.

 

Section 4.05.       
Status of Capital Contributions. (a) No Member shall receive any interest, salary or drawing with respect to its
Capital Contributions or its Capital Account or, except pursuant to any Related Party Transaction between the Company and a Member
that is in writing and approved by the Board of Managers as expressly provided herein, for services rendered on behalf of the Company
or otherwise in its capacity as a Member. Except as otherwise expressly provided herein, no Member will be permitted to borrow,
make an early withdrawal of, or demand or receive a return of any Capital Contributions. Under circumstances requiring a return
of any Capital Contributions, except as otherwise expressly provided in this Agreement, no Member will have the right to receive
property other than cash.

 

    	 	18	 

     

    

(b)               
Except as otherwise provided herein, the Members shall be liable only to make their Capital Contributions pursuant to this
Article IV, and no Member shall be required to lend any funds to the Company or, after a Member’s Capital Contributions have
been fully paid pursuant to this Article IV, to make any additional capital contributions to the Company. No Member shall
have any personal liability for the repayment of any Capital Contribution of any other Member or Transferee. A Member’s obligation
to contribute capital to the Company is conditional; payable only to the extent, and only in such amounts, required to be paid
to the Company pursuant to this Agreement. Notwithstanding any other provision in this Agreement, the obligations of the Members
pursuant to this Section 4.05 shall not be, and shall not be deemed to be, a guaranty, maintenance agreement or other similar agreement,
or under any circumstances utilized to satisfy the general obligations and liabilities of the Company.

 

Section 4.06.       
Capital Accounts. (a) An individual Capital Account shall be established and maintained for each Member.

 

(b)               
The Capital Account of each Member shall be maintained in accordance with the following provisions:

 

(i)                  
to each Member’s Capital Account there shall be credited all such Member’s Capital Contributions (including
all Prior Capital Contributions), such Member’s distributive share of Net Profits, any items in the nature of income or gain
that are specially allocated to such Member pursuant to Article VII and the amount of any Company liabilities that are assumed
by such Member or that are secured by any Company assets distributed to such Member;

 

(ii)                
to such Member’s Capital Account there shall be debited the amount of cash and the Asset Value of any Company assets
distributed to such Member pursuant to any provision of this Agreement, such Member’s distributive share of Net Losses, any
items in the nature of deductions or losses that are specially allocated to such Member pursuant to Article VII and the amount
of any liabilities of such Member that are assumed by the Company or that are secured by any property contributed by such Member
to the Company;

 

(iii)              
in the event all or some of a Member’s interest in the Company is sold in accordance with Article X, the Transferee
shall succeed to the Capital Account of the assignor to the extent it relates to the transferred interest; and

 

(iv)              
no Member shall be required to pay to the Company or to any other Member or Person any deficit in such Member’s Capital
Account upon dissolution of the Company or otherwise.

 

Article
V

Board of managers; managers and officers

 

Section 5.01.       
Management of the Company. The management of the Company shall be vested exclusively in the Board of Managers (the
“Board of Managers”), which may from time to time by resolution delegate authority to the Officers pursuant
to Section 5.12, to act on behalf of the Company. Except as otherwise agreed by the Members, no Member shall have any right or
authority to take any action on behalf of the Company or to bind or commit the Company with respect to Third Parties or otherwise.
Each Member hereby (a) specifically delegates to the Board of Managers its rights and powers to manage and control the business
and affairs of the Company in accordance with the provisions in Section 18-407 of the Act, and (b) revokes its right to bind the
Company, as contemplated by the

 

    	 	19	 

     

    

provisions of Section 18-402 of the Act. Each Manager shall have
the right to one (1) vote on all matters to be decided by the Board of Managers, except as otherwise provided for Related Party
Transactions.

 

Section 5.02.       
Board of Managers; Quorum Requirements. (a) So long as a Member owns at least sixteen percent (16%) of the total
number of Membership Units of the Company, such Member shall have the right to appoint one (1) individual, as set forth below,
to act on its behalf at meetings of the Board of Managers (each a “Manager”). So long as a Member owns at least
twenty-eight percent (28%) of the total number of Membership Units of the Company, such Member shall have the right to appoint
two (2) Managers. For clarity, if a Member owns less than sixteen percent (16%) of the total number of Membership Units of the
Company, such Member shall have no right to appoint any Manager. Initially, the Board of Managers of the Company shall be composed
of six (6) Managers. The President, who shall be designated by the Board of Managers from time to time, shall be a Board observer
(so long as such person holds such officer position) but shall not be considered a Manager and has no voting capacity on the Board
of Managers. The President also does not count toward establishing a quorum for any meeting of the Board of Managers. Furthermore,
as long as each of Amyris, Cosan US and ARG hold at least twenty-eight percent (28%) of the Membership Units of the Company, each
of Amyris, Cosan US and ARG shall alternate the appointment of the chairman of the Board of Managers (the “Chair”)
from one of its appointed Managers. For clarity, the Chair is treated as any other Manager for purposes of this Agreement (e.g.,
his or her vote carries no additional weight or significance). If one of the Members, at any time, becomes the Company’s
Controlling Member, then such Member shall always have the right to appoint the Chair while such Member remains the Company’s
Controlling Member. The Chair shall be appointed for a two (2) year term and shall preside over meetings of the Board of Managers
during his or her term of office. The first Chair following the Effective Date shall be appointed by Amyris. Any Managers appointed
by Amyris shall be designated as “Amyris Managers”, any Managers appointed by Cosan US shall be designated as
“Cosan US Managers”, and any Managers appointed by ARG shall be designated as “ARG Managers”.
Each of the Amyris Managers, the Cosan US Managers and the ARG Managers shall be officers or employees of Amyris or its Affiliates,
Cosan US or its Affiliates, or ARG or its Affiliates, respectively.

 

(b)               
A Manager appointed as provided herein shall serve for a two (2) year term or until such Manager’s successor is appointed
by the Member who appointed such Manager, including in the event of any retirement, removal, resignation or death of a Manager.
A Manager may be re-appointed to serve as a Manager of the Company, with no maximum number of consecutive terms.

 

(c)                
In addition to the Amyris Managers, the Cosan US Managers and the ARG Managers, the officers, directors, employees or other
professional representatives (including the accountants, attorneys and/or financial advisors) of Amyris, Cosan US and ARG and their
Affiliates shall be permitted to attend Board of Managers meetings as observers upon unanimous approval of the Managers.

 

(d)               
At all meetings of the Board of Managers, the presence of at least a majority of the Managers (whether present in person
or via phone or video conference) will be required for, and will constitute, a quorum for the transaction of business. However,
for as long as a Member holds at least twenty-eight percent (28%) of the Membership Units, the presence of at least one (1) of
its Managers is required for a quorum. A quorum must exist at all times of a meeting, including the reconvening of any meeting
that has been adjourned, for any action taken at such meeting to be valid. If no quorum is present at such duly called meeting
of the Board of Managers, the Managers present shall adjourn the meeting to a time not less than three (3) Business Days from the
time of such adjournment (taking into account any circumstances that may prevent any Manager from attending or participating in
such reconvened meeting), and shall promptly give written notice to the Managers of the time and place at which the meeting shall
reconvene. If no quorum is present at such reconvened meeting, the Managers present shall re-adjourn the

 

    	 	20	 

     

    

meeting to a time not less than three (3) Business
Days from the time of such adjournment (taking into account any circumstances that may prevent any Manager from attending or participating
in such reconvened meeting), and shall promptly give written notice to the Managers of the time and place at which the meeting
shall reconvene. The presence of any two (2) Managers at the re-adjourned meeting will constitute a quorum for such meeting, provided
that such two (2) Managers must have been appointed by different Members.

 

(e)                
At any time a Member ceases to own at least sixteen percent (16%) or at least twenty-eight percent (28%) of the total number
of Membership Units of the Company as applicable, such Member shall remove or cause the removal of one or more Managers appointed
by such Member so that the total number of Managers appointed by such Member complies with Section 5.02(a). Such removed Manager(s)
will not be replaced and the Board will operate with such decreased number of Managers, unless another Member(s) acquires sufficient
Membership Units to reach or surpass another sixteen percent (16%) ownership threshold and thereby qualifies to appoint an additional
Manager(s).

 

Section 5.03.       
Removal of Managers; Vacancies. A Member may at any time remove any Manager appointed by such Member pursuant to
Section 5.02, with or without cause. Except as required by Section 5.02(e), in the event a vacancy occurs on the Board of Managers
as a result of the retirement, removal, resignation or death of a Manager designated pursuant to Section 5.02, such vacancy shall
be filled by a person designated by the Member, the retirement, removal, resignation or death of whose designee or nominee created
the vacancy.

 

Section 5.04.       
Frequency of Meetings; Notice of Meetings; Agenda. (a) The Board of Managers shall hold ordinary meetings at such
time and place as shall be determined by the Board of Managers by Majority Vote. In the first month of every Fiscal Year, the Board
of Managers shall meet and approve the schedule of meetings for the starting Fiscal Year. In the absence of an agreement, the Board
of Managers shall hold ordinary meetings every quarter during each Fiscal Year. Special meetings of the Board of Managers, to be
held at the offices of the Company as herein provided (or such other place as shall be agreed by Majority Vote), shall be called
at the direction of the Chair. Per Section 5.08, a Manager may attend any meeting via phone or video conference, instead of attending
a meeting in-person.

 

(b)               
The Chair shall call all meetings of the Board of Managers by his or her own initiative or at the written request of any
Manager. The notice of meeting shall be delivered, either personally, by facsimile or by international mail. Failure by the Chair
to call any meeting requested by any Manager within five (5) calendar days from the date of receipt of the request by any Manager
allows any other Manager to call the requested meeting. The meetings of the Board of Managers shall be called at least eight (8)
calendar days prior to the date of each meeting. The notice of meeting shall specify the place, date and time of the meeting and
shall inform the detailed agenda, subject to the provisions of Section 5.04(c) below, and attach any proposal of resolutions,
any document prepared by the Company in advance of the meeting in order to support any resolution and all necessary documentation
related thereto. Notice may be waived in writing or by the attendance of all Managers. The attendance of a Manager at a meeting
shall constitute a waiver of notice of such meeting, except when the Manager attends the meeting for the express purpose of objecting
at the beginning thereof to the transaction of any business because the meeting has not been properly called or convened. Unless
otherwise agreed by Majority Vote, the Board of Managers’ meetings shall be held at the Company’s headquarters, but
per Section 5.08, a Manager may attend any meeting via phone or video conference, instead of attending a meeting in-person.

 

(c)                
With respect to quarterly meetings and non-quarterly non-emergency meetings, not later than five (5) Business Days before
each such meeting, the Chair shall deliver to each Manager, together with the notice of each such meeting, an agenda specifying
in reasonable detail the matters to be discussed at the applicable Board of Managers meeting, which agenda shall include any matters
the

 

    	 	21	 

     

    

Managers are required to discuss pursuant to the
terms of this Agreement; it being expressly forbidden to include generic items such as, for example, “general matters of
interest of the Company”. Moreover, no resolutions shall be passed on any matters that are not expressly included in the
agenda, as stated in the notice of such meeting, and any such resolutions shall be void and of no force and effect unless such
resolutions are approved by the unanimous vote of all of the Managers representing one hundred percent (100%) of the Board of Managers.

 

Section 5.05.       
Board of Managers Voting; Approval Matters. (a) Except with respect to Member Approval Matters pursuant to Section
5.06(e) and as delegated to the Officers pursuant to Section 5.12, the Board of Managers shall have the authority with respect
to all aspects of the operation of the Company. All decisions of the Board of Managers shall be made by Majority Vote, except that
resolutions on the following matters shall always require the approval of at least one (1) Manager appointed by each Member then-owning
at least twenty-eight percent (28%) of the Membership Units (each of the following enumerated matters being referred to as a “Board
of Managers Approval Matter”):

 

(i)                  
approval of any annual business and R&D plans and annual operating and investment budgets of the Company, as prepared
and recommended by the Officers, and material modifications thereto; provided, however, that the Officers will be
responsible for the execution of any approved annual business and R&D plans and operational and investment budgets;

 

(ii)                
any decision to make distributions to the Members, to the extent not otherwise required pursuant to Section 7.01, or any
decision not to make a quarterly distribution to the Members as required by Section 8.01(b);

 

(iii)              
incurrence, amending, modifying, refinancing or alteration of material terms by the Company of any indebtedness, which incurrence,
amendment, modification, refinancing or alteration was not contemplated by the approved annual business or R&D plans or in
the approved budget(s);

 

(iv)              
granting of guarantees, sureties or indemnities by the Company, except for those guarantees related to Company indebtedness
specified in the approved annual business plan or in the budget(s) and those indemnities required in connection with contracts
entered into in the ordinary course of business consistent with the approved business or R&D plans or approved budget(s);

 

(v)                
acquisition and/or disposal of or divestiture of any material assets outside of the ordinary course of business and not
contemplated by the approved annual business or R&D plans or approved budget(s);

 

(vi)              
any transaction that creates any non-capital expenditure by, or obligation of, the Company not contemplated by the approved
annual business or R&D plans or approved budget(s);

 

(vii)            
any capital expenditure not contemplated in the approved annual business plan, R&D plan, or budget(s) or which otherwise
exceeds the amount of such expenditure in the approved annual business or R&D plans or approved budget(s);

 

(viii)          
any non-compete or exclusivity obligation binding on the Company;

 

    	 	22	 

     

    

(ix)              
decision whether the Company (or any if its Subsidiaries) shall produce its own BioFene or purchase it from Amyris or Third
Parties, based on a substantiated proposal to be prepared and recommended by the Officers;

 

(x)                
decision for the Company (or any if its Subsidiaries) to build a manufacturing facility for the production of the Company’s
products and the site for such facility, based on a substantiated proposal to be prepared and recommended by the Officers;

 

(xi)              
the sending of any notice requesting Capital Contributions or cash advances or other credit or loan facilities to a Member
pursuant to Section 4.04; and

 

(xii)            
the entering into of any contract, arrangement, understanding or other similar agreement with respect to any of the foregoing
(i)-(xi).

 

Section 5.06.       
Members’ Meetings; Notice; Agenda; Voting; Member Approval Matters. (a) Members’ meetings shall be annual
or special. The Members acknowledge that an annual Members’ meeting shall be held within the four (4) months following the
close of each Fiscal Year. Furthermore, special Members’ meetings may be held whenever and insofar as the business of the
Company so requires. The Members’ meetings may be called at any time by the Chair, by his or her own initiative or at the
written request of any Member or otherwise as contemplated by the Act. Failure by the Chair to call any such meeting requested
by any Member within five (5) calendar days from the date of receipt of the pertinent request shall allow such Member to call the
applicable meeting. Subject to the applicable Law, the call notices shall be delivered to each Member at least eight (8) calendar
days in advance of the date scheduled for the holding of each Members’ meeting and shall contain information on the place,
date and time the relevant Members’ meeting will be held and the detailed agenda, as well as any documentation that shall
be used to support the matters to be discussed at such meeting, subject to the provisions of Subsection (b) below. Unless otherwise
agreed by the Members, Members’ meetings shall be held at the Company’s headquarters, but per Section 5.08, a Member
may attend any meeting via phone or video conference, instead of attending a meeting in-person.

 

(b)               
The call notice to the Members’ meeting shall set forth, in detail, the relevant agenda, which agenda shall include
any matters the Members are required to discuss pursuant to the terms of this Agreement; it being expressly forbidden to include
generic items such as, for example, “general matters of interest of the Company”. Moreover, no resolutions shall be
passed on any matters that are not expressly included in the agenda set forth in the call notice, under penalty of being deemed
void, except for (i) the resolutions that are approved by the unanimous vote of all of the Members representing one hundred percent
(100%) of the Membership Units; or (ii) as provided in the Act.

 

(c)                
At all meetings of Members, the presence of the holder(s) of at least a majority of the Membership Units (whether present
in person or via phone or video conference) will be required for, and will constitute, a quorum for the transaction of business.
However, for as long as Amyris, Cosan US and ARG each hold at least twenty-eight percent (28%) of the Membership Units, the presence
of each of Amyris, Cosan US and ARG is required to constitute a quorum for a Members’ meeting. A quorum must exist at all
times of a Member meeting, including the reconvening of any Member meeting that has been adjourned, for any action taken at such
meeting to be valid. If the required quorum is not present at a duly called Members’ meeting, the meeting shall be adjourned
to a time not less than three (3) Business Days from the time of such adjournment (taking into account any circumstances that may
prevent a Member from attending or participating in such reconvened meeting) and written notice shall be promptly given to the
Members of the time and place at which the meeting shall reconvene. If the required quorum is not met at such reconvened meeting,
that meeting shall be re-adjourned to a time not less than three (3)

 

    	 	23	 

     

    

Business Days from the time of such adjournment
(taking into account any circumstances that may prevent a Member from attending or participating in such reconvened meeting) and
written notice shall be promptly given to the Members of the time and place at which the meeting shall reconvene. The presence
of at least a majority of the Membership Units of the Company at the re-adjourned meeting will constitute a quorum.

 

(d)               
Each Membership Unit shall have the right to one (1) vote on all matters to be decided by Members. Except for those special
matters provided for by applicable Law or referred to in Subsection (e) below, resolutions at Members’ meetings shall be
passed by a majority vote of the Membership Units present at the meetings or, in lieu of a meeting, by written consent of at least
that number of Member Units, as the case may be, required to approve the matter at a meeting.

 

(e)                
Notwithstanding anything contained in this Agreement to the contrary, resolutions on the following matters shall always
require the approval of at least seventy-five percent (75%) of the Membership Units (each of the following enumerated matters being
referred to as a “Member Approval Matter”):

 

(i)                  
any proposed funding of, or financing for, the Company, whether from the Members or third parties, beyond the Prior Capital
Contributions and the ARG Initial Capital Contribution;

 

(ii)                
admission of any new Member, except as expressly otherwise permitted in this Agreement;

 

(iii)              
the authorization, issuance, sale, acquisition, repurchase or redemption by the Company of any Membership Units or other
equity interest (or option, warrant, conversion or similar right with respect to any equity interest) in or of the Company, or
any change in the characteristics, rights and privileges of the Membership Units;

 

(iv)              
redemption, amortization or repurchase of Membership Units or any convertible securities, or changes in the conditions applicable
to redemption, amortization or repurchase of Membership Units or convertible securities;

 

(v)                
any merger or other form of corporate reorganization, or any spin-off or drop down of assets and liabilities, involving
the Company; provided however that in connection with the sale of the Company, whether through a merger or consolidation in which
the Company is a constituent party, or the sale, transfer or other disposition of all or substantially all of the assets of the
Company (a “Sale Transaction”), except a Sale Transaction in which the net proceeds to be received by each Member
is sufficient to return at least two (2) times each Member’s cumulative Capital Contributions (a “Qualified Sale
Transaction”) which transaction shall require approval of only a simple majority of the Membership Units and upon such
majority approval any Member who abstained or voted against such Qualified Sale Transaction shall be deemed to have voted all of
its Membership Units to approve such Qualified Sale Transaction;

 

(vi)              
change in accounting or tax principles or policies with respect to the financial statements, except as required by GAAP
or by applicable Law;

 

(vii)            
change of corporate type or conversion into any other form of entity;

 

    	 	24	 

     

    

(viii)          
the conduct by the Company of any business other than, or the engagement by the Company in any transaction not substantially
related to, the Company Business;

 

(ix)              
the dissolution, liquidation or winding up of the Company or the commencement of a voluntary proceeding seeking reorganization
or other similar relief;

 

(x)                
approval of any stock option, profit sharing or similar compensation plan and any amendments thereto;

 

(xi)              
approval of the Company’s initial public offering of any equity or convertible debt securities;

 

(xii)            
the amendment or restatement of the Certificate or other constituent documents of the Company;

 

(xiii)          
any change in the number of, or method of designating, Managers on the Board of Managers;

 

(xiv)          
the continuing of the Company under the Laws of another jurisdiction; and

 

(xv)            
the entering into of any contract, arrangement, understanding or other similar agreement with respect to any of the foregoing
(i)-(xiv).

 

Section 5.07.       
Action by Written Consent. Except as expressly otherwise provided in Sections 5.05 or 5.06(e), any action required
or permitted to be taken by the Members or the Board of Managers, either at a meeting or otherwise, may be taken without a meeting
if the Members or the Managers, as the case may be, consent in writing to such action and the writing or writings are filed with
the minutes of proceedings of the Members or the Managers, as the case may be. For such written consent to be effective, at least
that number of Member Units or Managers and that type of Member or Manager (e.g., ≥28% holder), as the case may be, required
to approve the matter shall also be required to execute such written consent. Written notice of the action to be taken by written
consent will be given by the Chair to all Members or the Managers, as the case may be, at least five (5) Business Days prior to
the effectiveness of any such action.

 

Section 5.08.       
Telephonic Meetings. Members and Managers may participate in a meeting by means of a conference telephone or similar
communications equipment through which all persons participating in the meeting can hear each other, and such participation in
a meeting shall constitute presence in person at such meeting.

 

Section 5.09.       
Company Minutes. The decisions and resolutions of the Members and the Board of Managers shall be reported in minutes,
which shall state the date, time and place of the meeting (or the date of the written consent in lieu of meeting), the Members
or Managers, as the case may be, present at the meeting, the resolutions put to a vote (or the subject of a written consent) and
the results of such voting (or written consent). The minutes shall be entered in a minute book kept at the principal office of
the Company, and a copy of the minutes shall be provided to each Member or Manager, as the case may be.

 

Section 5.10.       
Manager Compensation and Reimbursement. Only Managers that are neither (a) Officers nor (b) employees or shareholders
of any of Amyris, Cosan US or ARG or of their respective Affiliates, shall be entitled to receive any compensation for their service
as a Manager. The compensation of any such Managers shall be based on market practices, not exceeding the annual gross

 

    	 	25	 

     

    

amount approved by the Members. Moreover, all Managers shall be
entitled to be reimbursed by the Company for any reasonable travel expenses arising from the performance of their activities and
functions.

 

Section 5.11.       
Audit Committee. The Company shall establish and maintain an Audit Committee, which shall consist of three (3) Managers
of the Board of Managers - one Manager nominated by each of Amyris, Cosan US and ARG.

 

Section 5.12.       
Officers. (a) The Company shall have certain employees or agents appointed by the Board of Managers, per Section
5.05, serve as the officers of the Company (the “Officers”). Such Officers will include a president (the “President”)
and may include, at the Board of Managers’ discretion, one or more vice presidents, a chief financial officer, a treasurer,
one or more assistant treasurers, chief operations officer, chief technical officer, a secretary, and/or one or more assistant
secretaries. All Officers must be professionals with proven qualification and experience in their respective areas of responsibility,
as determined by the Board of Managers. The Board of Managers will establish the annual compensation for each Officer. The Officers
shall operate under the supervision and direction of the Board of Managers and generally obtain the written approval of the Board
of Managers prior to taking any actions relating to or on behalf of the Company. Notwithstanding the foregoing, the Officers shall,
subject to Subsection (b) below, maintain powers to perform the following tasks without prior written approval of the Board of
Managers:

 

(i)                  
designate one or more banks or similar financial institutions as depositories of the funds of the Company;

 

(ii)                
open, maintain and close general and special accounts with any such depositories;

 

(iii)              
deposit in such accounts funds of the Company as the Officers deem necessary or advisable;

 

(iv)              
sign or countersign checks, drafts, or other orders (including authorizations of electronic transfers) for the payment of
money of the Company against any funds deposited in any of such accounts, for amounts up to US$250,000;

 

(v)                
approve the use of facsimile signatures for the signing or countersigning of checks, drafts or other orders for the payment
of money, and to enter into such agreements as banks and similar financial institutions customarily require as a condition for
permitting the use of facsimile signatures;

 

(vi)              
make such general and special rules and regulations with respect to such accounts, respecting the funding limits mentioned
in items (iii) and (iv) above as such Officers deem necessary or advisable for the Company and execute and certify any customary
printed blank signature card forms in order to exercise conveniently the authority granted by this Section 5.12(a);

 

(vii)            
negotiate and execute equipment or office lease agreements and related documents of up to US$250,000;

 

(viii)          
negotiate and execute ordinary agreements and/or contracts, bids and proposals that do not exceed the amount of US$250,000
and that shall not last longer than twelve (12) months; and

 

    	 	26	 

     

    

(ix)              
approve, sign, execute and implement any transaction contemplated by, or consistent with, the annual business or R&D
plans or budget(s) approved by the Board of Managers, up to the amounts provided therein;

 

(x)                
day-to-day management, administration and oversight of the Company’s business and affairs and all decisions related
to the Company’s daily activities, including development, production, sales and distribution (except to the extent such decisions
are the responsibility of a particular Member as set forth in this Agreement);

 

(xi)              
preparation of the Company’s annual business plan or any operational and investment budgets and recommendation to
the Board of Managers;

 

(xii)            
implementation of the Company’s annual business plan and operational and investment budgets that are approved by the
Board of Managers;

 

(xiii)          
preparation of the Company’s R&D plan and amendments thereto under any R&D agreement;

 

(xiv)          
preparation of an R&D and commercialization plan regarding any BioFene-derived Additive the Officers would like the
Company to pursue;

 

(xv)            
preparation of a substantiated proposal regarding whether the Company (or any of its Subsidiaries) shall produce its own
BioFene or purchase it from Amyris or Third Parties, and recommending a decision to the Board of Managers;

 

(xvi)          
negotiating any supply agreement, off-take agreement or any agreements related to the actual production and sale of the
Company’s products;

 

(xvii)        
preparation of a substantiated proposal regarding whether the Company (or any of its Subsidiaries) shall build a manufacturing
facility for the production of the Company’s products and the site for such facility, and recommending a decision to the
Board of Managers;

 

(xviii)      
determination of the products to be manufactured by or on behalf of the Company as well as the volumes to be produced and
the pricing thereof;

 

(xix)          
compromise, waive, settle and sign commitments, assume obligations, invest funds, acquire, dispose, mortgage, pledge or
otherwise create a lien on the Company’s assets, in each case that do not exceed the amount of US$250,000;

 

(xx)            
approve all necessary measures and perform the ordinary acts of a management, financial and economic nature in accordance
with the provisions set forth in this Agreement and the resolutions approved by the Members and the Board of Managers meetings;
and

 

(xxi)          
prepare the Company’s financial statements and be responsible for the bookkeeping of the Company’s corporate,
tax and accounting books and records.

 

(b)               
(A) In the event that the Company has an opportunity or an obligation to perform any of the acts listed in items (iv), (vii),
(viii) and (xix) of Section 5.12(a) hereto involving an amount greater than US$250,000 and up to US$1,000,000, the Officers shall
be authorized to perform such acts after receiving written authorization from three (3) Managers, constituting one Manager appointed
by each of Amyris, Cosan US and ARG, without the requirement to have a prior written approval of the

 

    	 	27	 

     

    

Board of Managers or a meeting of the Board of
Managers for such purpose. In this case, the three (3) Managers shall send a letter, fax or e-mail to the Officers of the Company
confirming his or her approval for the performance of such act. A copy of such confirmations by the Managers will be kept with
the Company records with regard to the relevant act. (B) (i) All checks, drafts, or other orders (including authorizations of electronic
transfers) for the payment of money by the Company and (ii) any contract (other than a confidentiality agreement or a material
transfer agreement) to which the Company will be a party shall require the signature of two (2) Officers to bind the Company, preferably
one of which is always the President.

 

(c)                
The Officers shall at all times be subject to the supervision and control of the Board of Managers and shall conform to
policies and programs established by the Board of Managers, and the scope of the Officers’ authority shall be limited to
such policies and programs. Except as otherwise authorized by the Members, no other Person shall have authority to bind or act
for, or assume any obligations or responsibilities on behalf of, the Company. The President shall keep the Board of Managers informed
as to all matters of concern to the Company.

 

Section 5.13.       
Language. The meetings of the Board of Managers shall be held in English, with simultaneous translation to Portuguese
if requested by any Member. All materials to be presented at such meeting, the minutes of such meetings, as well as any action
of the Board of Managers taken by written consent, shall be drafted in English, together with a Portuguese translation, but the
English version of such materials, minutes and written consents shall prevail between the parties.

 

Section 5.14.       
D&O Insurance. The Company shall contract, with a reputable insurer, at its own cost, in favor of the Managers
and the Officers that shall so desire, directors and officers liability insurance, consistent with market terms and conditions.

 

Section 5.15.       
Subsidiaries. The Managers shall cause the Company to exercise its voting rights in its Subsidiaries in accordance
with this Agreement. Therefore, any matter that would be deemed to be a Member Approval Matter or a Board of Managers Approval
Matter, when it relates to a Subsidiary, shall be treated as a Board of Managers Approval Matter, and, therefore, before the Company
exercises its voting rights in the Subsidiary in favor of any such matter, the matter shall be voted at a Company’s Board
of Managers’ meeting and receive the necessary approval required for any Board of Managers Approval Matter.

 

Section 5.16.       
Deadlock of Members or Managers. (a) Declaration of a Deadlock. Subject to Subsection (c) below, at any time
after the date hereof, a Member may declare a deadlock by delivering a written notice of the deadlock (“Deadlock Notice”)
to the other Members (each such case, a “Deadlock”) if:

 

(i)                  
the Board of Managers is unable, at any two (2) consecutive meetings, within fifteen (15) days of one another and called
in accordance with Section 5.04 above, to reach a decision concerning a Deadlock Issue (to the extent such Deadlock Issue is required
to be acted on by the Board of Managers); or

 

(ii)                
the Members are unable, for a period of more than thirty (30) days, to reach a decision concerning a Deadlock Issue (to
the extent such Deadlock Issue constitutes a Member Approval Matter).

 

(b)               
Non-Deadlock Matters. A Member may not declare a Deadlock (i) for failure to achieve a quorum at a duly convened
Board of Managers meeting if such failure results from the failure of such Member’s designated Managers to attend such meeting
or if such failure results from the fact that such Member’s designated Managers have refrained from voting either for or
against the relevant matter;

 

    	 	28	 

     

    

(ii) for failure to achieve approval for a Member
Approval Matter if such failure results from the fact that such Member has refrained from voting either for or against the relevant
matter; (iii) by virtue of its disapproval of any proposal by the other Member unless such disapproval of such proposal is made
in good faith; or (iv) in respect of any proposal it has made unless such proposal is delivered in good faith.

 

(c)                
Deadlock Question Arbitration. In the event a Deadlock is declared by a Member (the “Declaring Member”)
and another Member(s) reasonably believes that such Member was not entitled to make such declaration pursuant to this Section 5.16,
such other Member(s) may deliver, within five (5) Business Days of such declaration, to the Declaring Member a detailed
written request for an expedited arbitration, to be held pursuant to the provisions of Section 14.08 and this Section 5.16(c) to
determine the question of whether the Declaring Member was entitled to make such declaration.

 

(i)                  
Within five (5) Business Days after delivery of such request, the Members will meet to select one arbitrator to decide and
settle the question whether the Declaring Member was entitled to declare a Deadlock pursuant to this Section 5.16 (such question,
the “Deadlock Question”). Except as provided herein or as otherwise agreed by the Members, such arbitrator shall
decide no other question. The Members will select the arbitrator at random by a drawing from the list of available arbitrators
provided by the Arbitration Chamber and shall immediately contact such nominee by telephone to confirm such nominee’s acceptance
as arbitrator. If such nominee declines to be the arbitrator, then immediately upon such notice (or, in the event that, by the
close of business on the date of selection, such nominee either has not been contacted or has not accepted such appointment for
whatever reason, then at the opening of business on the next succeeding Business Day), the Members shall, in accordance with the
preceding sentence, select at random by drawing another arbitrator from the same list and shall proceed to confirm such nominee’s
acceptance as arbitrator and shall repeat such process until a nominee accepts the appointment.

 

(ii)                
Within five (5) Business Days following the arbitrator’s acceptance, the arbitrator shall convene the arbitral proceedings
at the place of arbitration provided for in Section 14.08(d) hereunder and shall conduct such proceedings in such manner as
such arbitrator considers appropriate, but in accordance with the rules of the Arbitration Chamber and any applicable Law, provided
that the Members are treated with equality and that each Member is given a full and fair opportunity in accordance with the Arbitration
Rules to present its ease. The arbitrator shall use his/her best efforts to resolve the Deadlock Question within five (5) Business
Days after the arbitration is first convened. The resolution shall be final (not subject to appeal of any nature whatsoever) and
binding on the Members, shall state the reasons upon which it is based, shall be signed by the arbitrator and shall contain the
date on which, and place where, it was made.

 

(iii)              
The arbitrator shall be entitled to reasonable fees, taking into account the time spent by the arbitrator, the relative
complexity of the issues considered and the scheduling conditions hereby imposed by the Members. Notwithstanding anything herein
to the contrary, all of the costs and expenses of the arbitration (including the reasonable fees and expenses of counsel of the
prevailing Member(s)) in connection with such arbitration shall be borne by the non-prevailing Member(s) pro rata in accordance
with their respective ownership of the total number of Membership Units owned by such non-prevailing Member(s). For the avoidance
of doubt and notwithstanding anything herein to the contrary, any dispute, controversy or claim between or among the Members relating
to a Deadlock Question shall be resolved exclusively in accordance with this Section 5.16(c).

 

    	 	29	 

     

    

(d)               
Escalation. Each Member agrees that immediately following delivery of a Deadlock Notice (the “Declaration”)
or, if such delivery is challenged pursuant to Section 5.16(c), immediately following the arbitrator’s determination that
a Deadlock was properly declared, representatives of the senior management of each of Amyris, Cosan US and ARG, or any of their
respective Affiliates (which representatives shall in each case not be Managers or Officers of the Company or of any of its Subsidiaries)
shall endeavor in good faith, for a period of thirty (30) days immediately following such delivery or decision (the “Negotiation
Period”), to reach a mutually satisfactory resolution of the Deadlock Issue (the “Applicable Deadlock Issue”).

 

(e)                
Deadlock Mediation. If by the end of the Negotiation Period the Members have been unable to reach a mutually satisfactory
resolution of the Applicable Deadlock Issue, then the Members shall appoint an impartial Third Party (“Mediator”),
for a period of thirty (30) days (the “Deadlock Mediation Period”), to assist the Members to reach a mutually
satisfactory resolution of the Applicable Deadlock Issue. The Mediator shall be chosen upon mutual consent of the Members among
trusted individuals and with no relations whatsoever to the Members or any of their Affiliates, and the costs and expenses for
hiring such Mediator shall be shared equally by the Members.

 

(f)                
Buy/Sell Option. If by the end of the Deadlock Mediation Period the Members have been unable to reach a mutually
satisfactory resolution of the Applicable Deadlock Issue because the approval of one Member (or such Manager(s) designated by such
Member) holding at least twenty-eight percent (28%) of the Membership Units does not approve the proposed resolution relating to
the Applicable Deadlock Issue (the “Initiating Member”), then commencing on the first Business Day following
the expiration of the Deadlock Mediation Period (the “Termination Date”), the Initiating Member shall be required
to:

 

(i)                  
deliver a written notice (the “Offer Notice”) to the other Members (the “Deciding Members”)
specifying in such notice that the Initiating Member offers to sell all, but not less than all, of its Membership Units in the
Company to the Deciding Members on a pro rata basis upon the terms and conditions specified in reasonable detail in the Offer Notice,
at a price equal to the greater of the Fair Market Value of the Membership Units as hereinafter determined, or an amount equal
to the full return such Member’s Capital Account plus a 5% per annum return compounded annually the “Sale Price”);

 

(ii)                
upon receipt of an Offer Notice, the Members shall promptly determine, per Exhibit B, the Fair Market Value of the Membership
Units; and

 

(iii)              
each Deciding Member shall have ten (10) Business Days after receipt of the final Sale Price to deliver a written notice
(the “Response Notice”) to the Initiating Member, which notice shall indicate that such Deciding Member agrees
to buy its pro rata portion of the Membership Units from the Initiating Member, within thirty (30) days of the Initiating Member’s
receipt of the Response Notice, at the Sale Price and upon the terms and conditions specified in the Offer Notice. Provided that
all Deciding Members have delivered a Response Notice (or a single Deciding Member delivers a Response Notice, after otherwise
agreeing with the other Deciding Members, to buy 100% of the Initiating Member’s Membership Units), the Initiating Member
shall sell, and such Deciding Member(s) shall purchase, all but not less than all of the Initiating Member’s Membership Units,
within thirty (30) days of the Initiating Member’s receipt of the Response Notice, at the Sale Price and upon the terms and
conditions specified in the Offer Notice.

 

    	 	30	 

     

    

(g)                
An Offer Notice shall only be valid if delivered on or after the Termination Date, and any Offer Notice delivered prior
to such time shall be deemed null and void and have no force or effect. Each Member agrees that if a Response Notice is not sent
by all Deciding Members (or by a single Deciding Member if, after otherwise agreeing with the other Deciding Members, buying 100%
of the Initiating Member’s Membership Units) or if the Deciding Members collectively have not otherwise agreed to buy 100%
of the Initiating Member’s Membership Units within ten (10) Business Days after receipt of the final Sale Price determination,
then any Response Notice sent by a Deciding Member will be void and the Initiating Member shall be entitled to sell all, but not
less than all, of its Membership Units in the Company to a third party; provided that (i) such third party is not a Competitor
of the Company, and (ii) if the purchase price offered to the third party is less than the final Sale Price and/or the other terms
and conditions are more favorable than specified in the Offer Notice, then the Initiating Member shall be required to offer such
Membership Units at such price, terms and conditions as offered to the third party in accordance to Section 4.16(f) above. Until
such sale of such Initiating Member’s Membership Units, the Members shall continue to discuss in good faith such Applicable
Deadlock Issue until it is satisfactorily resolved but shall cause the Company to conduct its business during such time as if the
matter that raised the Applicable Deadlock Issue had not been approved by the Managers or the Members, as the case may be.

 

Article
VI

Change of control event

 

Section 6.01.       
Change of Control Event. (a) A “Change of Control Event” shall occur if, after the Effective Date:

 

(i)                  
with respect to Amyris, Cosan US or ARG, a Change of Control of Amyris occurs, a Change of Control of Cosan US occurs, or
a Change of Control of ARG occurs, respectively; and

 

(ii)                
the Members which have not undergone the Change of Control described in clause (i) above are able to reasonably substantiate,
within sixty (60) days afterwards, that the Change of Control will likely have a Material Adverse Effect on the Company Business.

 

Section 6.02.       
Change of Control Event Consequence. If a Change of Control Event occurs, then the Member that is the object of such
Change of Control Event will no longer be entitled to exercise, or benefit from, the Right of First Refusal and/or the Tag Along
Right in Section 10.02(c) with regard to other Members’ proposed transfers of Membership Units.

 

Article
VII

Allocations; tax matters

 

Section 7.01.       
Allocations. (a) The Company’s Net Profits and Net Losses, subject to the special allocations pursuant to Sections
7.02 and 7.03, shall be allocated for each Fiscal Year to the Members as follows:

 

(i)                  
Net Profits shall be allocated:

 

(A)               
first, to offset previous allocations of Net Loss pursuant to Sections 7.01(a)(ii)(B) and (C)) hereof on a cumulative basis,
in reverse order of the priorities described therein; and

 

    	 	31	 

     

    

(B)               
second, the balance to the Members in proportion to their respective Membership Units;

 

(ii)                
Net Losses shall be allocated:

 

(A)               
first, to offset previous allocations of Net Income pursuant to Section 7.01(a)(i)(B), to the extent such Net Income has
not been distributed;

 

(B)               
second, to the Members in proportion to their positive Capital Account balances until such Capital Account balances have
been reduced to zero; and

 

(C)               
third, the balance to the Members in proportion to their respective Membership Units.

 

(b)               
Notwithstanding anything to the contrary in Section 7.01(a), in the event of the winding up and termination of the Company
pursuant to Section 11.05 hereof, Net Profit and Net Loss (and items of gross income, loss or deduction, if necessary), including
gain or loss realized by the Company upon the sale (or deemed sale) of its property or assets, shall be allocated to the extent
possible, subject to the special allocations of Sections 7.02 and 7.03, in a manner so as to cause the Capital Accounts of the
Members to equal the amounts due the respective Members pro rata in accordance with their respective Membership Units consistent
with the provisions of Section 11.05.

 

Section 7.02.       
Special Allocations. (a) Minimum Gain Chargeback. Except as otherwise provided in Section 1.704-2(f) of the
Regulations, notwithstanding any other provision of this Article VII, if there is a net decrease in partnership minimum gain during
any Fiscal Year, each Member shall be specially allocated items of Company income and gain for the Fiscal Year (and, if necessary,
subsequent Fiscal Years) in an amount equal to such Member’s share of the net decrease in partnership minimum gain, determined
in accordance with Regulations Section 1.704-2(g). Allocations pursuant to the previous sentence shall be made in proportion to
the respective amounts required to be allocated to each Member pursuant thereto. The items to be so allocated shall be determined
in accordance with Sections 1.704-2(f)(6) and 1.704-2(j)(2) of the Regulations. This Section 7.02(a) is intended to comply with
the minimum gain chargeback requirement in Section 1.704-2(f) of the Regulations and shall be interpreted consistently therewith.

 

(b)               
Minimum Gain Chargeback. Except as otherwise provided in Section 1.704-2(i)(4) of the Regulations, notwithstanding
any other provision of this Article VII, if there is a net decrease in partner nonrecourse debt minimum gain attributable to a
partner nonrecourse debt during any Fiscal Year, each Member who has a share of the partner nonrecourse debt minimum gain attributable
to such partner nonrecourse debt, determined in accordance with Section 1.704-2(i)(5) of the Regulations, shall be specifically
allocated items of Company income and gain for such Fiscal Year (and, if necessary, subsequent Fiscal Years) in an amount equal
to such Member’s share of the net decrease in partner nonrecourse debt minimum gain attributable to such partner nonrecourse
debt, determined in accordance with Section 1.704-2(i)(4) of the Regulations. Allocations pursuant to the previous sentence shall
be made in proportion to the respective amounts required to be allocated to each Member pursuant thereto. The items to be so allocated
shall be determined in accordance with Sections 1.704-2(i)(4) and 1.704-2(j)(2) of the Regulations. This Section 7.02(b) is intended
to comply with the minimum gain chargeback requirement in Section 1.704-2(i)(4) of the Regulations and shall be interpreted consistently
therewith.

 

(c)                
Qualified Income Offset. In the event any Member unexpectedly receives any adjustments, allocations or distributions
described in Section 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) or 1.704-1(b)(2)(ii)(d)(6) of the Regulations, items of Company
income and gain shall be specially allocated to each such Member in an amount and manner sufficient to eliminate, to the extent

 

    	 	32	 

     

    

required by the Regulations, the Adjusted Capital
Account Deficit of such Member as quickly as possible, provided that an allocation pursuant to this Section 7.02(c) shall
be made only if and to the extent that such Member would have an Adjusted Capital Account Deficit after all other allocations provided
for in this Article VII have been tentatively made as if this Section 7.02(c) were not in the Agreement.

 

(d)               
Gross Income Allocation. In the event any Member has a deficit Capital Account at the end of any Fiscal Year which
is in excess of the sum of (i) the amount such Member is obligated to restore pursuant to any provision of this Agreement, and
(ii) the amount such Member is deemed to be obligated to restore pursuant to the penultimate sentences of Sections 1.704-2(g)(1)
and 1.704-2(i)(5) of the Regulations, each such Member shall be specially allocated items of Company income and gain in the amount
of such excess as quickly as possible; provided that an allocation pursuant to this Section 7.02(d) shall be made only if
and to the extent that such Member would have an Adjusted Capital Account Deficit in excess of such sum after all other allocations
provided for in this Article VII have been made as if Section 7.02(c) and this Section 7.02(d) were not in the Agreement.

 

(e)                
Nonrecourse Deductions. Nonrecourse deductions for any Fiscal Year shall be allocated to the Members pro rata
in accordance with the number of Membership Units owned by such Member.

 

(f)                
Partner Nonrecourse Deductions. Partner nonrecourse deductions for any Fiscal Year shall be specially allocated to
the Member who bears the economic risk of loss, or to the Members in the proportions in which they bear the economic risk of loss,
with respect to the partner nonrecourse debt to which such partner nonrecourse deductions are attributable in accordance with Section
1.704-2(i)(1) of the Regulations.

 

(g)                
Net Loss Limitation. The Net Losses and items of deduction or loss allocated pursuant to Sections 7.01 and 7.02 shall
not exceed the maximum amount of Net Losses and items of deduction and loss that can be so allocated without causing any Member
to have an Adjusted Capital Account Deficit at the end of any Fiscal Year. All Net Losses and items of deduction or loss in excess
of the limitations set forth in this Section 7.02 shall be allocated to the Members who do not have Adjusted Capital Account Deficits
in proportion to their Adjusted Capital Accounts. To the extent that Members have been allocated Net Losses pursuant to the previous
sentence, prior to any allocation of Net Profits pursuant to Section 7.01(a) such Members shall be allocated Net Profits pro
rata in proportion to such allocated Net Losses.

 

Section 7.03.       
Curative Allocations. The allocations set forth in Section 7.02 hereof (the “Regulatory Allocations”)
are intended to comply with certain requirements of the Regulations. It is the intent of the Members that, to the extent possible,
all Regulatory Allocations shall be offset either with other Regulatory Allocations or with special allocations of other items
of Company income, gain, loss or deduction pursuant to this Section 7.03. Therefore, notwithstanding any other provision of this
Article VII (other than the Regulatory Allocations), the Members shall make such offsetting special allocations of Company income,
gain, loss or deduction in whatever manner they determine appropriate so that, after such offsetting allocations are made, each
Member’s Capital Account balance is, to the extent possible, equal to the Capital Account balance such Member would have
had if the Regulatory Allocations were not part of the Agreement and all Company items were allocated pursuant to this Article VII
without regard to the Regulatory Allocations. In exercising their discretion under this Section 7.03, the Members shall take
into account future Regulatory Allocations under Section 7.02 that, although not yet made, are likely to offset other Regulatory
Allocations previously made under Section 7.02.

 

Section 7.04.       
Tax Allocations. (a) In accordance with Code Section 704(c) and the Regulations thereunder, income, gain, loss, and
deduction with respect to any property contributed to the

 

    	 	33	 

     

    

capital of the Company shall, solely for tax purposes, be allocated
among the Members so as to take account of any variation between the adjusted basis of such property to the Company for United
States federal income tax purposes and its initial Asset Value (computed in accordance with the definition of Asset Value).

 

(b)       In
the event the Asset Value of any Company asset is adjusted pursuant to subparagraph (ii) of the definition of Asset Value, subsequent
allocations of income, gain, loss, and deduction with respect to such asset shall take account of any variation between the adjusted
basis of such asset for United States federal income tax purposes and its Asset Value in the same manner as under Code Section
704(c) and the Regulations thereunder.

 

(c)       Any
elections or other decisions relating to such allocations shall be made by the Tax Matters Partner in any manner that reasonably
reflects the purpose and intention of this Agreement. Allocations pursuant to this Section 7.04 are solely for purposes of United
States federal, state, and local taxes and shall not affect, or in any way be taken into account in computing, any Member’s
Capital Account or share of Net Profit, Net Loss, other items, or distributions pursuant to any provision of this Agreement.

 

(d)       Except
as otherwise provided in this Agreement, all items of Company gain, loss, deduction, and any other allocations not otherwise provided
for shall be divided among the Members in the same proportions as they share Net Profit or Net Loss, or amounts specially allocated
pursuant to Section 7.02 or 7.03 hereof, as the case may be, for the Fiscal Year.

 

Section 7.05.       
Tax Matters. (a) The Company shall file as a partnership for United States federal and state income tax purposes.

 

(b)               
All decisions with respect to Taxes of the Company shall be made by the Board of Managers in accordance with the provisions
of Article V.

 

(c)                
Amyris shall (i) be the initial tax matters partner within the meaning of Section 6231 of the Code and any comparable provision
of state or local income tax Law, and (ii) the initial “partnership representative” for purposes of Section 6223 and
Section 6231 of the Code, as amended by the Revised Partnership Audit Procedures (the designated roles in clauses (i) and (ii)
above shall collectively be referred to herein as the “Tax Matters Partner”). A different Tax Matters Partner
may be selected at any time by Members representing at least seventy-five percent (75%%) of the Membership Units.

 

(d)               
Tax audits, controversies and litigations shall be conducted under the direction of the Tax Matters Partner, in consultation
with the Company’s attorneys and/or accountants, and if desired by a Member with the Member’s attorneys and/or accountants.
The Tax Matters Partner shall furnish promptly to the Company which shall furnish promptly to the other Members a copy of all notices
or other written communications received by the Tax Matters Partner from the Internal Revenue Service or any state of local taxing
authority. The Tax Matters Partner shall submit to the Board of Managers, for their review, comment, and approval, any settlement
or compromise offer with respect to any disputed item, including any item of income, gain, loss, deduction or credit of the Company.

 

(e)                
The Tax Matters Partner shall cause all tax returns of the Company to be timely prepared in consultation with the Company’s
attorneys and/or accountants, and if desired by a Member with the Member’s attorneys and/or accountants, and timely filed.
Copies of such returns shall be kept at the Company’s principal place of business or at such other place as the Tax Matters
Partner shall determine and shall be available for inspection by the Members or their duly authorized representatives during regular
business hours. The Tax Matters Partner shall distribute to the Company which shall

 

    	 	34	 

     

    

distribute to each of the Members, as soon as
practicable after the end of the Fiscal Year of the Company, information with respect to the Company necessary for each Member
to prepare its United States federal, state and local, or foreign, tax returns. Each Member agrees to promptly provide to the Tax
Matters Partner any information requested by the Tax Matters Partner so as to enable the Company to make any election under Section
6225 or 6226 of the Code (as amended by the Revised Partnership Audit Procedures), comply with any documentation requirements in
connection with any such election, modify any “imputed underpayment” as defined under the Revised Partnership Audit
Procedures, and comply with any other requirements in the Revised Partnership Audit Procedures. The Company shall retain all information
collected from each Member pursuant to this Section 7.05(e). All elections required or permitted to be made by the Company, and
all other tax decisions and determinations relating to United States federal, state or local tax matters that may affect the Company
or any Member shall be communicated to the relevant governmental taxing authorities on behalf of the Company by the Tax Matters
Partner, in consultation with the Company’s attorneys and/or accountants, and if desired by a Member with the Member’s
attorneys and/or accountants, but only after prior approval by the Board of Managers of such communication by the Tax Matters Partner.

 

(f)                
Any taxes, penalties, and interest payable under the Revised Partnership Audit Procedures by the Company or any fiscally
transparent entity in which the Company owns an interest shall be treated as specifically attributable to the Members, and the
Tax Matters Partner shall use commercially reasonable efforts to allocate the burden of (or any diminution in distributable proceeds
resulting from) any such taxes, penalties or interest to those Members to whom such amounts are specifically attributable (whether
as a result of their status, actions, inactions or otherwise), as determined in good faith by the Tax Matters Partner and approved
by the Board of Managers. In connection with the foregoing, to the extent that the Company is assessed amounts under Section 6221(a)
of the Code (as amended by the Revised Partnership Audit Procedures), each current or former Member to which the assessment relates
shall remit to the Company, within thirty (30) days’ written notice by the Tax Matters Partner, an amount equal to such Member’s
allocable share of the assessment, including such Member’s allocable share of any interest imposed on the Company. The foregoing
sentence shall survive the dissolution of the Company, the withdrawal of any Member from the Company and the Transfer of any Member’s
Membership Units.

 

Article
VIII

Distribution

 

Section 8.01.       
Distribution. (a) Subject to Section 8.01(b), the Company, as determined by the Board of Managers in accordance with
Article V, may make distributions to the Members, pro rata in accordance with their respective Membership Units.

 

(b) Unless determined by the Managers in accordance
with Section 5.05(a)(vi) (taking into account the ongoing capital needs of the Company), the Company shall make quarterly distributions,
to the extent of available cash, to each Member, in an amount equal to such Member’s share, pro rata in accordance
with their respective Membership Units, of the Company’s Assumed Tax Liability. For the purposes of this Section 8.01(b),
“Assumed Tax Liability” means the product of the Company’s assumed taxable income through the payment
date multiplied by the highest combined maximum effective United States federal, state and local income tax rate applicable to
any Member. The Company will make a good faith estimate of the Assumed Tax Liability each quarter, and cash distributions will
be made, the extent of available cash, to the Members in an amount equal to the appropriate percentage of such estimate adjusted
for prior distributions on April 14, June 14, September 14 and December 14 of such year. A final determination of Assumed Tax Liability
will be made no later than March 1 of the year succeeding the year with respect to which such Assumed Tax Liability is being calculated,
with adjusting payments to be made to or from the Company by March 15 of such year.

 

    	 	35	 

     

    

Distributions not made for any reason pursuant
to this Section 8.01(b) shall accumulate without interest until paid. In addition, any distribution made by the Company in excess
of the required distributions for a required distribution date shall be applied towards the next scheduled distribution.

 

Section 8.02.       
Liquidation Distribution. Distributions made upon liquidation of the Company shall be made as provided in Section
11.05.

 

Section 8.03.       
Distribution Rules. (a) All amounts withheld pursuant to the Code or any provision of any state or local tax Law
with respect to any payment, distribution or allocation by the Company to the Members shall be treated as amounts distributed to
the Members pursuant to this Article VIII for all purposes of this Agreement. The President is authorized and directed to withhold
from distribution, or with respect to allocations, to the Members and to pay over to any United States federal, state or local
government any amounts required to be so withheld pursuant to the Code or any provision of any other applicable United States federal,
state or local Law and shall allocate such amounts to those Members with respect to which such amounts were withheld. Promptly
-upon learning of any requirement under any provision of the Code or any other applicable Law requiring the Company to withhold
any sum from a distribution to a Member or to make any payment to any taxing authority in respect of such Member, the Company shall
give written notice to such Member of such requirement and, if practicable and if requested by such Member, shall cooperate with
such Member in all lawful respects to minimize or to eliminate any such withholding or payment.

 

(b)               
A Member shall not have the status of, and is not entitled to the remedies available to, a creditor of the Company with
regard to distributions that such Member becomes entitled to receive pursuant to this Agreement and the Act.

 

Section 8.04.       
Limitations on Distribution. Notwithstanding any provision to the contrary contained in this Agreement, the Company
shall not make a distribution to any Member on account of its Membership Units if such distribution would violate Section 18-607
of the Act or other applicable Law.

 

Article
IX

Books and records; financial statements

 

Section 9.01.       
Books and Records; Financial Statements. (a) At all times during the continuance of the Company, the Company shall
prepare and maintain separate books of account for the Company that shall show a true and accurate record of all costs and expenses
incurred, all charges made, all credits made and received and all income derived in connection with the operation of the Company
Business in accordance with GAAP consistently applied, and, to the extent inconsistent therewith, in accordance with this Agreement.
Such books of account, together with a certified copy of this Agreement and of the Certificate, shall at all times be maintained
at the principal place of business of the Company. The books of account and the records of the Company shall be examined by and
reported upon as of the end of each Fiscal Year by a firm of independent certified public accountants that shall be selected by
the Board of Managers per Section 5.05 (the “Auditors”).

 

(b)               
The following financial information, prepared, in accordance with GAAP, together with an operating report in a form to be
determined by the Board of Managers analyzing such information, shall be transmitted by the Company to each Member at the times
hereinafter set forth:

 

(i)                  
Within sixty (60) days after the close of each Fiscal Year, the following financial statements, examined, and certified
to, by the Auditors:

 

    	 	36	 

     

    

(A)               
the balance sheet of the Company as of the close of such Fiscal Year;

 

(B)               
a statement of Company Net Profits and Net Losses for such Fiscal Year;

 

(C)               
a statement of the Company’s cash flows for such Fiscal Year; and

 

(D)               
a statement of such Member’s Capital Account as of the close of such Fiscal Year, and changes therein during such
Fiscal Year.

 

(ii)                
Within sixty (60) days after the close of each Fiscal Year, a statement indicating such Member’s share of each item
of Company income, gain, loss, deduction or credit for such Fiscal Year for income tax purposes.

 

(iii)              
As soon as available and in any event within forty (40) days after the end of each three-month period ended March 31, June
30 and September 30 of each Fiscal Year, balance sheets of the Company as of the end of such three-month period and statements
of income and Company Net Profits and Net Losses for the period commencing at the end of the previous Fiscal Year and ending with
the end of such three-month period, certified by the chief financial officer or treasurer of the Company.

 

(iv)              
As soon as practicable and in any event within twenty (20) days following the end of each calendar month, a monthly operating
summary of the Company’s activities in a form to be established by the Board of Managers.

 

(c)                
Each Member shall provide to the Company upon request tax basis information about contributed assets and other tax information
reasonably requested by the Company.

 

(d)               
The following financial information, prepared by the Company in accordance with International Financial Reporting Standards
- IFRS, together with an operating report in a form to be determined by the Board of Managers analyzing such information, shall
be transmitted by the Company to each Member at the times hereinafter set forth:

 

(i)                  
Within ten (10) Business Days after the end of each three-month period ended March 31, June 30, September 30 and December
31 of each Fiscal Year, the following financial statements:

 

(A)               
the balance sheet of the Company as of the three-month period ended compared with the last Fiscal Year;

 

(B)               
the income statement as of the three-month period ended and year-to-date compared with the relative three-month period and
year-to-date;

 

(C)               
the statement of cash flow as of the three-month period ended and year-to-date compared with the relative three-month period
and year to-date;

 

(D)               
the statement of changes in equity as of the three-month period ended compared with the last Fiscal Year.

 

    	 	37	 

     

    

Section 9.02.       
Reporting Requirements. The President shall furnish or cause to be furnished to each Manager:

 

(i)                  
as soon as possible and in any event within ten (10) days after the Company has received notice of the occurrence of any
default or event of default continuing on the date of such statement under any agreement relating to any material obligation of
the Company, a statement of the Company setting forth details of such default or event of default and the action which the Company
has taken and proposes to take with respect thereto;

 

(ii)                
promptly after the sending or filing thereof, copies of all reports that the Company sends to any of its lenders or creditors,
and copies of all tax returns that the Company files with any United States federal or state taxing authority;

 

(iii)              
within fifteen (15) days of the filing by the Tax Matters Partner of the Company’s United States federal tax return
(United States federal Form 1065), a copy of Schedule K-1 of United States federal Form 1065 reporting the Member’s allocable
share of Net Profits, Net Losses and other items of income, gain, deductions or loss for such Fiscal Year, and, from time to time,
such additional information as the Member may reasonably require for tax purposes; and

 

(iv)              
such other information regarding the condition or operations, financial or otherwise, of the Company as any Member may from
time to time reasonably request including any information that any Member determines to be necessary for such Member or its Affiliates
to fulfill legal or statutory reporting and disclosure requirements.

 

Section 9.03.       
Access; Due Diligence.1.1             
 Any Member, along with its respective Affiliates and auditors, shall have access to the Company’s financial records
and personnel to enable such Member, along with its respective Affiliates and auditors, to undertake review and audit procedures
in accordance with the auditing standards in force in the United States or in Brazil, as applicable. The Board of Managers shall
cause the Company to keep accurate and complete records, books and accounts on the basis appropriate to the Company’s business,
as required by applicable Law. Each Member shall have the right (which it may exercise through any of its duly authorized employees
or agents or its independent accountants or the duly authorized employees or agents or its independent accountants of its Affiliates,
as applicable) to audit, examine and make copies of or extracts from any books, accounts and records of the Company, at such Member’s
own cost and expense, upon prior written notice to the Company and/or the other Members, during the regular business hours of the
Company, on the premises of the Company or where such records, books and accounts are kept; provided, however that no Member shall
have the right to have a private audit of the Company books and records conducted more than once in any Fiscal Year. If the Company
incurs any additional costs to produce and deliver such information to the requesting Member, such requesting Member shall bear
the costs related thereto. In addition, the Company will give, or cause to be given, to each Member and its representatives, during
normal business hours, such reasonable access (upon reasonable notice and in a manner as to not unreasonably interfere with normal
business operations) to the personnel, properties, contracts, books, records, files and documents as may be reasonably necessary
to allow the Members to participate fully in the continued operations of the Company as appropriate in their respective roles as
Members, including the negotiation of financing for the Company’s initial plant and the subsequent management of the construction
process for such plant.

 

Section 9.04.       
Semi-Annual Updates to Members regarding Company BioFene Transformation Technology. Every January 15 and July 15
while Amyris’s license under Section 2.2 of

 

    	 	38	 

     

    

the IP License Agreement is in effect, the Company will provide
the Members with a written update on Company BioFene Transformation Technology. Such semi-annual updates will include a list of
any Patents in the Company BioFene Transformation Technology identified by their respective title, inventors, serial numbers, filing
date, and status. The Company also agrees to copy the Members on any official correspondence between the Company (or the Company’s
counsel) and any patent office regarding Patents in Company BioFene Transformation Technology.

 

Article
X

Restrictions on transfer

 

Section 10.01.   
Legends. (a) If the Company issues to Members a certificate evidencing Membership Units issued to Members, it shall
affix to each such certificate a legend in substantially the following form:

 

“THE MEMBERSHIP UNITS REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT
IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES ACT OF 1933 OR AN EXEMPTION THEREFROM AND, IN
EACH CASE, IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

THE MEMBERSHIP UNITS REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE SECOND AMENDED AND RESTATED OPERATING AGREEMENT DATED AS OF JULY 19, 2016,
AS IT MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE COMPANY. NO REGISTRATION
OF TRANSFER OF THESE MEMBERSHIP UNITS WILL BE MADE ON THE BOOKS OF THE COMPANY UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN
COMPLIED WITH.”

 

(b)               
Certificates representing Membership Units issued prior to the date hereof shall bear the legend set forth in Section 10.01(a).

 

(c)                
In the event that any Membership Units shall cease to be Restricted Membership Units and the Company issues Membership Unit
certificates to Members, the Company shall, upon the written request of the holder thereof, issue to such holder a new certificate
evidencing such Membership Units without the first paragraph of the legend required by Section 10.01(a) endorsed thereon. In the
event that the Membership Units shall cease to be subject to the restrictions on transfer set forth in this Agreement and the Company
issues Membership Unit certificates to Members, the Company shall, upon the written request of the holder thereof, issue to such
holder a new certificate evidencing such Membership Units without the legend required by the second paragraph of Section 10.01(a).
Before issuing a new certificate omitting part or all of the legend set forth in Section 10.01(a), the Company may request an opinion
of counsel reasonably satisfactory to it to the effect that the restrictions discussed in the legend to be omitted no longer apply
to the Membership Units represented by such certificate.

 

    	 	39	 

     

    

Section 10.02.   
Restrictions on Transfer; Required Transfers.

 

(a)                
Restrictions on Transfer and Encumbrance. Each of the Members hereby agrees that it shall not be permitted to Transfer,
or create, incur or assume any Encumbrance with respect to, any of its Membership Units, and the Company shall be prohibited from
registering any such Transfer or Encumbrance on any of its corporate documents and books, except (i) where otherwise agreed upon
in writing by all of the Members or (ii) for any Transfer made in accordance with the provisions of this Agreement. Any voluntary
or involuntary Transfer or Encumbrance of Membership Units or rights to subscribe for additional Membership Units by the Members
shall be subject to the provisions of this Agreement. Notwithstanding any provision to the contrary, the Members hereby agree and
covenant not to Transfer to any Third Party any of their Membership Units before December 31, 2016.

 

(b)               
Transfers to Affiliates. Irrespective of the restrictions on Transfer set forth in this Section 10.02, at any time
a Member may, after giving prior written notice to the other Members, Transfer all or part of its Membership Units to an Affiliate,
provided that:

 

(i)                  
the transferring Member jointly guarantees with such Affiliate all of the obligations of such Affiliate under this Agreement;

 

(ii)                
the Membership Units are transferred back to the transferring Member prior to the Affiliate ceasing to be an Affiliate of
such Member. The transferring Member shall provide to the other Members such information as may be reasonably requested to ascertain
that the Affiliate has not ceased to be an Affiliate of the transferring Member; and

 

(iii)              
the Affiliate unconditionally adheres to this Agreement and the corresponding instrument of adhesion is filed with the Company,
together with this Agreement.

 

(c)                
Right of First Refusal; Tag Along Right. Subject to the provisions of this Agreement, including Section 10.02(a)
above, in case any Member (the “Selling Member”) wishes to Transfer any of its Membership Units, directly or
indirectly, to any Third Party, the other Members shall have the right of first refusal to acquire all—and not less than
all—of the Membership Units that such Selling Member wishes to Transfer (the “Right of First Refusal”).
As long as a Member owns Membership Units representing fifty percent (50%) or less of the Company’s Membership Units, such
Member shall also have the right to include in the offer of the Selling Member its own Membership Units, as per the provisions
below (“Tag Along Right”). Each such right shall be exercised in accordance with the terms set forth below.

 

(i)                  
Sale Notice. If the Selling Member has received a good-faith binding purchase offer from a Third Party for its Membership
Units (which is a condition precedent to any Transfer although such binding purchase offer may be made in response to an offer
to sell by the Selling Member) and is willing to accept the terms of such purchase offer, then the Selling Member shall notify
the other Members in writing of its intention to Transfer its Membership Units, indicating the purchase offer terms, which shall
include the name (and, if a legal entity, the owners) of the purchaser, the number of Membership Units intended to be Transferred,
and the price, payment terms, and any other commercial terms applicable to such transaction, and enclose a copy of the offer received
from the relevant Third Party evidencing such terms and conditions (“Sale Notice”). The Sale Notice shall be
delivered to the other Members within five (5) Business Days from the acceptance by the Selling Member of the Third Party offer,
which acceptance shall be subject in all respects to the provisions of this Section 10.02. Such

 

    	 	40	 

     

    

terms indicated in the Sale Notice shall
be applicable to the Transfer of the Membership Units by the Selling Member, to the Right of First Refusal and to the exercise
of the Tag Along Right, if applicable.

 

(ii)                
Payment Terms on Sale Notice. The payment terms on the Sale Notice shall always provide for payment in cash or in
shares that are listed and publicly traded in the BM&FBOVESPA, New York Stock Exchange, or NASDAQ Global Select Market (“Non
Cash Consideration”). In case of payment in shares, if the Right of First Refusal is exercised by any of the other Members,
the purchase price under the Sale Notice shall be computed based on the market price of such Non Cash Consideration, as per the
weighted average of the sale prices per share of the Non Cash Consideration (or if no closing sale price is reported, the weighted
average of the bid and asked prices or, if more than one in either case, the average of the average bid and average asked prices)
in the last sixty (60) trading days prior to the Sale Notice. Once such purchase price is computed, payment by any non-Selling
Member, if it exercises its Right of First Refusal, shall be made in cash.

 

(iii)              
Right of First Refusal. No later than thirty (30) days following the receipt of the Sale Notice, each non-Selling
Member may send the Selling Member a written notice expressing its intention to exercise its Right of First Refusal (each, a “ROFR
Notice” and collectively, the “ROFR Notices”). Each Member’s ROFR Notice must indicate the maximum
number of Membership Units such Member is willing to purchase from the Selling Member. If the ROFR Notices do not contain an offer
to acquire all of the Selling Member’s Membership Units that such Member wishes to Transfer, then the Right of First Refusal
of each non-Selling Member that delivered a ROFR Notice with respect to the transactions set forth in the Sale Notice shall be
deemed terminated. If the ROFR Notices contain an offer to acquire exactly all of the Selling Member’s Membership Units,
then the Right of First Refusal of each non-Selling Member that delivered a ROFR Notice is deemed to be exercised, with each such
Member agreeing to purchase from the Selling Member the maximum number of Membership Units such Member indicated a willingness
to purchase in its ROFR Notice. If the combined ROFR Notices contain an offer to acquire Membership Units in excess of the Selling
Member’s Membership Units, then the Right of First Refusal of each non-Selling Member that delivered a ROFR Notice is deemed
to be exercised, with each such Member agreeing to purchase from the Selling Member that number of Membership Units that equals
(A) the total number of Membership Units offered for sale by the Selling Member multiplied by (B) the ratio of (1) the number of
Membership Units such non-Selling Member indicated a willingness to purchase divided by (2) the aggregate of the number of Membership
Units that all non-Selling Members indicated a willingness to purchase. In any case where a non-Selling Member successfully exercises
its Right of First Refusal as set forth in this Section 10.02(c)(iii), it shall be obligated to acquire, and the Selling Member
obligated to sell to such non-Selling Member, those Membership Units of the Selling Member required under the terms of this Section
10.02(c)(iii) within sixty (60) days following the receipt of the Sale Notice, pursuant to the terms and conditions set forth in
the Sale Notice.

 

(iv)              
Tag Along Right. If no non-Selling Member successfully exercises its Right of First Refusal, each non-Selling Member
(if it owns fifty percent (50%) or less of the Company’s Membership Units) may instead send the Selling Member, no later
than thirty (30) days following the receipt of the Sale Notice, a written notice expressing its intention to exercise its Tag Along
Right (each, a “Tag Along Notice” and collectively, the “Tag Along Notices”). Each Member’s
Tag Along Notice must indicate the maximum

 

    	 	41	 

     

    

number of Membership Units such Member
is willing to sell to the Third Party for the consideration stated in the Sale Notice. If the Third Party is unwilling to purchase
any number of Membership Units greater than the Selling Member’s Membership Units, then each Member that exercised its Tag
Along Right will have a right to sell a number of Membership Units equal to (A) the total number of Membership Units offered for
sale by the Selling Member multiplied by (B) such Member’s Percentage Interest. If the Third Party is willing to purchase
a number of Membership Units greater than the Selling Member’s Membership Units, but less than all of the Membership Units
offered for sale in the Tag Along Notices, then each Member that exercised its Tag Along Right will have a right to sell a number
of Membership Units equal to (Y) the total number of Membership Units the Third Party is willing to purchase multiplied by (Z)
such Member’s Percentage Interest. In any case where a non-Selling Member successfully exercises its Tag Along Right as set
forth in this Section 10.02(c)(iv), the number of Membership Units of each Member that successfully exercised its Tag Along Right
will replace an equal number of the Membership Units offered for sale by the Selling Member, and such Member shall be obligated
to sell those Membership Units required under the terms of this Section 10.02(c)(iv) within sixty (60) days following receipt the
receipt of the Sale Notice, pursuant to the terms and conditions set forth in the Sale Notice.

 

(v)                
Rights not Exercised; Transfer to Third Party. If no non-Selling Member successfully exercises its Right of First
Refusal or Tag Along Right within the above mentioned thirty (30)-day period, the Selling Member may, within one hundred and twenty
(120) days from the expiry of such thirty (30)-day period, freely Transfer all of its Membership Units mentioned in the Sale
Notice to the relevant Third Party, pursuant to the terms set forth in the Sale Notice. The transferee shall agree in writing,
per Section 10.04, to be bound by the terms of this Agreement, as amended from time to time. Once the transferee formally adheres
to this Agreement, it will inherit all rights and obligations of the Selling Member, except in any case where the Third Party does
not acquire all of the Membership Units owned by the Selling Member, in such case, all voting rights inherent to the acquired Membership
Units under this Agreement shall be exercised by the Selling Member and the Third Party collectively, as a block.

 

(vi)              
Failure to Complete Transfer. If the final terms and conditions for the Transfer under Section 10.02(c)(v) above
have changed in any material respect in relation to those originally contained in the Sale Notice, or if at the end of the one
hundred and twenty (120)-day period referred to in such Section, the Selling Member has not Transferred its Membership Units, but
still intends to do so, then the procedures described above shall be resumed and repeated.

 

(vii)            
Solicitation of Offers. The Members hereby agree that in the event the Selling Member wishes to solicit an offer
for a part or all of its Membership Units from a Third Party, the Selling Member shall inform, in writing, the non-Selling Members
of its intention to initiate a process to solicit offers for the Transfer of its Membership Units. The non-Selling Members have
no right of first offer or right of first negotiation with regard to the Selling Member’s solicitation for offers; however,
if the Selling Member receives a good-faith binding purchase offer from any Third Party as a result of such solicitation, such
offer will be subject to this Section 10.02(c) (as noted in Section 10.02(c)(i)).

 

(d)               
Indemnification. In the case of a Transfer, Encumbrance, or attempted Transfer or Encumbrance of Membership Units
or other interest in the Company contrary to the provisions of the

 

    	 	42	 

     

    

Agreement, the parties engaging or attempting
to engage in such Transfer shall indemnify and hold harmless the Company and each of the Members from all losses that such indemnified
Persons may incur (including, without limitation, incremented tax liability and reasonable lawyers’ fees and expenses) in
enforcing the provisions of this Agreement.

 

Section 10.03.   
Improper Transfer or Encumbrance. Any attempt not in compliance with this Agreement to make any Transfer of, or create,
incur or assume any Encumbrance with respect to, any Membership Units shall be null and void and of no force and effect, the purported
transferee shall have no rights or privileges in or with respect to the Company, and the Company shall not give any effect in the
Company’s records to such attempted Transfer or Encumbrance.

 

Section 10.04.   
Transferees to Execute Agreement. Each Member agrees that it will not, during the term of this Agreement, directly
or indirectly, make any Transfer of any Membership Units Beneficially Owned by such Member unless prior to the consummation of
any such Transfer, the Person to whom such Transfer is proposed to be made (a “Prospective Transferee”) (i)
executes and delivers to the Company a Joinder Agreement and (ii) unless such Prospective Transferee is a recognized institutional
investor, delivers to the Company an opinion of counsel, satisfactory in form and substance to the Company, to the effect that
the execution of the Joinder Agreement by such Prospective Transferee makes this Agreement a legal, valid and binding obligation
of such Prospective Transferee enforceable against such Prospective Transferee in accordance with its terms. Upon the execution
and delivery by such Prospective Transferee of the Joinder Agreement, compliance of the Transfer with the provisions of this Agreement
(including Section 2.15), and, if required, the delivery of the opinion of counsel referred to in clause (ii) of the preceding
sentence, such Prospective Transferee shall be deemed a “Member” for purposes of this Agreement and shall have the
rights and be subject to the obligations of a Member under this Agreement with respect to the Membership Units owned by such Prospective
Transferee.

 

Article
XI

dissolution, liquidation and termination

 

Section 11.01.   
No Dissolution. The Company shall not be dissolved by the admission of additional Members in accordance with the
terms of this Agreement.

 

Section 11.02.   
Events Causing Dissolution. (a) The Company shall be dissolved and its affairs shall be wound up upon the occurrence
of any of the following events:

 

(i)                  
the expiration of the term of the Company as provided in Section 2.03;

 

(ii)                
the unanimous vote of the Members to dissolve, wind up and liquidate the Company;

 

(iii)              
the Insolvency Event of a Member, unless, within one hundred twenty (120) days after the occurrence of such event, the other
Members, in their sole discretion, agree in writing to continue the business of the Company and to exercise the right to purchase
all of the bankrupt or insolvent Member’s Membership Units as described below;

 

(iv)              
the entry of a decree of judicial dissolution under Section 18-802 of the Act; or

 

(v)                
the termination of the IP License Agreement.

 

If the Company is continued pursuant to clause (iii) above after
the Insolvency Event of a Member (the “Former Member”), the remaining Members shall have the right to purchase
all, but not less than all, of the Membership Units of such Former Member at the Fair Market Value of such Membership Units, and

 

    	 	43	 

     

    

each Member shall be entitled to purchase from the Former Member
that number of Membership Units that equals (A) the total number of Membership Units of such Former Member multiplied by (B) the
ratio of (1) such Member’s Membership Units divided by (2) the aggregate of the Membership Units of all Members other than
the Former Member. The Former Member shall, upon exercise of such right, sell to such Members all such Membership Units at such
price. Any acquisition pursuant to this Section 11.02 shall be completed within thirty (30) days from the final determination of
the Fair Market Value of the Membership Units of the Former Member. In case an Insolvency Event occurs and the non-insolvent Members
exercise their rights to purchase hereunder, then any and all actions pursuant to any meeting resolutions or written consents of
the Members or the Board of Managers thereafter shall be decided by the non-insolvent Members, except if otherwise required under
applicable Law.

 

Section 11.03.   
Notice of Dissolution. Upon the dissolution of the Company, the Person or Persons unanimously approved by the Members
to carry out the winding up of the Company (the “Liquidating Trustee”) shall promptly notify the Members of
such dissolution, except that, in the case of a dissolution pursuant to Section 11.02(a)(iii), the Liquidating Trustee shall be
the Person or Persons approved by the Members that are not bankrupt or insolvent.

 

Section 11.04.   
Liquidation.

 

(a)                
Upon dissolution of the Company, the Liquidating Trustee shall immediately commence to wind up the Company’s affairs;
provided however, that a reasonable time shall be allowed for the orderly liquidation of the assets of the Company and the
satisfaction of liabilities to creditors so as to enable the Members to minimize the normal losses attendant upon a liquidation.
The Members shall continue to share Net Profits and Net Losses during liquidation in the same proportions, as specified in Article
VII hereof, as before liquidation. Each Member shall be furnished with a statement audited by the Auditors that shall set forth
the assets and liabilities of the Company as of the date of dissolution. Each Member (and its Affiliates) shall pay to the Company
all amounts then owing by it (and them) to the Company. The proceeds of liquidation shall be distributed, as realized, in the following
order and priority:

 

(i)                  
to creditors of the Company (including holders of Membership Units that are creditors to the extent otherwise permitted
by applicable Law), in satisfaction of the liabilities of the Company (whether by payment or the making of reasonable provision
for payment thereof), other than liabilities for distributions to holders of Membership Units; and

 

(ii)                
to the Members pro rata in accordance with their positive Capital Account balances to the extent thereof, after giving
effect to all contributions, distributions and allocations for all periods.

 

To the extent that the Members determine that any or all of the
assets of the Company shall be sold, such assets shall be sold as promptly as practicable, in a commercially reasonable manner.
For purposes of making the liquidating distributions required by this Section 11.04, the Liquidating Trustee may determine, subject
to the direction of the Members per Section 5.06(e), whether to distribute all or any portion of the assets of the Company in kind
or to sell all or any portion of the assets of the Company and distribute the proceeds therefrom.

 

(b)               
Notwithstanding any provision to the contrary in this Section 11.04, upon dissolution of the Company, the Liquidating Trustee
shall, to the extent practicable and consistent with Sections 11.04(a)(i) and 11.04(a)(ii) and the direction of the Members in
Subsection (a) above, (i) distribute in kind to each Member the respective assets contributed or transferred by such Member
to the Company, (ii) distribute in kind to Amyris any assets primarily used in or related to the business of Amyris and its Affiliates,
(iii) distribute in kind to Cosan US any assets primarily used in or related to the

    	 	44	 

     

    

 

business of Cosan US and its Affiliates, and (iv)
distribute in kind to ARG any assets primarily used in or related to the business of ARG and its Affiliates. To the extent the
principles set forth in the preceding sentence would result in a Member receiving more than the portion of distributions it would
otherwise be entitled to receive pursuant to Section 11.04(a) upon dissolution of the Company, such Member shall, at its election,
pay an amount in cash to the other Members equal to such excess value received pursuant to the preceding sentence or direct the
Company to sell assets otherwise distributable to such Member, for the benefit of the other Members, for a price equal to such
excess value received pursuant to the preceding sentence, with each other Member receiving the portion of such amount it would
otherwise be entitled to receive pursuant to Section 11.04(a). The value of each such asset at dissolution shall be determined
using the same methodology that was used to determine the value of the assets to be contributed to the Company.

 

(c)                
As soon as practicable, the Liquidating Trustee shall deliver a written notice to each Member setting forth the value assigned
to each asset and the Member to which such asset will be distributed, in connection with the provisions of subsections (a) and
(b) above. Each Member shall have fifteen (15) days to dispute such valuation, and if no written notice of dispute is delivered
to the Liquidating Trustee and the other Members, the notice of valuation shall become final. If such notice of dispute is delivered,
the matter shall be submitted to an internationally recognized investment banking firm, accounting firm or valuation firm selected
by the Liquidating Trustee from a list of three such firms provided by the disputing Member. The banking, accounting or valuation
firm shall make a decision within sixty (60) days of referral, which decision shall be final and binding, and the fees and expenses
of such firm shall be borne by the Company.

 

Section 11.05.   
Termination of the Company.

 

The Company shall terminate when all of the assets of the Company,
after payment of or due provision for all debts, liabilities and obligations of the Company, shall have been distributed to the
holders of Membership Units in the manner provided for in this Article XI, and the Certificate has been cancelled in the manner
required by the Act.

 

Section 11.06.   
Claims of the Members.. The Members shall look solely to the Company’s assets for the return of their Capital
Contributions, and if the assets of the Company remaining after payment of or due provision for all debts, liabilities and obligations
of the Company are insufficient to return such Capital Contributions, the Members shall have no recourse against the Company or
the other Members or any other Person. No Member with a negative balance in such Member’s Capital Account shall have any
obligation to the Company or to the other Members or to any creditor or other Person to restore such negative balance upon dissolution
or termination of the Company or otherwise.

 

Article
XII

Liability and indemnification

 

Section 12.01.   
Liability of Members. (a) Except as otherwise provided by the Act or this Agreement, the debts, obligations and liabilities
of the Company, whether arising in contract, tort or otherwise, shall be solely the debts, obligations and liabilities of the Company,
and no Covered Person shall be obligated personally for any such debt, obligation or liability of the Company solely by reason
of being a Covered Person.

 

(b)               
Except as otherwise expressly required by applicable Law, a Member, in its capacity as such, shall have no liability to
the Company or to any other Members in respect of any distributions wrongfully distributed to it unless such Member had actual
knowledge at the time of the distribution of facts indicating the impropriety of the distribution and if immediately after giving
effect to

 

    	 	45	 

     

    

such distribution all liabilities of the Company
(other than liabilities to Members or assignees on account of their Membership Units and liabilities as to which recourse is limited
to specific property of the Company) exceed the fair market value of the Company’s assets; provided however, that
a Member shall have no liability under this Section 12.01 in respect of any distribution on or after the fourth anniversary of
the distribution unless an action to recover such distribution from such Member is commenced prior to such fourth anniversary and
an adjudication of liability against such Member is made in such action.

 

Section 12.02.   
Indemnification of Covered Person. The Company shall indemnify each Covered Person against, and hold each Covered
Person harmless from, all claims, suits, judgments, losses, damages, fines or costs (including reasonable legal fees and expenses)
(“Losses”) arising out of or resulting from any breach of any representation or warranty made by the Company
herein or the breach of or failure to perform any agreement or covenant made by the Company and contained herein.

 

Section 12.03.   
Indemnification by the Company. (a) To the fullest extent permitted by applicable Law, a Covered Person shall be
entitled to indemnification from the Company for any Losses incurred by such Covered Person by reason of any act or omission performed
or omitted by such Covered Person in good faith on behalf of the Company and in a manner reasonably believed to be within the scope
of authority conferred on such Covered Person by this Agreement, except that no Covered Person shall be entitled to be indemnified
in respect of any Losses incurred by such Covered Person by reason of gross negligence, bad faith or willful misconduct with respect
to such acts or omissions; provided however, that any indemnity under this Section 12.03 shall be provided out of and to
the extent of Company assets only, and no other Covered Person shall have any personal liability on account thereof.

 

(b)               
(i) In the event that any claim, demand, action, suit or proceeding shall be instituted or asserted or any Losses shall
arise in respect of which indemnity may be sought by a Covered Person pursuant to Section 12.03(a), such Covered Person shall promptly
notify the Company thereof in writing. Failure to provide notice shall not affect the Company’s obligations hereunder except
to the extent the Company is actually and materially prejudiced thereby.

 

(ii)                
The Company shall have the right, exercisable subject to the approval of the disinterested Members, to participate in and
control the defense of any such claim, demand, action, suit or proceeding and, in connection therewith, to retain counsel reasonably
satisfactory to each Covered Person, at the Company’s expense, to represent each Covered Person and any others the Company
may designate in such claim, demand, action, suit or proceeding. The Company shall keep the Covered Person advised of the status
of such claim, demand, action, suit or proceeding and the defense thereof and shall consider in good faith recommendations made
by the Covered Person with respect thereto.

 

(iii)              
In any such claim, demand, action, suit or proceeding, any Covered Person shall have the right to retain its own counsel
at its own expense; provided however, that the fees and expenses of such Covered Person’s counsel shall be at the
expense of the Company if (A) each other Member and such Covered Person shall have mutually agreed to the retention of such counsel,
(B) the Company shall have failed, within a reasonable time after having been notified of the existence of an indemnified claim,
to assume the defense of such indemnified claim or (C) the named parties to any such claim, demand, action, suit or proceeding
(including any impleaded parties) include both the Company and such Covered Person and representation of both parties by the same
counsel would be inappropriate in the judgment of the Covered Person (as evidenced by an opinion of counsel) due to actual or potential
differing interests between them and the Company shall have failed, within a reasonable time after having been notified of the
Covered Person’s objection under this Section 12.03(b)(iii)(C) to such joint representation, to

 

    	 	46	 

     

    

retain counsel for such Covered Person
reasonably satisfactory to such Covered Person. It is understood that the Company shall not, in respect of the legal expenses of
any Covered Person, in connection with any claim, demand, action, suit or proceeding or related claims, demands, actions, suits
or proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any
local counsel reasonably satisfactory to the Company) for all such Covered Persons and that all such fees and expenses shall be
reimbursed as they are incurred; provided however, that if there exists or is reasonably likely to exist a conflict of interest
that would make it inappropriate in the judgment of a Covered Person (as evidenced by an opinion of counsel) for the same counsel
to represent such Covered Person and any other Covered Person, then such Covered Person shall be entitled to retain its own counsel,
in each jurisdiction for which the Covered Person reasonably determines counsel is required, at the expense of the Company.

 

(iv)              
The Company shall not be liable for any settlement of any claim, demand, action, suit or proceeding effected without its
written consent (which consent shall not be unreasonably withheld or delayed), but if settled with such consent or if there be
a final judgment for the plaintiff, the Company agrees to indemnify each Covered Person, to the extent provided in Section 12.03(a),
from and against all Losses by reason of such settlement or judgment. The Company shall not effect any settlement of any pending
or threatened claim, demand, action, suit or proceeding in respect of which any Covered Person is seeking indemnification hereunder
without the prior written consent of each such Covered Person (which consent shall not be unreasonably withheld or delayed by any
such Covered Person), unless such settlement includes an unconditional release of each such Covered Person from all liability and
claims that are the subject matter of such claim, demand, action, suit or proceeding.

 

(v)                
As necessary or useful to the defending party in effecting the foregoing procedures, the parties shall cooperate in the
execution and delivery of agreements, instruments and other documents and in the provision of access to witnesses, documents and
property (including access to perform interviews, physical investigations or other activities).

 

(vi)              
No amendment or repeal of any of the provisions of this Agreement shall limit or eliminate the benefits provided to the
Members under this Section 12.03 or this Article XII.

 

Section 12.04.   
Advancement of Expenses. To the fullest extent permitted by applicable Law, expenses (including legal fees) actually
and reasonably incurred by a Covered Person in defending any claim, demand, action, suit or proceeding shall, from time to time,
be advanced by the Company prior to the final disposition of such claim, demand, action, suit or proceeding upon receipt by the
Company of an undertaking by or on behalf of the Covered Person to repay such amount if it shall be determined that the Covered
Person is not entitled to be indemnified therefor as authorized in this Article XII.

 

Article
XIII

Exclusivity

 

Section 13.01.   
Exclusivity. Subject to the Exclusivity Exceptions as defined in the IP License Agreement and also excepting viscosity
index improvers, the Members agree that, effective as of the Effective Date, the Company shall be the exclusive vehicle through
which they and their respective Affiliates (either individually, together, or with Third Parties) shall develop, make (have made),
offer for

    	 	47	 

     

    

 

sale, sell, and import Base Oils and Additives derived from BioFene
for the Lubricant Market. To the extent that Cosan US or Amyris licenses or sells an Alternative Technology to the Company per
the terms of the IP License Agreement or Cosan US License Agreement (as applicable), then the above exclusivity will also include
Base Oils and Additives derived from such Alternative Technology for the Lubricants Market. Notwithstanding the foregoing, ARG
(directly or through one or more of its Affiliates) may develop, manufacture and sell Base Oils derived from Alternative Technology.

 

Each Member acknowledges and agrees that the covenant contained
in this Section has been negotiated in good faith, is reasonable and not more restrictive or broader than is necessary to protect
the interests of the Members, and would not achieve its intended purpose if it was on different terms or for a period of time shorter
than the period provided for herein or was applied in more restrictive geographical areas than is provided herein. Each Member
further acknowledges and agrees that it would not have entered into this Agreement, but for the covenant contained in this Section
and that such covenant is essential to protect the value of the Company. Each Member acknowledges that the Company would be irreparably
harmed by any breach or threatened breach of this Section and that there will be no adequate remedy at law or in damages to compensate
the Company and the other Members for any such breach.

 

Section 13.02.   
Non-Solicitation. (a) Each of the Members shall not, and shall cause its respective Affiliates, during the term of
each contract between the Company and each employee of the Company, and for a period of one (1) year after the date of such employee’s
termination not to, directly or indirectly:

 

(i)                  
employ or contract, attempt to employ or contract, or assist anyone in employing or contracting any person who is then,
or was, an employee of the Company; or

 

(ii)                
persuade or attempt to persuade any employee of the Company to leave such employment or to become employed by anyone other
than the Company.

 

Notwithstanding the foregoing, the provisions of this Section 13.02
shall not apply to (1) any advertisement or general solicitation (or hiring as a result thereof) that is not specifically targeted
at the persons described in Section 13.02(a)(i) or (ii) above; (2) any Member’s hiring of any such person who has terminated
employment with the Company at least twelve (12) months prior to the commencement of the solicitation of such employee; (3) any
Company employee or former employee who initiates such interest in employment; or (4) any employee or former employee of the Company
that was an employee of a Member or its Affiliate immediately prior to being an employee of the Company, exclusively in relation
to the respective Member that was the employer.

 

Article
XIV

Miscellaneous

 

Section 14.01.   
Confidential Information. (a) As used herein, “Confidential Information” means any and all information
provided by or on behalf of a party hereto (“Disclosing Party”) to another party (or parties) hereto (each a
“Receiving Party”) or to their Representatives between March 26, 2013 and the termination of this Agreement,
regardless of the form or medium of communication, that relates to the Company or a Member in each case which information is either
proprietary to the Company or a Member, as applicable, or is otherwise not available to the general public including, but not limited
to, information about properties, employees, finances, strategies, businesses and operations of the Company or of a Member or its
Affiliates. In addition, those portions of any notes, analyses, compilations, studies, forecasts, interpretations or other documents
prepared by a Receiving Party or its Representatives that contain, reflect or are based upon, in whole or in part, Confidential
Information furnished to or acquired by such Receiving Party shall also be considered Confidential Information. As used herein,

 

    	 	48	 

     

    

“Representative” means the officers, directors,
employees, attorneys, accountants, advisors, consultants, auditors, agents, and actual or prospective investors, underwriters,
or acquirers of the applicable party hereto and of its Affiliates.

 

(b)               
Except with the prior written consent of the Disclosing Party or as specifically authorized in this Agreement, each Receiving
Party shall, and shall cause its Representatives (to the extent such Persons receive any Confidential Information) to, (i) maintain
in confidence any and all Confidential Information, (ii) take reasonable precautions to protect Confidential Information, (iii)
not disclose Confidential Information to any Person, and (iv) not make any use of such Confidential Information except for the
purposes specifically authorized herein.

 

(c)                
A Receiving Party may disclose Confidential Information, without the Disclosing Party’s consent, to those of its Representatives
who (1) need to know such Confidential Information for the purpose of assisting such Receiving Party (1) fulfill its obligations
or exercise its rights under this Agreement or (ii) evaluate or assist the Company and its business activities and (2) are bound
by written obligations of confidentiality and non-use substantially similar to those herein. A Receiving Party may also disclose
Confidential Information, without the Disclosing Party’s consent, to the Company and to other Members, but such Receiving
Party is not responsible for any breach of this Section 14.01 by the Company or other Members with such Confidential Information.
Finally, a Receiving Party or its Affiliates may disclose the terms of this Agreement to actual or prospective investors, underwriters,
or acquirers who need to know such Confidential Information to evaluate the Receiving Party’s (or its Affiliates’)
business and who are bound by written obligations of confidentiality and non-use substantially similar to those herein.

 

(d)               
In addition, a Receiving Party may disclose Confidential Information (including filing this Agreement and all necessary
documents regarding this transaction), without the Disclosing Party’s consent, to the extent such disclosure is required,
on advice of counsel, by applicable Law (including pursuant to any listing agreement with, or the rules or regulations of, any
national securities exchange on which any securities of such Receiving Party (or any Affiliate thereof) are listed or traded);
provided, that the Receiving Party making such disclosure or whose Affiliates are making such disclosure shall so notify the other
parties hereto as promptly as practicable (and if possible and legally allowed, prior to making such disclosure) and shall seek
confidential treatment of such information to the extent available.

 

(e)                
Notwithstanding Section 14.01(a), the provisions of Section 14.01 shall not apply to, and Confidential Information shall
not include:

 

(i)                  
any information that is or has become generally available to the public other than as a result of a disclosure by any Receiving
Party or any Representative thereof in breach of any of the provisions of this Section 14.01;

 

(ii)                
any information that has been independently developed by a Receiving Party (or any Affiliate thereof) without violating
any of the provisions of this Agreement or any other similar contract to which such Receiving Party or any of its Representatives,
is or are bound; or

 

(iii)              
any information made available to such Receiving Party (or any Affiliate thereof), on a non-confidential basis by any third
party who is not prohibited from disclosing such information to such Person by a legal, contractual or fiduciary obligation to
the Disclosing Party or any of its Representatives.

 

    	 	49	 

     

    

(f)                
Except as otherwise provided for in this Section 14.01, Confidential Information received hereunder shall be used by each
Receiving Party and its Representatives solely for use in connection with such Receiving Party fulfilling its obligations or exercising
its rights under this Agreement or evaluating or assisting the Company and its business activities.

 

(g)                
The obligations under this Section 14.01 shall survive for two (2) years after the termination of this Agreement, notwithstanding
the possible earlier occurrence of a dissolution of the Company, a Member’s Transfer of its Membership Units, a withdrawal
by a Member from the Company and/or any Person ceasing to be an Affiliate of a Member.

 

(h)               
Nothing in this Agreement shall be interpreted as vesting, in favor of any Receiving Party or any other Person, any right
of ownership or other right in Confidential Information or other intellectual property of a Disclosing Party.

 

Section 14.02.   
Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall
be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by courier service, by fax or by registered
or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such
other address for a party as shall be specification notice given in accordance with this Section 14.02:

 

(i)                  
If to the Company:

 

Novvi LLC

5885 Hollis Street

Emeryville, CA 94608

Attention: Jeff Brown, President

 

(ii)                
if to a Member, then to the address or fax number set forth opposite such Member’s name on Schedule 2.01 hereto.

 

In addition, in case of any notice
to Cosan US, with a copy to (which shall not constitute notice):

 

Cosan Lubrificantes e Especialidades S.A.

Rua Victor Civita n° 77, Bloco 1, 4° andar

Rio de Janeiro − RJ − Brazil

CEP: 22775-905

Attention: Departamento Juridico

 

Jones Day

222 East 41st Street

New York, NY 10017-6702

Attention:

 

Mattos Filho, Veiga Filho, Marrey Jr. e Quiroga Advogados

Alameda Joaquim Eugenio de Lima, 447,

São Paulo − SP − Brazil

Attention:

 

Section 14.03.   
Public Announcements. Except per Section 14.01(d), no party to this Agreement (including the Company) shall (i) make,
or cause to be made, any press release or public announcement in respect of this Agreement, (ii) use, or caused to be used, the
names of any Member or any Affiliate of any Member in any press release or public announcement regarding this Agreement or the

 

    	 	50	 

     

    

Company, or (iii) otherwise communicate with any news media about
this Agreement or the Company without the prior written consent of the Members, not to be unreasonably withheld. The parties shall
cooperate as to the timing and contents of any such press release or public announcement. Following the initial press release or
other authorized public disclosure announcing the existence of this Agreement (if any), each party hereto shall be free to disclose,
without the other parties’ prior written consent, the existence of this Agreement, the identity of the other the other parties,
and those terms of this Agreement, each to the extent they have already been publicly disclosed in accordance herewith.

 

Section 14.04.   
Interpretation. Throughout this Agreement, nouns, pronouns and verbs shall be construed as masculine, feminine, neuter,
singular or plural, whichever shall be applicable, Unless otherwise specified, all references herein to “Articles,”
“Sections” and paragraphs shall refer to corresponding provisions of this Agreement.

 

Section 14.05.   
Severability. If any term or other provision of this Agreement is held to be invalid, illegal or incapable of being
enforced by any rule of applicable Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless
remain in full force and effect so long as the economic or legal substance of the transactions is not affected in any manner materially
adverse to any party. Upon a determination that any term or other provision is invalid, illegal or incapable of being enforced,
the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally
contemplated to the fullest extent possible.

 

Section 14.06.   
Counterparts. This Agreement may be executed and delivered (including by facsimile or email transmission) in one
or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall
be deemed to be an original but all of which taken together shall constitute one and the same agreement. Copies of executed counterparts
transmitted by telecopy, email, or other electronic transmission service shall be considered original executed counterparts for
purposes of this Section 14.06.

 

Section 14.07.   
Entire Agreement. This Agreement, together with the Purchase Agreement, the IP License Agreement and the Cosan US
License Agreement, constitutes the entire agreement among the parties hereto pertaining to the subject matter hereof and supersedes
all prior agreements and understandings pertaining thereto.

 

Section 14.08.   
Governing Law; Submission to Jurisdiction; Arbitration. (a) This Agreement shall be governed by, and construed, interpreted
and enforced in accordance with, the Laws of the State of Delaware, without giving effect to the principles or rules of conflicts
of law or of choice of law thereof.

 

(b)               
In the event of any dispute between the Members and/or the Company involving any of this Agreement, the activities of the
Company, or the Company Business, or any combination of the foregoing (other than a dispute subject to Section 5.16), such dispute
shall be governed by and resolved subject to this Section 14.08. Notwithstanding anything contained in this Agreement, the Members
undertake to use their reasonable efforts to amicably resolve by mutual negotiation of their chief executive officers (or their
designees) any disputes between themselves and/or the Company arising from or in connection to this Agreement and/or related hereto,
including but not limited to any issues relating to the existence, validity, effectiveness, contractual performance, interpretation,
breach or termination hereof. In case such mutual agreement is not reached under this Section, within thirty (30) days after submission
of the dispute to the Members’ chief executive officers (or their designees), either Member may refer the dispute to binding
arbitration under the then-existing rules (“Arbitration Rules”) of

 

    	 	51	 

     

    

the American Arbitration Association (“Arbitration
Chamber”), which will exclusively and finally settle such dispute. The Arbitration Rules are deemed to be incorporated
by reference to this Agreement, except as such Arbitration Rules may be modified herein or by mutual agreement by the Members.
The arbitration proceedings filed based on this Agreement shall be administered by the Arbitration Chamber. Any such arbitration
shall be conducted in accordance with, and subject in all respect to, the following: For the avoidance of doubt, this Section 14.08
equally binds all parties hereto (including the Company) to this Agreement, and such parties hereby agree to submit to and comply
with all the terms and conditions of this Section 14.08, which shall be in full force and effect irrevocably, and subject to specific
performance. The Company expressly agrees to be bound to these arbitration provisions for all legal purposes. Unless otherwise
agreed in writing, the Members shall continue to diligently perform their respective duties and obligations under this Agreement
while an arbitral proceeding is pending.

 

(c)                
Any arbitration under this Section 14.08 will be settled by a panel of three (3) arbitrators. If there are only two parties
to the arbitration, each party shall nominate one arbitrator in accordance with the Arbitration Rules and the two arbitrators so
nominated shall nominate jointly a third arbitrator, who shall serve as the chair of the arbitral tribunal (“Arbitral
Tribunal”), within fifteen (15) days from the receipt of a communication from the Arbitration Chamber by the
two previously nominated arbitrators. If there are multiple parties, whether as claimants or as respondents, the multiple claimants,
jointly, and the multiple respondents, jointly, shall nominate an arbitrator within the time limits set forth in the Arbitration
Rules. If any arbitrator has not been nominated within the time limits specified herein and/or in the Arbitration Rules, as applicable,
such appointment shall be made by the Arbitration Chamber upon the written request of any party within fifteen (15) days of such
request, If at any time a vacancy occurs in the Arbitral Tribunal, the vacancy shall be filled in the same manner and subject to
the same requirements as provided for the original appointment to that position. The Company as an intervening party to this Agreement
shall be a party to the arbitration proceeding only to the extent it may have to implement the award to be rendered, but it waives
its right to appoint any arbitrator.

 

(d)               
The place of arbitration shall be the city of New York, New York, U.S.A., where the award(s) shall be rendered, and all
arbitration proceedings shall be conducted in English.

 

(e)                
An arbitration award shall be final, unappealable and binding on the parties, including the Company, their successors and
assignees, who agree to comply with it and spontaneously and expressly waive any form of appeal, except for the request for fraud,
correction of material error or clarification of uncertainty, doubt, contradiction or omission of the arbitration award. If necessary,
an arbitration award may be enforced in any court that has jurisdiction or authority over the Members, the Company, or their assets.
The arbitration award will include the distribution of costs, including reasonable attorney’s fees and reasonable expenses
as the Arbitral Tribunal sees fit.

 

(f)                
The Members and the Company are fully aware of all terms and effects of the arbitration provisions herein agreed upon and
irrevocably agree that arbitration hereunder is the only form of resolution of any disputes between any of the Members or any Member
and the Company or among themselves arising from or in connection with this Agreement and/or related thereto (except those subject
to Section 5.16). Without prejudice to the validity of these arbitration provisions, the Members and/or the Company may seek judicial
assistance and/or relief, if and when necessary, for the sole purposes of:

 

(i)                  
executing obligations that admit, forthwith, specific performance;

 

(ii)                
obtaining coercive or precautionary measures or procedures of a preventive, provisional or permanent nature, as security
for the arbitration to be commenced or already in course between the Members and/or to ensure the existence and efficacy of the
arbitration proceeding; or

 

    	 	52	 

     

    

(iii)              
fraud, correction of material error or clarification of uncertainty, doubt, contradiction or omission of the arbitration
award; or

 

(iv)              
obtaining measures of a mandatory and specific nature;

 

it being understood that, upon accomplishment of the mandatory or
specific enforcement procedures sought, the dispute shall be returned to the Arbitral Tribunal to be established or already established,
as applicable, full and exclusive authority to decide on all and any issues, whether related to procedure or merit, which has caused
the mandatory or specific enforcement claim, with the respective judicial proceeding being interrupted until the partial or final
decision of the Arbitral Tribunal.

 

For the measures indicated in (i) through (iv) above, the Members
and/or the Company elect any state or U.S. federal court located in the city of New York, New York, U.S.A., to the exclusion of
any other courts, and the Members and/or the Company hereby irrevocably submit to the exclusive jurisdiction of any state or U.S.
federal court located within the city of New York, New York, U.S.A. over any such action. The Members and/or the Company hereby
irrevocably waive, to the fully extent permitted by applicable Law, any objection which they may now or hereafter have to the laying
of venue of any such action brought in such court or any defense of inconvenient forum for the maintenance of such action. The
filing of any measure under this Subsection (f) does not entail any waiver to the arbitration under this Section 14.08 or to the
full jurisdiction of the Arbitral Tribunal.

 

(g)                
The Members, the Company, and their respective Representatives, the witnesses, the Arbitral Tribunal, the Arbitration Chamber
and its secretariat agree to treat the existence, content, awards and decisions relating to an arbitration proceeding hereunder,
together with all the materials, information and testimony used therein or created for the purposes thereof, as well as other documents
produced or disclosed by the other Member or by the Company during the arbitration proceeding as Confidential Information of the
other Member or the Company, subject to the obligations and exceptions in Section 14.01.

 

(h)               
In order to facilitate the comprehensive resolution of related disputes under this Agreement, the Purchase Agreement, the
IP License Agreement, and/or the Cosan US License Agreement, any or all such disputes may be brought in a single arbitration under
the following circumstances and conditions: If one or more arbitrations are already pending between the Members and/or the Company
hereunder or under the Purchase Agreement, the IP License Agreement or under the Cosan US License Agreement and a new dispute arises
between the Members and/or the Company under any of said agreements or a subsequently filed arbitration is brought between the
Members and/or the Company under any said agreements, then a Member or the Company may request that such new dispute or any subsequently
filed arbitration be consolidated into any prior pending arbitration. Within twenty (20) days of a request to consolidate, the
parties to the new dispute or the subsequently filed arbitration shall select one of the prior pending arbitrations into which
the new dispute or subsequently filed arbitration may be consolidated (“Selected Arbitration”). If the parties
to the new dispute or subsequently arbitration are unable to agree on the Selected Arbitration within such twenty (20) day
period, then the Arbitration Chamber shall indicate the Selected Arbitration within twenty (20) days of a written request
by a party to the new dispute or the subsequently filed arbitration. If the Arbitration Chamber fails to indicate the Selected
Arbitration within the 20-day time limit indicated above, the arbitration first initiated shall be considered the Selected Arbitration.
The new dispute or subsequently filed arbitration shall be so consolidated, provided that the Arbitral Tribunal for the Selected
Arbitration determines that: (i) the new dispute or subsequently filed arbitration presents significant issues of law or fact common
with those in the Selected Arbitration; (ii) no party to the new dispute or to the Selected Arbitration would be unduly harmed;
and (iii) consolidation under these circumstances would not result in undue delay for the Selected Arbitration, Any such order
of consolidation issued by the Arbitral Tribunal shall be final and binding

 

    	 	53	 

     

    

upon the parties to the new dispute, the Selected
Arbitration and subsequently filed arbitrations, The Members and the Company waive any right they may have to appeal or to seek
interpretation, revision or annulment of such order of consolidation under the Arbitration Rules and/or the applicable Law in any
court. The Arbitral Tribunal for the Selected Arbitration into which a new dispute or subsequently filed arbitration is consolidated
shall serve as the Arbitral Tribunal for the consolidated arbitration.

 

(i)                 
Subject to applicable Law and this Section 14.08, process in any dispute, claim, action, suit or proceeding to enforce any
arbitral award rendered pursuant to and as provided in this Agreement may be served on a Member or the Company anywhere in the
world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each Member and the Company
agrees that service of process on a Member or the Company at the location, and as provided, in Section 14.02 shall be deemed effective
service of process on such Member or the Company, as applicable. Nothing herein shall affect the right of any Member or the Company
to serve legal process in any other manner permitted by applicable Law or at equity.

 

(j)                 
WITH RESPECT TO ANY DISPUTE, CLAIM, ACTION, SUIT OR PROCEEDING BETWEEN THE PARTIES IN CONNECTION WITH THIS AGREEMENT THAT,
PER THIS AGREEMENT OR APPLICABLE LAW MAY BE BROUGHT IN A COURT, EACH OF THE PARTIES IRREVOCABLY WAIVES AND RELEASES TO THE OTHER
ITS RIGHT TO A TRIAL BY JURY, AND AGREES THAT IT WILL NOT SEEK A TRIAL BY JURY IN ANY SUCH DISPUTE, CLAIM, ACTION, SUIT OR PROCEEDING.

 

Section 14.09.   
Specific Performance. Subject to compliance with Section 14.08 above, the parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties
hereto shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity.

 

Section 14.10.   
Expenses. Except as otherwise specified in this Agreement, all costs and expenses, including, without limitation,
fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions
contemplated hereby shalt be paid by the party incurring such costs and expenses.

 

Section 14.11.   
Amendments and Waivers; Assignment. (a) Any provision of this Agreement may be amended or waived if, and only if,
such amendment or waiver is in writing and signed, in the case of an amendment, by all parties hereto, or in the case of a waiver,
by the party or parties against whom the waiver is to be effective; provided, however, that Schedule 2.01 to this
Agreement shall be deemed amended from time to time to reflect the admission of a new Member, the withdrawal or resignation of
a Member and the adjustment of the Membership Units resulting from any Transfer or other disposition of a Membership Unit, in each
case that is made in accordance with the provisions hereof.

 

(b)               
No failure or delay by any party in exercising any right, power or privilege hereunder (other than a failure or delay beyond
a period of time specified herein) shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by applicable Law.

 

(c)                
The respective rights and obligations of the Members under this Agreement may not be assigned without the prior written
consent of the other Members. The consent of the other Members shall not be unreasonably withheld. In case of an assignment to
a Controlled company, Controlling company or company under common Control, such consent shall not be withheld in any circumstance
if the assigning party remains liable for the obligations of the assignee under this Agreement

 

    	 	54	 

     

    

or guarantees the fulfillment of such obligations,
as provided for in Section 10.02(b), except in the case in which Cosan US requests assignment to a joint venture company formed
by Cosan US or any Affiliate thereof and Shell International Petroleum Company Limited or any Affiliate thereof, in which case
the consent of Amyris may be withheld in its sole and absolute discretion.

 

Section 14.12.   
No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the parties
hereto and their permitted assigns and successors and nothing herein, express or implied, is intended to or shall confer upon any
other Person or entity, any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Without limiting the foregoing, any obligation of the Members to make Capital Contributions to the Company under this Agreement
is an agreement only between the Members and no other person or entity, including the Company, shall have any rights to enforce
such obligations.

 

Section 14.13.   
Headings. The headings and subheadings in this Agreement are included for convenience and identification only and
are in no way intended to describe, interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof.

 

Section 14.14.   
Construction. Each party hereto acknowledges and agrees it has had the opportunity to draft, review and edit the
language of this Agreement and that no presumption for or against any party arising out of drafting all or any part of this Agreement
will be applied in any controversy, claim or dispute relating to, in connection with or involving this Agreement. Accordingly,
the parties hereby waive the benefit of any rule of applicable Law, including California Civil Code Section 1654 and any successor
or amended statute, or any legal decision which would require that in cases of uncertainty, the language of a contract should be
interpreted most strongly against the party who drafted such language.

 

Section 14.15.   
Further Assurances. Each of the Members hereto shall use reasonable efforts to take, or cause to be taken, all appropriate
action, and to do, or cause to be done, all things necessary, proper or advisable under applicable Law to consummate and make effective
the transactions contemplated hereunder, including, without limitation, using reasonable efforts to obtain all licenses, permits,
consents, approvals, authorizations, qualifications and orders of the competent governmental entities. Each of the Members shall
cooperate with the other when required in order to effect the transactions contemplated hereunder. In case at any time after the
date hereof, any further action is necessary or desirable to carry out the purposes of this Agreement, the proper officers and
directors of each of the parties hereto shall use their reasonable efforts to take all such action.

 

    	 	55	 

     

    

IN WITNESS WHEREOF, the parties hereto have
entered into this Agreement or have caused this Agreement to be duly executed by their respective authorized officers, in each
case as of the Effective Date.

 

	 	AMYRIS, INC.	 
	 	 	 	 
	 	By:	   /s/ R. Asadorian	 
	 	 	Name: R. Asadorian	 
	 	 	Title:   CFO	 
	 	 	 	 
	 	COSAN US, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	American Refining Group, Inc.
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	NOVVI LLC	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 

 

    	[Second Amended and Restated Operating Agreement]

     

    

 

IN WITNESS WHEREOF, the parties hereto have
entered into this Agreement or have caused this Agreement to be duly executed by their respective authorized officers, in each
case as of the Effective Date.

 

 

	 	AMYRIS, INC.	 
	 	 	 	 
	 	By:	   	 
	 	 	Name: 	 
	 	 	Title:   	 
	 	 	 	 
	 	COSAN US, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	COSAN US, INC.
	 	 	 	 
	 	By:	/s/ (ILLEGIBLE)	 
	 	 	Name: (ILLEGIBLE)	 
	 	 	Title: Director	 
	 	 	 	 
	 	American Refining Group, Inc.
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	NOVVI LLC
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 

 

    
[Second Amended and Restated Operating Agreement]

     

    

IN WITNESS WHEREOF, the parties hereto have entered into this Agreement
or have caused this Agreement to be duly executed by their respective authorized officers, in each case as of the Effective Date.

 

	 	AMYRIS, INC.	 
	 	 	 	 
	 	By:	   	 
	 	 	Name: 	 
	 	 	Title:   	 
	 	 	 	 
	 	COSAN US, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	American Refining Group, Inc.
	 	 	 	 
	 	By:  	/s/ Timothy M. Brown	 
	 	 	Name: Timothy M. Brown	 
	 	 	Title: CEO	 
	 	 	 	 
	 	NOVVI LLC
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 

 

    
[Second Amended and Restated Operating Agreement]

     

    

IN WITNESS WHEREOF, the parties hereto have entered into this Agreement
or have caused this Agreement to be duly executed by their respective authorized officers, in each case as of the Effective Date.

 

	 	AMYRIS, INC.	 
	 	 	 	 
	 	By:	   	 
	 	 	Name: 	 
	 	 	Title:   	 
	 	 	 	 
	 	COSAN US, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	American Refining Group, Inc.
	 	 	 	 
	 	By:  		 
	 	 	Name: 	 
	 	 	Title: 	 
	 	 	 	 
	 	NOVVI LLC
	 	 	 	 
	 	By: 	/s/ Jason R. Wells	 
	 	 	Name: Jason R. Wells	 
	 	 	Title: CTO	 
	 	 	 	 
	 	By: 	/s/ Jeffrey Brown	 
	 	 	Name: Jeffrey Brown	 
	 	 	Title: President & CEO	 
	 	 	 	 

 

 

    
[Second Amended and Restated Operating Agreement]

     

    

Schedule
2.01

 

List of Members and Addresses

 

 

 

Amyris, Inc.

5885 Hollis Street, Suite 101

Emeryville, CA 94608

Attn:     General Counsel

 

Cosan US, Inc.

2711 Centerville Road, Suite 400

Wilmington, Delaware 19808

Attn:     President

 

American Refining Group, Inc.

100 Four Falls, Suite 215

West Conshohocken, PA 19428

Attn:     General Counsel

 

 

    i

     

    

SCHEDULE 4.01(a)

 

Prior Capital Contributions

 

Amyris:

 

	Capital Contribution        	M. Units	Event
	 	 	 
	$10,000,100*	100,001	Original allocation upon execution of
Amended & Restated Operating Agreement (March 26, 2013) ($100 was from the original incorporation
of Novvi LLC)
	 	 	 
	$237,266.78	2,372	LAO reconciliation
(April 1, 2014)
	 	 	 
	$2,075,000.00	20,750	Capital Call (April 10, 2014)
	 	 	 
	$545,219.26**	5,452	Capital Call (February 4, 2016)
	 	 	 
	$4,778,673.00**	71,425	Conversion of Member Loans (July 19, 2016)
	 	 	 
	$17,636,259.04	200,000	TOTAL
	 	 	 
	*Represents entrance into an expanded IP License Agreement as its contribution
	**Represents forgiveness of past due rent & Glycotech payments as its contribution
	 
	Cosan US:
	 
	Capital Contribution	M. Units	Event
	 	 	 
	$10,000,100	100,001	Original allocation upon execution of
Amended & Restated Operating Agreement (March 26, 2013) ($100 was from the original incorporation
of Novvi LLC)
	 	 	 
	$237,266.78	2,372	LAO reconciliation
(April 1, 2014)
	 	 	 
	$2,075,000.00	20,750	Capital Call (April 10, 2014)
	 	 	 
	$545,219.26	5,452	Capital Call (February 4, 2016)
	 	 	 
	$ 4,778,673.00	71,425  	Conversion of Member Loans (July 19, 2016)
	 	 	 
	$17,636,259.04	200,000	TOTAL
	 	 	 
	ARG:
	 	 	 
	Capital Contribution	M. Units	Event
	 	 	 
	$4,000,000	200,000	Initial cash investment pursuant to that
certain Equity Purchase Agreement, dated July 19, 2016.

 

    i

     

    

SCHEDULE 4.01(c)

 

Holder of Membership Units

 

	Membership Units	Initial Percentage Interest	Holder
	200,000	33.33%	Amyris
	200,000	33.33%	Cosan US
	200,000	33.33%	ARG
	600,000	100%	 

 

 

 

    i

     

    

Exhibit
A

 

Member Certificate

Second Amended and Restated Operating Agreement of Novvi LLC

 

THE MEMBERSHIP UNITS REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE
WITH THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES ACT OF 1933 OR AN EXEMPTION THEREFROM AND, IN EACH CASE, IN
COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

THE MEMBERSHIP UNITS REPRESENTED BY THIS CERTIFICATE ARE SUBJECT
TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE SECOND AMENDED AND RESTATED OPERATING AGREEMENT DATED AS OF JUNE ___, 2016,
AS IT MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE COMPANY. NO REGISTRATION
OF TRANSFER OF THESE MEMBERSHIP UNITS WILL BE MADE ON THE BOOKS OF THE COMPANY UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN
COMPLIED WITH.

 

All capitalized terms used herein, and not otherwise defined, have
the meaning set forth in the Second Amended and Restated Operating Agreement of Novvi LLC, dated as of June ___, 2016, as amended
from time to time (the “Agreement”).

 

The undersigned hereby acknowledges that [in exchange for a capital
contribution with a value of US$___________,] the undersigned [has received/is the Transferee of] [__] Membership Units in Novvi LLC
(the “Company”).

 

The undersigned further acknowledges that it has been given a copy
of, and has reviewed carefully, the Agreement. The undersigned agrees to be bound by all terms and provisions of the Agreement
[and to assume all obligations of the transferor of such Membership Units]. The undersigned hereby accepts, ratifies and agrees
to be bound by all actions duly taken pursuant to the terms and provisions of the Agreement by the Company prior to the date hereof.

 

	Dated	,	 	.	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	[Name of Member]
	 	 	 	 	 	 	 

 

 

    	A-1

     

    

Exhibit
B

 

Fair Market Value Methodology

 

“Fair Market Value”, for
purposes of the Agreement, shall be calculated in accordance with the rules set forth below.

 

The Fair Market Value of the Company and its
corresponding Membership Units shall be calculated according to the following procedure:

 

		(i)	the Fair Market Value shall be determined by two (2) internationally recognized and reputable investment
banks, with experience in the appraisal of assets in the lubricants (or similar market), being chosen by unanimous agreement of
Amyris, Cosan US, and ARG (“Appraisers”) within ten (10) Business Days as from the date the determination of
a Fair Market Value is triggered. The Appraisers shall be engaged by the Company, but the costs arising in connection with the
determination of the Fair Market Value shall be equally shared by the Members. The Company shall provide both Appraisers with the
same information that may be required by any Appraiser;

 

		(ii)	with respect to the Membership Units, the Fair Market Value shall be determined by the Appraisers
based on the following criteria: (a) such Membership Units shall be appraised as if the total number of Membership Units were
available for purchase and were purchased by Third Parties on an arms’ length basis, without any discount; (b) the then-current
status and the expected future results of the Company; and (c) the discounted projected future cash flows of the Company, based
on the Company’s applicable business plan and budget, or, if the Company has not started to conduct the business, the Fair
Market Value shall be determined considering the capital employed by the Members;

 

		(iii)	if any Appraiser presents a value range/band instead of a single value, the Fair Market Value provided
by such Appraiser shall be the mean of such value range/band, provided that the Appraisers shall be aware that in no event
such band, for the purposes of the assessment of the Fair Market Value, shall exceed twenty percent (20%) of either the minimum
or the maximum value amongst the value range/bands presented;

 

		(iv)	the Appraisers shall determine the Fair Market Value within thirty (30) days as from the date on
which they were engaged for such purpose, and the result of their work shall be submitted simultaneously to the Company and all
Members in writing;

 

		(v)	the binding Fair Market Value shall be the mean of both appraisals

 

		(vi)	absent of a manifest error, the Fair Market Value assessed according to the terms hereof shall
be final, binding and shall not be subject to any opposition from any Member, and shall remain valid for the purposes hereof for
a period of one hundred and twenty (120) days from the date it was finally assessed.

 

B-1Exhibit 10.03

 

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

CONFIDENTIAL

Amended & Restated IP License Agreement

 

 

 

This Amended & Restated IP License
Agreement (the “License Agreement”) is made and entered into effective as of July 19, 2016 (the “Effective
Date”) by and between Amyris, Inc., a Delaware corporation, having its place of business at 5885 Hollis Street,
Suite 100, Emeryville, California 94608 (“Amyris”) and Novvi LLC, a Delaware limited liability corporation,
having its place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“Novvi LLC”). Amyris
and Novvi LLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 

WHEREAS, Amyris
and Cosan US, Inc. formed Novvi LLC on September 6, 2011, with each owning fifty percent (50%) of the membership units of
Novvi LLC, to operate a joint venture involving the development, production, marketing and sale of Base Oils (as defined
below), Additives (as defined below), and Lubricants (as defined below) for use in the Lubricants Markets (as defined below);

 

WHEREAS, on
March 26, 2013, Amyris and Cosan US executed an Amended and Restated Operating Agreement for Novvi LLC (“Amended and Restated
Operating Agreement”) to memorialize their respective initial capital contributions to Novvi LLC and to establish how
they will operate Novvi LLC;

 

WHEREAS, in
order to fulfill its initial capital contribution to Novvi LLC under the Amended and Restated Operating Agreement and to enable
Novvi LLC to fulfill its intended purpose to develop, produce, market, and sell Base Oils, Additives, and Lubricants, Amyris and
Novvi LLC executed an IP License Agreement (the “Original License Agreement”) under which Amyris agreed to license
Novvi LLC rights under certain of its intellectual property;

 

WHEREAS, the
Parties amended certain portions of the Original License Agreement on March 21, 2016 through an amendment #1 to the Original License
Agreement;

 

WHEREAS, on
July 19, 2016, due to the addition of American Refining Group, Inc. as a new member of Novvi LLC, Amyris and Cosan US amended and
restated the Amended and Restated Operating Agreement (as such document may be further amended from time-to-time, the “Second
Amended and Restated Operating Agreement”);

 

WHEREAS, in
conjunction with the execution of the Second Amended and Restated Operating Agreement, the Parties desire to further amend and
restate the Original License Agreement through their execution of this License Agreement; and

 

NOW, THEREFORE,
in consideration of the foregoing premises and the mutual covenants contained in this License Agreement, the Parties hereby agree
as follows:

 

ARTICLE 1

 

DEFINITIONS

 

Terms defined in this Article 1 and parenthetically
elsewhere, including the introductory paragraph and the recitals, will have the same meaning throughout this License Agreement
unless otherwise specified.

 

“Additive” means any
material added to a Base Oil to change its properties, characteristics, or performance (e.g., anti-foam, anti-wear, corrosion
inhibitor, detergent, dispersant, pour point depressant, anti-oxidant, viscosity index improver, or friction modifier).

    Page 1 of 37

    CONFIDENTIAL

    

“Affiliate” means, with
regard to a particular entity (a “First Person”), any person or entity who, directly or indirectly, through
one or more intermediates, Controls the First Person, is Controlled by the First Person, or is under common Control with the First
Person. Notwithstanding the preceding definition, for purposes of this License Agreement, Novvi LLC is not considered an Affiliate
of Amyris or Cosan US (or their respective Affiliates) nor are Amyris and Cosan US (or their respective Affiliates) considered
Affiliates of Novvi LLC.

 

“Alternative Technology”
means a technology (other than a BioFene-related technology) from a renewable source or a molecule (other than a BioFene-derived
molecule) from a renewable source from which Base Oils or Additives, in each case, for the Lubricants Market could reasonably be
expected to be developed or made.

 

“Amyris Base Technology”
means the Patents and Know-How that (i) are Controlled by Amyris as of the Effective Date or become Controlled by Amyris during
the term of Novvi LLC’s licenses under Section 2.1 and (ii) are necessary or reasonably useful for the development, making
(and having made), offering for sale, sale, and importing of Base Oils, Additives, and Lubricants derived from BioFene. For the
avoidance of doubt, the term “Amyris Base Technology” expressly excludes any Amyris BioFene Manufacturing Technology.

 

“Amyris BioFene Manufacturing
Technology” means the Patents and Know-How that (i) are Controlled by Amyris and (ii) are necessary or reasonably useful
for the development, making (and having made), offering for sale, sale, and importing of BioFene itself, including, but not limited
to, the escrowed BioFene Production Strain and any Patents and Know-How related to the genetic engineering of such BioFene Production
Strain, the fermentation methods for making BioFene, the methods of recovery of BioFene from fermentation broth, the processes
of isolating BioFene directly from fermentation broth, and the methods of purifying BioFene. The term “Amyris BioFene Manufacturing
Technology” also includes any and all Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements,
but expressly excludes any Novvi LLC BioFene Transformation Technology

 

“Amyris Breach Invention”
means any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable, conceived, reduced
to practice, made, observed or developed (together with all intellectual property rights related thereto) by or on behalf of Amyris
or its Affiliates or sublicensees, solely or jointly with others, in violation of the license granted to it in Section 2.2.

 

"Amyris Invention" means
any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable, conceived, reduced to practice,
made, observed or developed (together with all intellectual property rights related thereto) by or on behalf of Amyris, solely
or jointly with others. The term “Amyris Invention” includes any improvement by or on behalf of Amyris, solely or jointly
with others, during the term of Amyris’s license under Section 2.2 to Novvi LLC BioFene Transformation Technology, but excludes
Amyris Breach Inventions.

 

“Amyris Pre-Signature Base Technology”
means Amyris Base Technology used by Amyris or an Amyris Affiliate to produce Base Oils or Lubricants offered for sale, sold, or
sampled to Third Parties before the Effective Date.

 

“Applicable Law” means
any law, rule, treaty, or regulation of any governmental authority or any judgment, order, write, decree, permit or license of
any governmental authority of competent jurisdiction, in each case applicable to the Party or activity at issue.

    Page 2 of 37

    CONFIDENTIAL

    

“Base Oil” means a fluid
base compound to which other oils, Additives, or components are added to produce a Lubricant.

 

“BioFene” means farnesene
produced through Amyris BioFene Manufacturing Technology.

 

“By-Products” means
those by-products directly resulting from (1) Novvi LLC’s manufacture, under its license in Section 2.1(a)(i), of Base Oils,
Additives, or Lubricants derived from BioFene solely for the Lubricants Market or (2) the manufacture of Base Oils, Additives,
or Lubricants derived from BioFene solely for the Lubricants Market by a permitted sublicensee of Novvi LLC per a sublicense under
Sections 2.1(b) or (c). For clarity, Diesel By-Products are a subset of By-Products.

 

“Copyrights” means all
copyrights, whether in published or unpublished works; databases, data collections and rights therein, mask work rights, software,
web site content; rights to compilations, collective works and derivative works of any of the foregoing and moral rights in any
of the foregoing; registrations and applications for registration for any of the foregoing and any renewals or extensions thereof;
and moral rights and economic rights of others in any of the foregoing.

 

“Control” (including
any variations such as “Controls, “Controlled” or “Controlling”) means:

 

		(i)	in the context of Patents and Know-How, rights under and to such Patents and Know-How held by a
Party, whether by ownership or license, sufficient to grant the applicable license or rights under this License Agreement without
violating the terms of any arrangement with any Third Party; and

 

		(ii)	in the definition of Affiliate, (1) possessing, directly or indirectly, the power to direct the
management or policies, whether through the ownership of voting securities, by contract relating to voting rights or corporate
governance, or otherwise, or (2) ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or
other ownership interest.

 

“Escrow Agreement” means the
Strain Escrow Agreement, dated July 19, 2016, by and between Amyris, Novvi LLC, and SciSafe Inc., as may be amended from time-to-time.

 

“European Union” means
those countries that were members of the European Union as March 21, 2016, which countries are listed on Exhibit A to this Agreement.”

 

“Exclusivity Exceptions”
means the rights retained by Amyris under Amyris Base Technology for (i) itself and its Affiliates working independently or together,
(ii) Total working independently, and (iii) Total and Amyris (and/or Amyris Affiliates) working together, to develop, make (and
have made), offer for sale, sell, and import Base Oils derived from BioFene for use in the Lubricants Market but only to the extent
such Base Oils are used as a component in such entities’ own Lubricants in such market. For clarity, Total, Amyris and/or
Amyris Affiliates have no retained rights under Amyris Base Technology to develop, make (have made), offer for sale, sell, or import
any Base Oil derived from BioFene for use in the Lubricants Market as a product separate and apart from a finished Lubricant.

 

“Exploit” means to make,
have made, import, use, sell, have sold, distribute, dispose of or offer to dispose of, market, promote or offer for sale including
to research and develop.

    Page 3 of 37

    CONFIDENTIAL

    

“Insolvency
Event” means:

 

		(i)	an involuntary petition under any bankruptcy or insolvency law or under the reorganization provisions
of any such law is filed with respect to a Party or a receiver of, or for, the property of a Party is appointed without acquiescence
or consent of such Party, which petition or appointment remains undischarged or unstayed for an aggregate period of ninety (90)
days (whether or not consecutive); or

 

		(ii)	a Party consents to the entry of an order for relief against it in an involuntary case under any
bankruptcy or insolvency law or under the reorganization provisions of any such law; or

 

		(iii)	a voluntary petition under any bankruptcy or insolvency law or under the reorganization provisions
of any such law is filed by a Party, a voluntary assignment of a Party’s property for the benefit of creditors is made, or
a receiver of, or for, the property of a Party is appointed by, or acquiesced or consented to, by such Party.

 

“Joint BioFene Manufacturing Improvements”
means any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable, conceived, reduced
to practice, made, observed or developed (together with all intellectual property rights related thereto) jointly by or on behalf
of Amyris and Novvi LLC (or their respective Affiliates, employees, sublicensees, contractors, or agents) that are based upon,
derived from, incorporating, in connection with or related to Amyris BioFene Manufacturing Technology, including in connection
with the conversion or operation of a sugar/ethanol mill to include the manufacture of BioFene or the operation of such mill or
facility in connection with Novvi LLC’s manufacture of BioFene.

 

“Joint Invention” means
any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable, conceived, reduced to practice,
made, observed or developed (together with all intellectual property rights related thereto) jointly by or on behalf of Amyris
and Novvi LLC (or their respective Affiliates, employees, sublicensees, contractors, or agents) during the term of this License
Agreement, other than Joint BioFene Manufacturing Improvements.

 

“Know-How” means any
non-patented information and tangible materials, including: (i) technical and non-technical data, specifications, formulae, compounds,
formulations, assays, designs, results, information, conclusions, interpretations, inventions, developments, discoveries, ideas,
improvements, and trade secrets, (ii) methods, databases, tests, procedures, processes, and techniques, (iii) escrowed Production
Strains (if applicable), and (iv) other know-how and technology including Copyrights.

 

“Lubricant” means all
substances introduced between two moving surfaces to reduce the friction between them, improving efficiency and reducing wear,
or dissolving or transporting foreign particles, or distributing heat, in each case comprising a formulation of at least one Base
Oil combined or blended with Additives, sold as a finished product for automotive and industrial applications, for use in, by way
of example only: automotive, 2-cycle, marine and other engines, ship lubrication, hydraulic equipment, food processing equipment
and machinery, and wind turbines. However, the term “Lubricants” expressly excludes drilling oils, fluids and muds,
in accordance with the standards set by American Petroleum Institute.

 

“Lubricants Market”
means the worldwide market for automotive, commercial, and industrial Lubricants. For the avoidance of doubt, the following markets,
but not limited to the following markets, are expressly excluded from the term “Lubricants Market”: the markets for
flavors and fragrances, food additives, cosmetics and personal care, drilling oils, fluids and muds, fuels, cleaners, paints, coatings,
ink,

    Page 4 of 37

    CONFIDENTIAL

    

consumer-packaged goods, pesticides, and
pharmaceuticals.

 

“Novvi LLC BioFene Transformation
Technology” means the Patents and Know-How in each case that (i) are Controlled by Novvi LLC as of the Effective Date
or become Controlled by Novvi LLC during the term of Amyris’s license under Section 2.2 (in each case other than Patents
and Know-How licensed from Amyris) and (ii) are related to the chemical transformation of BioFene or a BioFene-derivative into
another compound. For clarity, the term “Novvi LLC BioFene Transformation Technology” does not include Novvi LLC Breach
Inventions.

 

"Novvi LLC BioFene
Manufacturing Improvement" means any and all inventions, discoveries, data, and information, whether or not copyrightable
or patentable, conceived, reduced to practice, made, observed or developed (together with all intellectual property rights related
thereto) by or on behalf of Novvi LLC or its Affiliates or sublicensees, solely or jointly with others that are based upon, derived
from, incorporating, in connection with or related to Amyris BioFene Manufacturing Technology.

 

“Novvi LLC Breach
Invention” means any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable,
conceived, reduced to practice, made, observed or developed (together with all intellectual property rights related thereto) by
or on behalf of Novvi LLC or its Affiliates or sublicensees, solely or jointly with others, in violation of the licenses granted
to it in Sections 2.1 or 2.3.

 

"Novvi
LLC Invention" means any and all inventions, discoveries, data, and information, whether or not copyrightable or patentable,
conceived, reduced to practice, made, observed or developed (together with all intellectual property rights related thereto) by
or on behalf of Novvi LLC, solely or jointly with others. The term “Novvi LLC Invention” includes any improvement
by or on behalf of Novvi LLC, solely or jointly with others, during the term of Novvi LLC’s licenses under Section 2.1 to
Amyris Base Technology, but excludes Novvi LLC Breach Inventions and any Novvi LLC BioFene Manufacturing Improvements or Joint
BioFene Manufacturing Improvements.

 

“Patents” means any
patents, patent applications, or certificates of invention, together with all additions, divisions, continuations, continuations-in-part,
provisionals, converted provisionals, substitutions, reissues, re-examinations, revalidations, extensions, registrations, patent
term extensions, supplemental protection certificates, renewals, and the like with respect to any of the foregoing.

 

“Production Strain”
means a recombinant yeast or some other microbial agent that has been genetically engineered to make a desired compound or product
by means of a fermentation process. For clarity, the term Production Strain encompasses populations, subpopulations, and derivatives
of such genetically engineered yeast or other microbial agent.

 

“Third Party” means
any person, corporation, joint venture or other entity, other than Novvi LLC, Amyris, Cosan US, their respective Affiliates, or
their respective permitted successors and assigns.

 

“Total” means Total
Gas & Power USA, SAS, a société par acions simplifiée organized under the laws of the Republic
of France, and its Affiliates.

 

The following terms have the meanings set
forth in the Section set forth opposite such term.

 

	Term	Section
	 	 
	Amended and Restated Operating Agreement
	Recitals
	Amyris	Introductory paragraph

 

 

    Page 5 of 37

    CONFIDENTIAL

    

	Amyris Designate	5.9(a)
	Amyris Indemnitees	7.2
	Amyris Third Party Claim	7.2
	Arbitral Tribunal	8.2(c)
	Arbitration Chamber	8.2(b)
	Arbitration Rules	8.2(b)
	Assumption Notice	7.3(b)
	Code	2.6
	Confidential Information	5.10(a)
	Diesel By-Products	4.1
	Disclosing Party	5.10(a)
	Effective Date	Introductory paragraph
	Escrow Agent	2.3(c)
	Escrowed Materials	2.3(c)
	Exercise Notice	3.3(a)
	Indemnification Claim Notice	7.3(a)
	Indemnified Party	7.3(a)
	Indemnifying Party	7.3(a)
	Jet Fuel By-Product	4.2(a)
	License Agreement	Introductory paragraph
	License Conversion Event	2.3(b)
	Losses	7.1
	Novvi LLC	Introductory paragraph
	Novvi LLC Designate	5.9(b)
	Novvi LLC Indemnitees	7.1
	Novvi LLC Third Party Claim	7.1
	Original License Agreement	Recitals
	Parties	Introductory paragraph
	Party	Introductory paragraph
	Receiving Party	5.10(a)
	Representative	5.10(a)
	ROFO	3.1
	ROFO Notice	3.2
	Second Amended and Restated Operating Agreement	Recitals 
	Selected Arbitration	8.2(h)
	SOPs	2.3(c)
	Third Party Claim	7.3(a)

 

ARTICLE 2

 

LICENSE GRANTS

 

2.1Licenses
to Novvi LLC under Amyris Base Technology.

 

(a)Licenses
to Make Base Oils, Additives, and Lubricants from BioFene. Subject to the terms and conditions in this License Agreement, Amyris
hereby grants Novvi LLC:

 

		(i)	an exclusive (except as to the rights retained in the scope of the Exclusivity Exceptions), worldwide,
royalty-free, non-sublicensable (except as set forth in Subsections (b) and (c) below), and non-assignable license under Amyris
Base Technology to Exploit Base Oils, Additives (other than viscosity index improvers), and Lubricants derived from BioFene

 

    Page 6 of 37

    CONFIDENTIAL

    

solely for the Lubricants Market
and, as described below in this Section 2.1(a), for such customers outside the Lubricants Market for whom Amyris grants a waiver;
and

 

		(ii)	subject to the limitations in Article 4 restricting the sale of By-Products for use in or
as (i) diesel fuel in the European Union and (ii) jet fuel worldwide, a non-exclusive, worldwide, royalty-free, non-sublicensable,
and non-assignable license under Amyris Base Technology to offer for sale, sell, and import any By-Products

 

		(iii)	a non-exclusive, worldwide, royalty-free, non-sublicensable (except as set forth in Subsections
(b) and (c) below), and non-assignable license under Amyris Base Technology to Exploit Additives that are viscosity index improvers
derived from BioFene solely for the Lubricants Market.

 

Consistent with the scope of
its licenses in (a)(i) and (iii), Novvi LLC and its Affiliates shall not sell any Base Oil, Additive, or Lubricant derived from
BioFene to any Third Party that Novvi LLC or its Affiliates knows has previously resold or used, or intends to resell or use, such
product outside of the Lubricants Market, and Amyris acknowledges that Novvi LLC and its Affiliates will not be responsible for
any resale or use of a Novvi LLC or Novvi LLC Affiliate’s Base Oil, Additive, or Lubricant derived from BioFene outside of
the Lubricants Market by any Third Party whom Novvi LLC or its Affiliates did not know had previously resold or used, or intended
to resell or use, such product outside of the Lubricants Market.

 

If Novvi LLC or its Affiliate
identify an opportunity to sell Base Oil derived from BioFene outside of the Lubricants Market to a potential customer that is
currently using a Base Oil composed of any combinations of Base Oil Groups I-IV as defined by the American Petroleum Institute,
Novvi LLC will provide written notice to Amyris of the opportunity and state the rationale for seeking a waiver to the scope of
the license in Section 2.1(a)(i) regarding such opportunity.  Amyris will promptly consider such waiver request in good faith
and not unreasonably withhold its approval of such request. However, if Amyris has licensed such opportunity to a Third Party or
has an ongoing business relationship with such prospective customer as of the date of such notice, then declining to grant such
waiver will never be considered unreasonable. If Amyris approves a waiver, it must be in writing to be effective, and then the
sale of Base Oil derived from BioFene by Novvi LLC to such potential customer for such approved use, and future sales to such potential
customer for such approved use, will not be a breach of its license hereunder, subject to compliance with the preceding paragraph
regarding knowledge of such customer’s previous or intended use or resale of the products outside such approved use or the
Lubricants Market.

 

(b)Sublicense
Rights to Affiliates. Novvi LLC may sublicense its rights under the licenses granted in Subsections (a)(i) and (iii) to an
Affiliate of Novvi LLC; provided, that,:

 

		(i)	Novvi LLC shall grant such sublicense to an Affiliate only while such entity is and remains an
Affiliate;

 

		(ii)	such sublicense automatically and immediately terminates upon such entity no longer being an Affiliate
of Novvi LLC;

 

		(iii)	each such sublicense to an Affiliate shall be in writing and contain terms that are consistent
in all material respects with this License Agreement including confidentiality terms regarding non-disclosure and non-use of Amyris
Confidential Information and provisions governing intellectual property rights and obligations;

 

    Page 7 of 37

    CONFIDENTIAL

    

		(iv)	Novvi LLC shall only grant such a sublicense subject to terms that prohibit the Affiliate from
using the sublicensed Amyris Base Technology for any purpose other than to Exploit a Base Oil, Additive, or Lubricant derived from
BioFene solely for the Lubricants Market;

 

		(v)	Novvi LLC shall reasonably monitor such sublicensed Affiliate to ensure it is not violating the
prohibition in clause (iv), its confidentiality obligations, or its intellectual property obligations in a manner consistent with
the procedures Novvi LLC uses to monitor its own licensees and sublicensees to ensure proper use of Novvi LLC’s intellectual
property, but no less than commercially reasonable efforts;

 

		(vi)	Novvi LLC shall retain the right to terminate any such sublicense in the event the applicable sublicensed
Affiliate violates the prohibition in clause (iv), its confidentiality obligations, or its intellectual property obligations; and

 

		(vii)	Novvi LLC shall immediately terminate any such sublicense in the event the applicable sublicensed
Affiliate violates the prohibition in clause (iv), its confidentiality obligations, or its intellectual property obligations and
fails to cure such breach within a reasonable period, which, in no event, shall exceed thirty (30) days after written notice.

 

(c)Limited Sublicense
to Third Party Manufacturing and R&D Subcontractors. Novvi LLC may not sublicense any of its rights under the licenses
granted in Subsections (a)(i) or (iii) to Third Parties, except to a Third Party that is (x) manufacturing for Novvi LLC or an
Affiliate of Novvi LLC, in a subcontractor role, a Base Oil, Additive, and/or Lubricant derived from BioFene for the Lubricants
Market or (y) performing research and development for Novvi LLC or an Affiliate of Novvi LLC, in a subcontractor role, on a Base
Oil, Additive, and/or Lubricant derived from BioFene for the Lubricants Market; provided, that,:

 

		(i)	Novvi LLC shall grant such Third Party manufacturing subcontractor a sublicense only to make, solely
for Novvi LLC or its Affiliates, either a Base Oil, Additive, and/or Lubricant, as the case may be, derived from BioFene solely
for the Lubricants Market; shall grant such Third Party R&D subcontractor a sublicense only to perform research and development,
solely for Novvi LLC or its Affiliates, of Base Oils, Additives, and/or Lubricants, as the case may be, derived from BioFene solely
for the Lubricants Market; and, in each case, shall prohibit such sublicensed Third Party subcontractors from using the sublicensed
Amyris Base Technology for any other purpose;

 

		(ii)	each such sublicense agreement shall be in writing and contain terms that are consistent in all
material respects with this License Agreement including confidentiality terms regarding non-disclosure and non-use of Amyris Confidential
Information and provisions governing intellectual property rights and obligations;

 

		(iii)	Novvi LLC shall reasonably monitor such sublicensed Third Party subcontractors to ensure they are
not violating the prohibitions in clause (i), their confidentiality obligations, or their intellectual property obligations in
a manner consistent with the procedures Novvi LLC uses to monitor its own licensees and sublicensees to ensure proper use of Novvi
LLC’s intellectual property, but no less than commercially reasonable efforts;

 

		(iv)	Novvi LLC shall retain the right to terminate any such sublicense in the event the applicable sublicensed
Third Party subcontractor violates the prohibitions in clause (i),

 

    Page 8 of 37

    CONFIDENTIAL

    

its confidentiality
obligations, or its intellectual property obligations; and

 

		(v)	Novvi LLC shall immediately terminate any such sublicense in the event the applicable sublicensed
Third Party subcontractor violates the prohibitions in clause (i), its confidentiality obligations, or its intellectual property
obligations and fails to cure such breach within a reasonable period, which, in no event, shall exceed thirty (30) days after written
notice.

 

(d)No Right
to Manufacture BioFene. For clarity, under the licenses granted in Subsection (a) above, Novvi LLC has no right to make or
have made BioFene under any Amyris intellectual property. The rights of Novvi LLC to make or have made BioFene are set forth in
Section 2.3.

 

2.2License to
Amyris under Novvi LLC BioFene Transformation Technology.

 

(a)License.
Subject to the terms and conditions in this License Agreement, Novvi LLC hereby grants Amyris an exclusive, worldwide, royalty-free,
fully paid-up, sublicensable, and non-assignable license under Novvi LLC BioFene Transformation Technology for any use other than
to Exploit Base Oils, Additives, or Lubricants derived from BioFene for the Lubricants Market.

 

(b)Sublicense
Rights. Amyris may sublicense any of its rights under the license granted in Subsection (a) through multiple tiers of sublicensees;
provided, that,:

 

		(i)	Amyris shall only grant such sublicenses subject to terms that prohibit all such sublicensees,
including direct sublicensees, any sublicensees of such sublicensees, or any other sublicensee pursuant to one of the multiple
tiers of such sublicenses, from using the sublicensed Novvi LLC BioFene Transformation Technology to Exploit any Base Oil, Additive,
or Lubricant derived from BioFene for the Lubricants Market;

 

		(ii)	each such sublicense agreement shall be in writing and contain terms that are consistent in all
material respects with this License Agreement including confidentiality terms regarding non-disclosure and non-use of Novvi LLC’s
Confidential Information and provisions governing intellectual property rights and obligations;

 

		(iii)	Amyris shall reasonably monitor such sublicensees to ensure they are not violating the prohibition
in clause (i), their confidentiality obligations, or their intellectual property obligations in a manner consistent with the procedures
Amyris uses to monitor its own licensees and sub-licensees to ensure proper use of Amyris’s intellectual property, but no
less than commercially reasonable efforts;

 

		(iv)	Amyris shall retain the right to terminate any such sublicense in the event the applicable sublicensee
violates the prohibition in clause (i), its confidentiality obligations, or its intellectual property obligations; and

 

		(v)	Amyris shall immediately terminate any such sublicense in the event the applicable sublicensee
violates the prohibition in clause (i), its confidentiality obligations, or its intellectual property obligations and fails to
cure such breach within a reasonable period, which, in no event, shall exceed thirty (30) days after written notice.

 

2.3License
to Novvi LLC to Manufacture BioFene under Amyris BioFene Manufacturing Technology.

    Page 9 of 37

    CONFIDENTIAL

    

(a)Non-Exclusive
License to Manufacture BioFene. Amyris grants, subject to the conditions described below, Novvi LLC a non-exclusive, non-assignable,
royalty-free, and non-sublicensable (except as necessary to exercise its “have made” rights using Third Party subcontractor
manufacturers or Affiliates) license under Amyris BioFene Manufacturing Technology to make and have made BioFene solely to produce
Novvi LLC’s (and, if applicable, Novvi LLC’s Affiliates’) Base Oils, Additives, and Lubricants derived from BioFene
for the Lubricants Market.

 

(b)Conversion
to a Royalty-Bearing License. Should Amyris no longer own any membership units or other equity interest in Novvi LLC (the “License
Conversion Event”), the royalty-free license granted to Novvi LLC under subsection (a) above automatically becomes royalty-bearing,
and within thirty (30) days after the License Conversion Event, the Parties will agree in writing upon a commercially-reasonable
royalty rate and terms for such license. In the event the Parties do not agree within such time period, the Parties will promptly
engage in an accelerated “baseball arbitration” process to determine a commercially-reasonable royalty rate and terms
for the license.

 

(c)Escrowed
Materials. By September 1, 2016, Amyris shall deposit with SciSafe Inc. (the “Escrow Agent”), pursuant to the Escrow
Agreement, (1) the Production Strain presently used by Amyris to commercially produce BioFene and (2) the process, including the
applicable standard operating procedures (“SOPs”), presently used by Amyris to commercially produce BioFene with such
escrowed Production Strain (collectively (1) and (2), as annually updated per the next paragraph, the “Escrowed Materials”).

 

Amyris
shall, on or about every June 30, update the Escrowed Materials by replacing the escrowed Production Strain with the Production
Strain then being used by Amyris to commercially produce BioFene and replacing the escrowed BioFene production process information
with the process, including the applicable SOPs, then used by Amyris to commercially produce BioFene with the newly escrowed Production
Strain. Amyris’s obligations to update the Escrowed Materials shall terminate upon the earlier of (i) the date the Escrowed
Materials are released to Novvi LLC per the procedures in the Escrow Agreement and (ii) thirty (30) days after the date on which
Amyris concludes its BioFene strain development program.

 

(d)Release
of Escrowed Materials to Novvi LLC. Upon release of the Escrowed Materials to Novvi LLC per the procedures in the Escrow Agreement,
Novvi LLC may use the Escrowed Materials only to exercise its license under Subsection (a) above and only at a manufacturing location
(whether such location is owned by Novvi LLC, a Novvi LLC Affiliate, or a Third Party) approved in advance by Amyris in writing,
which approval will not be unreasonably withheld. Immediately upon expiration or earlier termination of its license in Subsection
(a), Novvi LLC will cease its and any Affiliate’s or Third Party’s use of, and will properly destroy, all of the Production
Strain, the other Escrowed Materials, and any other intellectual property of Amyris in Novvi LLC’s, a Novvi LLC’s Affiliate’s
or a Third Party’s possession and certify such destruction in writing to Amyris. 
Novvi LLC may not, and shall not allow any other person or entity to, reverse engineer, engineer, or otherwise genetically modify
the Production Strain or to genetically modify engineer any other strain from the Production Strain and, except as expressly permitted
in this Section 2.3, may not to distribute, disclose or transfer the Production Strain, the other Escrowed Materials, or any other
intellectual property of Amyris to any other person or entity. Despite a release to Novvi LLC, the Escrowed Materials remain the
exclusive property and Confidential Information of Amyris, and such release does not grant any ownership rights or, except as specifically
set forth herein, any other rights of use, express or implied, in the Escrowed Materials to Novvi LLC or any other person or entity.

 

(e)Manufacturing
through an Affiliate or Third Party. To the extent Novvi LLC, in the exercise of its “have made” rights under Subsection
(a), desires to engage an Affiliate or Third Party to

    Page 10 of 37

    CONFIDENTIAL

    

produce
BioFene for it, such Affiliate or Third Party must execute a binding written contract with Novvi LLC, subject to Amyris’s
prior written approval, containing at least the following provisions before Novvi LLC provides any of the released Escrowed Materials
(including the applicable Production Strain) to such Affiliate or Third Party:

 

		(i)	a covenant by the Affiliate or Third Party to not use the Escrowed Materials except to make BioFene
solely for Novvi LLC per Novvi LLC’s license under Section 2.3(a);

 

		(ii)	a covenant by the Affiliate or Third Party to not reverse engineer the Production Strain, to not
to engineer or genetically modify the Production Strain, and to not distribute, disclose or transfer the Production Strain, the
other Escrowed Materials, or any related intellectual property of Amyris to any other person or entity;

 

		(iii)	a covenant by the Affiliate or Third Party to hold in strict confidence, and to take all reasonable
precautions to protect, the Escrowed Materials (including the Production Strain) and any other Confidential Information of Amyris
that it obtains and to not divulge any of such information or any information derived therefrom to any person, except an employee
who has a need to know for the Affiliate or Third Party to produce BioFene for Novvi LLC;

 

		(iv)	a covenant by the Affiliate or Third Party that its manufacture and supply of BioFene on behalf
of Novvi LLC will, at all times, be conducted in accordance with applicable laws, rules and regulations;

 

		(v)	automatic termination of the Affiliate’s or Third Party’s contract with Novvi LLC and
of its use and possession of the Production Strain, the other Escrowed Materials, or any other intellectual property of Amyris
upon the Affiliate’s or Third Party’s breach of such contract;

 

		(vi)	a covenant by the Affiliate or Third Party that, immediately following termination of the Affiliate’s
or Third Party’s contract with Novvi LLC, it will properly destroy all of the Production Strain, the other Escrowed Materials,
or any other intellectual property of Amyris in the Affiliate’s or Third Party’s possession and certify such destruction
in writing to Amyris;

 

		(vii)	Amyris has the right, at least once per calendar quarter, upon reasonable prior notice and during
normal business hours, to inspect such Affiliate’s or Third Party’s facilities at which BioFene is being manufactured;

 

		(viii)	Amyris has the right, upon reasonable prior notice and during normal business hours, to have a
representative present from time-to-time during the Affiliate’s or Third Party’s manufacture of BioFene;

 

		(ix)	Amyris is expressly named in the contract as a third party beneficiary with the right to enforce
such contract against the Affiliate or Third Party;

 

		(x)	Amyris, as third party beneficiary, is entitled to injunctive or other equitable remedies, in addition
to all other available remedies, against the Affiliate’s or Third Party’s breach or threatened breach of contract with
regard to the Production Strain, the other Escrowed Materials, or any other intellectual property of Amyris without the necessity
of showing irreparable harm, balancing of harms, consideration of the public interest or

    Page 11 of 37

    CONFIDENTIAL

    

inadequacy of monetary damages
as a remedy and without posting any bond or other security as a condition for obtaining any such relief and the Affiliate or Third
Party irrevocably and unconditionally waives any such requirements;

 

		(xi)	agreement by the Affiliate or Third Party to fully defend, indemnify, and hold harmless Amyris
for the Affiliate’s or Third Party’s actions, inactions or breaches under such contract; and

 

		(xii)	agreement by the Affiliate or Third Party that to obtain and maintain insurance coverage with a
reputable carrier at coverage amounts commercially reasonable for its activities and commitments under such contract.

 

Amyris and Novvi LLC agree that Amyris
has the primary right, but not obligation, to pursue actions against the Affiliate or Third Party to protect the Production Strain,
other Escrowed Materials, and other intellectual property of Amyris.

 

(f)Tech
Transfer. Upon release of the Escrowed Materials to Novvi LLC per the procedures in the Escrow Agreement, Amyris agrees to
provide a one-time, site-specific, and reasonable amount (but no more than one hundred (100) hours) of technical assistance to
Novvi LLC to enable Novvi LLC to implement the Escrowed Materials consistent with the license in subsection (a). However, due to
the potential variances in manufacturing facilities, equipment, capabilities, personnel, experience, locations, infrastructure,
and/or operations, there is no guarantee of successful implementation or performance of the Escrowed Materials at any facility,
even after the one-time technical assistance.

 

(g)Disputes.
Any dispute between the Parties regarding the deposit or release of the Escrowed Materials shall be resolved as provided in Section 8.2.

 

2.4No Implied
or Additional Rights or Licenses. Except as specified in this License Agreement, Amyris grants no rights to Novvi LLC to use
any of Amyris’s Confidential Information or intellectual property. Except as specified in this License Agreement, Novvi LLC
grants no rights or licenses to Amyris to use any of Novvi LLC’s Confidential Information or intellectual property.

 

2.5Novvi LLC
Efforts in Brazil. Novvi LLC agrees it will exert commercially reasonable efforts to
use the licensed technology in order to try to maintain the validity of the Patents in the Amyris Base Technology and, if licensed
to Novvi LLC, in the Amyris BioFene Manufacturing Technology and any Alternative Technology, in each case in the territory of Brazil.

 

2.6Effect of
Bankruptcy on the Licenses. All rights and licenses granted under this Article 2 by Amyris or Novvi LLC are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code (the “Code”), licenses of rights
to “intellectual property” as defined under Section 101 of the Code. The Parties agree that, in the event of a Party’s
Insolvency Event, the other Party in its capacity as a licensee under this Article 2 will, to the extent that its license is still
in effect at the time of such Insolvency Event, retain and may fully exercise all of its rights and elections under the Code (or
any same or similar provision in any jurisdiction other than the United States) with regard to such license and rights, subject
to payments due the licensor Party (if any) as a result of the exercise of such rights and subject to the terms and conditions
of such license and rights set forth in this License Agreement.

 

The Parties further agree
that, in any Insolvency Event involving a Party, that the other Party will be entitled to a complete duplicate of (or complete
access to, as appropriate) any such intellectual property

    Page 12 of 37

    CONFIDENTIAL

    

licensed to such licensee
Party under its continuing license and all tangible embodiments of such intellectual property, and same, if not already in its
possession, will be promptly delivered to the licensee Party (i) upon any such commencement of a bankruptcy proceeding upon such
licensee Party’s written request or (ii) if not promptly delivered under (i) above, following any rejection of this License
Agreement by or on behalf of such Party (e.g. by a bankruptcy trustee), upon written request for such transfer by the licensee
Party. For the avoidance of doubt, nothing in this clause may be construed as forcing a Party to act in breach of any mandatory
bankruptcy laws and regulations applicable in its jurisdiction.

 

 

ARTICLE 3

 

RIGHT OF FIRST OFFER REGARDING ALTERNATIVE
TECHNOLOGY

 

3.1Right of
First Offer to Amyris’s Alternative Technology. Notwithstanding the exclusivity provisions in Section 13.01 of the Second
Amended and Restated Operating Agreement, if while Novvi LLC’s licenses under Section 2.1 are in effect, Amyris (i)
develops, acquires, or in-licenses an Alternative Technology and (ii) wishes to exclusively license or sell to a Third Party the
use or ownership of such Alternative Technology for purposes of developing, making (having made), offering for sale, selling, or
importing Base Oils, Additives, or Lubricants for the Lubricants Market, then, prior to engaging in a discussion with any Third
Party or soliciting an offer from any Third Party in this respect, Amyris shall first offer Novvi LLC the right to exclusively
license or acquire (subject to the Exclusivity Exceptions) use or ownership of such Alternative Technology for the development,
making (having made), offering for sale, sale, and importation of Base Oils, Additives, and Lubricants solely in the Lubricants
Market (“ROFO”); provided such ROFO does not violate the terms of any arrangement with any Third Party from
whom Amyris acquired or licensed such Alternative Technology, if applicable.

 

For the avoidance of doubt, the foregoing
ROFO obligation shall not apply to an Alternative Technology developed by Amyris in connection with activities that fall within
an Exclusivity Exception.

 

3.2ROFO Notice.
Amyris shall promptly notify Novvi LLC in writing when it has an Alternative Technology that is subject to the ROFO (a “ROFO
Notice”). The ROFO Notice shall include a reasonable description of the applicable Alternative Technology and the fundamental
license and/or sale terms and conditions proposed by Amyris.

 

 3.3 Exercise of the ROFO.

 

(a)Due Diligence
Period. Novvi LLC shall have sixty (60) days from receipt of a ROFO Notice to (i) conduct an assessment of the applicable Alternative
Technology (and, for such purpose, Amyris hereby undertakes to provide to Novvi LLC all information it believes in good faith is
necessary for Novvi LLC’s full and complete assessment) and (ii) deliver to Amyris a written notice expressing its intention
to exercise its ROFO (an “Exercise Notice”).

 

(b)Negotiation
Period. In the event it delivers an Exercise Notice per Subsection (a) above, Novvi LLC shall be obligated, within sixty (60)
days from Amyris’s receipt of the Exercise Notice, to enter into a definitive agreement with Amyris (separate from this License
Agreement) regarding either an exclusive license to, or acquisition of, (subject to the Exclusivity Exceptions) the use or ownership
of such Alternative Technology for the development, making (having made), offering for sale, sale, and importation of Base Oils,
Additives, and Lubricants solely in the Lubricants Market and on terms and conditions consistent with those referred to in the
ROFO Notice. In addition, any license granted by

    Page 13 of 37

    CONFIDENTIAL

    

Amyris to Novvi LLC with regard to Alternative
Technology shall be terminable upon the expiration or earlier termination of Novvi LLC’s licenses under Section 2.1.

 

(c)Negotiate
with Third Parties. If Novvi LLC does not deliver an Exercise Notice in compliance with Subsection (a) above or is not successful
in executing a definitive agreement with Amyris within the sixty (60) days in Subsection (b) above, then Amyris shall be free to
solicit and negotiate with any Third Party the exclusive license or sale of such Alternative Technology, provided that (i)
the economic terms offered by such Third Party shall be no less favorable to Amyris than those offered by Novvi LLC under the ROFO
Notice; (ii) the fundamental business terms, including the structure of the relevant transaction (e.g., sale, license, formation
of a joint venture and contribution of the Alternative Technology), are substantially the same as those offered to Novvi LLC under
the ROFO Notice; and (iii) Amyris and the Third Party have entered into a definitive agreement within one hundred and twenty (120)
days after the end of the sixty (60) day period in Subsections (a) or (b) above, whichever is applicable.

 

3.4Repetition
of ROFO. If Amyris and the Third Party have not entered into a definitive agreement in compliance with Section 3.3(c) above,
then Amyris must again comply with the provisions of the ROFO before exclusively licensing or selling to a Third Party the use
or ownership of such Alternative Technology for purposes of Base Oils, Additives, or Lubricants in the Lubricants Market.

 

3.5Alternative
Technology Production Strain Restrictions. If an Alternative Technology to be exclusively licensed to Novvi LLC by Amyris under
this Article 3 includes rights for Novvi LLC to manufacture or have manufactured such Alternative Technology with a Production
Strain, the Parties hereby agree that such manufacturing license granted to Novvi LLC shall be conditioned on, among other things,
compliance with provisions equivalent to those for BioFene in Section 2.3 above.

 

3.6Termination
of Article 3. Upon the expiration or earlier termination of Novvi LLC’s licenses under Section 2.1, all rights and obligations
of the Parties under this Article 3 automatically terminate, and this Article 3 will be of no further effect.

 

 

ARTICLE 4

 

SALE OF BY-PRODUCTS 

 

4.1No Sale of
By-Products as Diesel Fuel in the European Union. Novvi LLC agrees that it shall not, at any time, offer for sale or sell any
By-Products, including, but not limited to, any farnesane or diesel-related By-Products (“Diesel By-Products”),
for use in or as diesel fuel in any of the European Union.

 

4.2No Sale of
Jet Fuel By-Products except to Amyris; Amyris’s Obligation to Purchase.

 

(a)               
Novvi LLC agrees that it will not offer for sale or sell any Jet Fuel By-Products to any person or entity except to Amyris
as set forth in this Section 4.2, and Amyris agrees that it will purchase all such Jet Fuel By-Products. As used in this Section,
“Jet Fuel By-Product” means a By-Product (i) whose concentration of farnesane, partially hydrogenated farnesene
or farnesene, by volume, is at least [*] or greater; and (ii) that when blended with petroleum-derived jet fuel, meets the ASTM
D1655 and D7566 specifications (or successors thereto) for use as a jet fuel.

 

(b)              
The purchase price payable by Amyris to Novvi LLC for each liter of any Jet Fuel By-Product will be equal to the price per
liter that Amyris sells farnesene to Novvi LLC, in case such

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

    Page 14 of 37

    CONFIDENTIAL

    

price is higher than US$ [*] per liter. If the per liter of
farnesene price Amyris charges to Novvi LLC is below US$ [*] per liter, Amyris will purchase such Jet Fuel By-Product at the NYMEX
ULSD diesel one-month forward price.

 

(c)               
In connection with the sale of any By-Products by Novvi LLC to a third party, Novvi LLC shall require any such purchaser
to agree in writing that (i) such By-Products may not be used in or as diesel fuel in the European Union or in or as jet fuels
anywhere, and (ii) if any such By-Products are incorporated into any diesel fuel outside the European Union, that such diesel fuels
may not be imported into any of the European Union.

 

(d)              
Other than as set forth in this Section, Amyris has no obligation or rights to purchase any By-Products from Novvi LLC.

 

4.3No Other Limits on Novvi LLC.
Other than as set forth in this Article 4, Novvi LLC may, pursuant to its license in Section 2.1(a)(ii), freely offer for
sale, sell, and import its By-Products.

 

ARTICLE 5

 

INTELLECTUAL PROPERTY

 

5.1Inventorship.
Inventorship of all inventions and discoveries conceived, reduced to practice, discovered or made pursuant to this License
Agreement, whether or not patentable, shall be determined in accordance with U.S. patent laws. Other than as set forth below, as
among the Parties, ownership of all inventions and discoveries conceived, reduced to practice, discovered or made or created during
the Term of this License Agreement shall be determined consistent with inventorship.

 

5.2Amyris’s
Ownership. Amyris’s intellectual property ownership rights are as follows:

 

(a)               
Amyris Base Technology, Amyris BioFene Manufacturing Technology, Amyris Inventions, and Amyris Alternative Technology.
As between the Parties, all rights, title, and interest in and to Amyris Base Technology, Amyris BioFene
Manufacturing Technology, Amyris Inventions, and Amyris’s Alternative Technology are exclusively owned solely by Amyris.
Novvi LLC and its Affiliates, sublicensees, contractors, agents, and employees shall
have no right, license or permission to practice Amyris Base Technology, Amyris BioFene Manufacturing Technology, or Amyris Inventions,
or Amyris’s Alternative Technology except to the extent the licenses described in Sections 2.1 and 2.3 or Article 3 are in
place between the Parties.

 

(b)              
Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements. All rights, title, and
interest in and to Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements are exclusively owned
solely by Amyris. Novvi LLC will promptly disclose Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing
Improvements, if any, in writing to Amyris and, without further consideration, hereby assigns to Amyris any and all rights, title
and interests of Novvi LLC (and, as applicable, its Affiliates, sublicensees, contractors, agents, and employees) in and to all
Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements.

 

Upon Amyris’s reasonable request
and at Amyris’s expense, Novvi LLC will promptly perform (or cause, as applicable, its Affiliates, sublicensees, contractors,
agents, and employees to promptly perform) any and all acts necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required, to perfect
the delivery, assignment, and conveyance to Amyris, its successors, assigns, and nominees, of

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

    Page 15 of 37

    CONFIDENTIAL

    

the entire right, title, and interest in
and to all Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements.

 

For purposes of this License Agreement,
Joint BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing Improvements will be considered Amyris BioFene Manufacturing
Technology, and Novvi LLC and its Affiliates, sublicensees, contractors, agents, and employees shall have no right, license or
permission to practice Joint BioFene Manufacturing Improvements or Novvi LLC BioFene Manufacturing Improvements except to the extent
the license described in Section 2.3 is in place between the Parties.

 

(c)               
Novvi LLC Breach Inventions. All rights, title, and interest in and to Novvi LLC Breach Inventions are also exclusively
owned solely by Amyris. Novvi LLC will promptly disclose Novvi LLC Breach Inventions, if any, in writing to Amyris and, without
further consideration, hereby assigns to Amyris any and all rights, title and interests of Novvi LLC (and,
as applicable, its Affiliates, sublicensees, contractors, agents, and employees) in and to Novvi LLC Breach Inventions.

 

Upon Amyris’s reasonable request
and at Amyris’s expense, Novvi LLC will promptly perform (or cause, as applicable, its Affiliates, sublicensees, contractors,
agents, and employees to promptly perform) any and all acts necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required, to perfect
the delivery, assignment, and conveyance to Amyris, its successors, assigns, and nominees, of the entire right, title, and interest
in and to all Novvi LLC Breach Inventions.

 

For purposes of this License Agreement,
Novvi LLC Breach Inventions will be considered Amyris Inventions, and Novvi LLC and its Affiliates, sublicensees, contractors,
agents, and employees shall have no right, license or permission to practice Novvi LLC Breach Inventions.

 

5.3Novvi LLC’s
Ownership. Novvi LLC’s intellectual property ownership rights are as follows:

 

(a)Novvi LLC
BioFene Transformation Technology and Novvi LLC Inventions. As between the Parties, all rights, title, and interest in and
to Novvi LLC BioFene Transformation Technology and Novvi LLC Inventions are exclusively owned solely by Novvi LLC. Amyris and its
Affiliates, sublicensees, contractors, agents, and employees shall have no right, license or permission to practice Novvi LLC BioFene
Transformation Technology or Novvi LLC Inventions except to the extent the license described in Section 2.2 is in place between
the Parties.

 

(b)Amyris Breach
Inventions. All rights, title, and interest in and to Amyris Breach Inventions are also exclusively owned solely by Novvi LLC.
Amyris will promptly disclose Amyris Breach Inventions, if any, in writing to Novvi LLC and, without further consideration, hereby
assigns to Novvi LLC any and all rights, title and interests of Amyris (and, as applicable, its Affiliates,
sublicensees, contractors, agents, and employees) in and to Amyris Breach Inventions.

 

Upon Novvi LLC’s reasonable request
and at Novvi LLC’s expense, Amyris will promptly perform (or cause, as applicable, its Affiliates, sublicensees, contractors,
agents, and employees to promptly perform) any and all acts necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required, to perfect
the delivery, assignment, and conveyance to Amyris, its successors, assigns, and nominees, of the entire right, title, and interest
in and to all Amyris Breach Inventions.

 

For purposes of this License Agreement,
Amyris Breach Inventions will be considered Novvi Inventions,

    Page 16 of 37

    CONFIDENTIAL

    

and Amyris
and its Affiliates, sublicensees, contractors, agents, and employees shall have no right, license or permission to practice
Amyris Breach Inventions.

 

5.4Joint Inventions.
Joint Inventions will be jointly owned by Amyris and Novvi LLC, and the Parties will have co-exclusive rights to use and practice
Joint Inventions (i.e., neither Party can individually grant another person or entity any exclusive rights) and without
accounting.

 

5.5Semi-Annual
Updates to Amyris regarding Novvi LLC BioFene Transformation Technology. Every January 15 and July 15 while Amyris’s
license under Section 2.2 is in effect, Novvi LLC will provide Amyris with a written update on Novvi LLC BioFene Transformation
Technology. Such semi-annual updates will include a list of any Patents in the Novvi LLC BioFene Transformation Technology identified
by their respective title, inventors, serial numbers, filing date, and status. Novvi LLC also agrees to copy Amyris on any official
correspondence between Novvi LLC (or Novvi LLC’s counsel) and any patent office regarding Patents in Novvi LLC BioFene Transformation
Technology.

 

5.6Semi-Annual
Updates to Novvi LLC regarding Amyris Base Technology. Every January 15 and July 15 while Novvi LLC’s license under Section
2.1 is in effect, Amyris will provide Novvi LLC with a written update on Amyris Base Technology. Such semi-annual updates will
include a list of any Patents in the Amyris Base Technology identified by their respective title, inventors, serial numbers, filing
date, and status. Amyris also agrees to copy Novvi LLC on any official correspondence between Amyris (or Amyris’ counsel)
and any patent office regarding Patents in Amyris Base Technology.

 

5.7Semi-Annual
Updates to Novvi LLC regarding Amyris BioFene Manufacturing Technology. Following the technical transfer from Amyris to Novvi
LLC described in Section 2.3, every January 15 and July 15 while Novvi LLC’s license under Section 2.3 remains in effect,
Amyris will provide Novvi LLC with a written update on Amyris BioFene Manufacturing Technology. Such semi-annual updates will include
a list of any Patents in the Amyris BioFene Manufacturing Technology identified by their respective title, inventors, serial numbers,
filing date, and status. Amyris also agrees to copy Novvi LLC on any official correspondence between Amyris (or Amyris’ counsel)
and any patent office regarding Patents in Amyris BioFene Manufacturing Technology.

 

5.8Patent Strategy
and Prosecution.

 

(a)Amyris’s
Rights. As between the Parties, Amyris shall have the sole right and discretion to: (i) determine the process for protecting
any Amyris Inventions (as well as any Amyris Base Technology and any Amyris BioFene Manufacturing Technology) worldwide, including
whether or not to obtain Patent protection and in what countries and (ii) at its own expense, but without obligation, prepare,
file, prosecute, maintain, and defend throughout the world any and all Patents claiming or relating to the Amyris Inventions, Amyris
Base Technology and Amyris BioFene Manufacturing Technology or, at any time, abandon or discontinue such activities.

 

Upon Amyris’s reasonable request
and at Amyris’s expense, Novvi LLC will promptly perform (or cause, as applicable, its Affiliates, sublicensees, contractors,
agents, and employees to promptly perform) any and all acts necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other documentation as may be reasonably required, to allow
Amyris to apply for, register, obtain, maintain, defend, and enforce any Patent claiming or relating to any Joint BioFene Manufacturing
Improvements, Novvi LLC BioFene Manufacturing Improvements, or Novvi LLC Breach Inventions and/or its rights therein.

 

(b)Novvi LLC’s
Rights. As between the Parties, Novvi LLC shall have the sole right and

 

    Page 17 of 37

    CONFIDENTIAL

    

discretion to (i) determine the process
for protecting any Novvi LLC Inventions (as well as any Novvi LLC BioFene Transformation Technology) worldwide, including whether
or not to obtain Patent protection and in what countries and (ii) at its own expense, but without obligation, prepare, file, prosecute,
maintain, and defend throughout the world any and all Patents claiming or relating to the Novvi LLC Inventions and Novvi LLC BioFene
Transformation Technology or, at any time, abandon or discontinue such activities.

 

Upon Novvi LLC’s reasonable request
and at Novvi LLC’s expense, Amyris will promptly perform (or cause, as applicable, its Affiliates,
sublicensees, contractors, agents, and employees to promptly perform) any and all acts necessary, including the execution
and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documentation
as may be reasonably required, to allow Novvi LLC to apply for, register, obtain, maintain, defend, and enforce any Patent claiming
or relating to any Amyris Breach Invention and/or its rights therein.

 

(c)Joint
Inventions Rights. For each Joint Invention, the Parties will mutually select which Party
shall have the sole right and discretion to (i) determine the process for protecting such Joint Invention worldwide, including
whether or not to obtain Patent protection and in what countries and (ii) at its own expense, but without obligation, prepare,
file, prosecute, maintain, and defend throughout the world any and all Patents claiming or relating to such Joint Invention or,
at any time, abandon or discontinue such activities.

 

5.9Infringement
by Third Parties.

 

(a)Amyris Base
Technology and Amyris BioFene Manufacturing Technology. In the event either Party becomes aware of any Third Party activity
that infringes or misappropriates (or is likely to infringe or misappropriate) Amyris Base Technology or Amyris BioFene Manufacturing
Technology, that Party will notify the other Party promptly in writing of the actual or threatened infringement or misappropriation.
Whether or not to take action against such infringement or misappropriation will be the sole right, and at the sole discretion,
of Amyris or its designated representative (“Amyris Designate”). However, at Amyris’s expense, Novvi LLC
will cooperate to the extent reasonably required by Amyris or the Amyris Designate to stop such infringement or misappropriation,
and, if so requested by Amyris, will join with Amyris or the Amyris Designate as a party to any action brought by Amyris or the
Amyris Designate for such purpose. Amyris or the Amyris Designate will have full control over any action taken, including, without
limitation, the right to select counsel, to settle on any terms it deems advisable in its discretion, to appeal any adverse decision
rendered in any court, to discontinue any action taken by it, and otherwise to make any decision in respect thereto as it in its
discretion deems advisable.

 

(b)Novvi LLC
BioFene Transformation Technology. In the event either Party becomes aware of any Third Party activity that infringes or misappropriates
(or is likely to infringe or misappropriate) Novvi LLC BioFene Transformation Technology, that Party will notify the other Party
promptly in writing of the actual or threatened infringement or misappropriation. Whether or not to take action against such infringement
or misappropriation will be the sole right, and at the sole discretion, of Novvi LLC or its designated representative (“Novvi
LLC Designate”). However, Amyris will cooperate to the extent reasonably required by Novvi LLC or the Novvi LLC Designate
to stop such infringement or misappropriation, and, if so requested by Novvi LLC, will join with Novvi LLC or the Novvi LLC Designate
as a party to any action brought by Novvi LLC or the Novvi LLC Designate for such purpose. Novvi LLC or the Novvi LLC Designate
will have full control over any action taken, including, without limitation, the right to select counsel, to settle on any terms
it deems advisable in its discretion, to appeal any adverse decision rendered in any court, to discontinue any action taken by
it, and otherwise to make any decision in respect thereto as it in its discretion deems advisable.

    Page 18 of 37

    CONFIDENTIAL

    

5.10Confidentiality
Obligations.

 

(a)Confidential
Information. As used herein, “Confidential Information” means any and all
information provided by or on behalf of a Party (“Disclosing Party”) to the other Party (“Receiving
Party”) or to its Representatives between the Effective Date and the termination of this License Agreement, regardless
of the form or medium of communication, that relates to the Disclosing Party’s intellectual property licensed or created
under this License Agreement or its activities under this License Agreement, in each case which information is either proprietary
to the Disclosing Party or is otherwise not available to the general public. The Parties agree to treat this License Agreement
as the Confidential Information of the other Party. As used herein, “Representative” means the officers, directors,
members, shareholders, employees, attorneys, accountants, advisors, consultants, auditors, agents, contractors, and sublicensees
of the applicable Party and of its Affiliates. 

 

(b)Obligations.
Except with the prior written consent of the Disclosing Party or as specifically authorized in this License Agreement, each Receiving
Party shall, and shall cause its Representatives (to the extent such persons receive any Confidential Information) to,:

 

		(i)	maintain in confidence any and all Confidential Information;

 

		(ii)	take reasonable precautions to protect Confidential Information;

 

		(iii)	not disclose Confidential Information to any person or entity;
and 

 

		(iv)	not make any use of such Confidential Information except for
the purposes specifically authorized herein. 

 

(c)Permitted
Disclosures. A Receiving Party may disclose Confidential Information, without the Disclosing Party’s written consent,
to those of its Representatives who (i) need to know such Confidential Information for the purpose of assisting such Receiving
Party fulfill its obligations or exercise its rights under this License Agreement and (ii) are bound by written obligations of
confidentiality and non-use substantially similar to those herein.  A Receiving Party or its Affiliates may also disclose
the terms of this License Agreement to actual or prospective investors, underwriters, or acquirers who need to know such Confidential
Information to evaluate the Receiving Party’s (or its Affiliates’) business and who are bound by written obligations
of confidentiality and non-use substantially similar to those herein.

 

(d)Legally
Required Disclosures. In addition, a Receiving Party may disclose Confidential Information (including the terms of this License
Agreement), without the Disclosing Party’s written consent, to the extent such disclosure is required, on advice of counsel,
by Applicable Law (including pursuant to any listing agreement with, or the rules or regulations of, any national securities exchange
on which any securities of such Receiving Party or any Affiliate thereof are listed or traded); provided, that the Receiving
Party making such disclosure, or whose Affiliates are making such disclosure, shall notify the other Party as promptly as practicable
(and if possible and legally allowed, prior to making such disclosure) and shall minimize such disclosure as much as possible and
reasonably seek confidential treatment of such Confidential Information to the extent available. 

 

(e)Exceptions
to Confidential Information. The provisions of Subsection (b) above shall not apply to, and Confidential Information shall
not include, any information of a Disclosing Party that:

 

		(i)	is or has become generally available to the
public other than as a result of a disclosure by a Receiving Party or any of its Representatives in breach of this Section 5.10;

    Page 19 of 37

    CONFIDENTIAL

    

		(ii)	has been independently developed by a Receiving
Party (or any Affiliate thereof) without violating any of the provisions of this License Agreement or any other similar contract
to which such Receiving Party or any of its Representatives, is or are bound; or

 

		(iii)	was made available to a Receiving Party (or
any Affiliate thereof), on a non-confidential basis by a Third Party who is not prohibited from disclosing such information to
such person or entity by a legal, contractual or fiduciary obligation to the Disclosing Party or any of its Representatives.

 

(f)Public
Announcements. Except as required by Applicable Law or by the requirements of any national
securities exchange on which the securities of a Party (or its Affiliates) are listed or traded, no Party shall make, or
cause to be made, any press release or public announcement in respect of this License Agreement or otherwise communicate with
any news media without the prior written consent of the other Party, and the Parties shall cooperate as to the timing and
contents of any such press release or public announcement. 

 

(g)Duration
of Obligations. Except as otherwise provided for in this Section 5.10, Confidential Information received hereunder shall be
used by each Receiving Party and its Representatives solely in connection with such Receiving Party fulfilling its obligations
or exercising its rights under this License Agreement. Nothing in this License Agreement shall be interpreted as vesting, in favor
of any Receiving Party or any other person or entity, any right of ownership or other right in the Confidential Information of
a Disclosing Party. The obligations under this Section 5.10 shall survive for two (2) years after the termination of this
License Agreement.

 

 

ARTICLE 6

 

REPRESENTATIONS, WARRANTIES, AND DISCLAIMERS

 

6.1Representations
and Warranties by Amyris. Amyris hereby represents and warrants to Novvi LLC that, as of the Effective Date,:

 

(a)Organization;
Good Standing. Amyris is a corporation duly organized and in good standing under the laws of Delaware and has full power and
authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted
and as is contemplated to be conducted by this License Agreement.

 

(b)Corporate
Authority. Amyris has the power and authority and the legal right to enter into this License Agreement and perform its obligations
hereunder and has taken all necessary action on its part required to authorize the execution and delivery of this License Agreement
and the performance of its obligations hereunder. 

 

(c)Binding
Obligation. This License Agreement has been duly executed and delivered by Amyris and constitutes a legal, valid, and binding
obligation of Amyris and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency
or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability
of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity.

 

    Page 20 of 37

    CONFIDENTIAL

    

(d)Consents
and Approvals. All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other
persons or entities required to be obtained by Amyris in connection with the execution and delivery of this License Agreement and
the performance of its obligations hereunder have been obtained or will be obtained prior to such performance. 

 

(e)No
Conflicts. The execution and delivery of this License Agreement and the performance of Amyris’s obligations hereunder
(i) do not conflict with or violate any provision of Amyris’s articles of incorporation or bylaws, (ii) do not conflict with,
violate, or constitute a default of any contractual obligation of Amyris, or (iii), to its knowledge, do not conflict with or violate
any requirement of Applicable Law.

 

(f)Amyris Base Technology.
Amyris owns or otherwise has all necessary rights in and to the Amyris Base Technology to grant Novvi LLC the licenses described
in Sections 2.1 and 2.3.

 

6.2Representations
and Warranties by Novvi LLC. Novvi LLC hereby represents and warrants to Amyris that, as of the Effective Date,:

 

(a)Organization;
Good Standing. Novvi LLC is a limited liability company duly organized and in good standing under
the laws of Delaware and has full power and authority and the legal right to own and operate its property and assets and to carry
on its business as it is now being conducted and as it is contemplated to be conducted by this License Agreement.

 

(b)Corporate
Authority. Novvi LLC has the power and authority and the legal right to enter into this License Agreement and perform its obligations
hereunder and has taken all necessary action on its part required to authorize the execution and delivery of this License Agreement
and the performance of its obligations hereunder. 

 

(c)Binding
Obligation. This License Agreement has been duly executed and delivered by Novvi LLC and constitutes a legal, valid, and binding
obligation of Novvi LLC and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency
or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability
of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity.

 

(d)Consents
and Approvals. All necessary consents, approvals and authorizations of all regulatory and governmental authorities and other
persons or entities required to be obtained by Novvi LLC in connection with the execution and delivery of this License Agreement
and the performance of its obligations hereunder have been obtained or will be obtained prior to such performance. 

 

(e)No
Conflicts. The execution and delivery of this License Agreement and the performance of Novvi LLC’s obligations hereunder
(i) do not conflict with or violate any provision of Novvi LLC’s certificate of incorporation or Second Amended and Restated
Operating Agreement, (ii) do not conflict with, violate, or constitute a default of any contractual obligation of Novvi LLC, or
(iii), to its knowledge, do not conflict with or violate any requirement of Applicable Law.

 

6.3DISCLAIMER OF WARRANTIES.
EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTY, EXPRESS OR IMPLIED,
EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER
WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE

    Page 21 of 37

    CONFIDENTIAL

    

OR PURPOSE, OR SAFETY, ANY WARRANTY AS
TO THE ACCURACY, VALIDITY OR SCOPE OF ANY PATENTS OR KNOW-HOW LICENSED HEREUNDER, AND ANY WARRANTY AS TO THE NON-INFRINGEMENT OF
ANY THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS THROUGH THE PRACTICE OF ANY PATENTS OR KNOW-HOW LICENSED HEREUNDER.

 

 

ARTICLE 7

 

INDEMNIFICATION

 

7.1Amyris’s
Indemnification Obligations. Amyris will defend, indemnify, and hold harmless Novvi LLC, its Affiliates and its and their respective
members, directors, officers, employees, and agents and their respective successors, heirs, and permitted assigns (collectively,
“Novvi LLC Indemnitees”) from and against any and all losses, damages, liabilities, fines, costs, interest and
expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) arising from a Third
Party’s claim, action, suit, or demand (or judgments or settlements arising therefrom) against a Novvi LLC Indemnity, in
each case to the extent resulting from: 

 

		(i)	any breach by Amyris of this License Agreement;

 

		(ii)	the negligent, reckless, or intentionally
wrongful acts or omissions on the part of any Amyris Indemnitee in performing any activity related to this License Agreement;

 

		(iii)	Amyris’s development, making, having
made, offer for sale, sale, or import of any product for which it used Novvi LLC BioFene Transformation Technology licensed to
it under Section 2.2, including any claims of product liability or claims of infringement or misappropriation of a Third Party’s
intellectual property; 

 

		(iv)	Novvi LLC’s making (have made), offer
for sale, sale, or importing, in each case between the Effective Date and June 1, 2013, of any Base Oil or Lubricant for the Lubricants
Market derived from BioFene using Amyris Pre-Signature Base Technology allegedly infringing or misappropriating a Third Party’s
intellectual property but only to the extent such alleged infringement or misappropriation is directly attributable to Novvi LLC’s
adherence to the Amyris Pre-Signature Base Technology and not to any deviation or modification from such process made by or on
behalf Novvi LLC or a permitted sublicensee of Novvi LLC, other than a deviation or modification made by Novvi LLC at the written
direction of Amyris; 

 

		(v)	if Novvi LLC is licensed under Section 2.3
to make BioFene, Novvi LLC’s manufacture of BioFene in either the United States of America or Brazil allegedly infringing
or misappropriating a Third Party’s intellectual property, but only to the extent such alleged infringement or misappropriation
is directly attributable to Novvi LLC’s adherence to Amyris’s then-approved BioFene manufacturing process licensed
from Amyris as part of the licensed Amyris BioFene Manufacturing Technology and not to any deviation or modification from such
process made by or on behalf of Novvi LLC or a permitted sublicensee of Novvi LLC, other than a deviation or modification made
by Novvi LLC at the written direction of Amyris; or

 

		(vi)	Amyris’s or its Affiliates’ activities
prior to the Effective Date with regard to its use of Base Oils, Additives or Lubricants for the Lubricants Market, including any
sampling of

    Page 22 of 37

    CONFIDENTIAL

    

such
products by Amyris or its Affiliates to Third Parties prior to the Effective Date (collectively (i)-(vi), each a “Novvi
LLC Third Party Claim”); 

 

provided
that Amyris will not defend, indemnify, or hold harmless Novvi LLC Indemnities under this Section to the extent such Losses and/or
Novvi LLC Third Party Claim is determined to have resulted from the causes described in Section 7.2(i)-(iv).

 

7.2Novvi
LLC’s Indemnification Obligations. Novvi LLC will defend, indemnify, and hold harmless Amyris, its Affiliates and its
and their respective shareholders, directors, officers, employees, and agents and their respective successors, heirs, and permitted
assigns (collectively, “Amyris Indemnitees”) from and against any and all Losses arising from a Third Party’s
claim, action, suit, or demand (or judgments or settlements arising therefrom) against an Amyris Indemnity, in each case to the
extent resulting from:

 

		(i)	any breach by Novvi LLC of this License Agreement;

 

		(ii)	the negligent, reckless, or intentionally
wrongful acts or omissions on the part of any Novvi LLC Indemnitee in performing any activity related to this License Agreement;

 

		(iii)	except as set forth in Section 7.1(iv), Novvi
LLC’s development, making (have made), offer for sale, sale, or import of any Base Oil, Additive, or Lubricant derived from
BioFene, including any claims of product liability or claims of infringement or misappropriation of a Third Party’s intellectual
property; or 

 

		(iv)	except as set forth in Section 7.1(v), Novvi
LLC’s manufacture of BioFene allegedly infringing or misappropriating a Third Party’s intellectual property (collectively
(i)-(iv), each an “Amyris Third Party Claim”); 

 

provided that Novvi LLC will not
defend, indemnify, or hold harmless Amyris Indemnities under this Section to the extent such Losses and/or Amyris Third Party Claim
is determined to have resulted from the causes described in Section 7.1(i)-(vi).

 

7.3Indemnification
Procedures. The Parties’ obligations under Sections 7.1 and 7.2 shall be governed by and contingent upon the following:

 

(a)Notice
of Claim. All indemnification claims in respect of a Novvi LLC Indemnitee or Amyris Indemnitee
shall be made solely by Novvi LLC or Amyris, as applicable (each of Novvi LLC or Amyris in such capacity, the “Indemnified
Party”). Promptly after a Novvi LLC Indemnitee or an Amyris Indemnitee receives notice of a threatened, pending, or actual
Novvi LLC Third Party Claim or Amyris Third Party Claim (a “Third Party Claim”), the applicable Indemnified
Party shall give written notice of the Third Party Claim to the Party to whom that Indemnified Party is entitled to look for indemnification
pursuant to this Article 7 (the “Indemnifying Party”). Such written notice (an “Indemnification Claim
Notice”) shall contain a description of the claim, the nature and amount of such Loss (to the extent that the nature
and amount of such Loss is known at such time), and the basis for indemnification under this Article 7. An Indemnified Party’s
delay in providing, or failure to provide, an Indemnification Claim Notice will not relieve the Indemnifying Party of its obligations
under this Article 7 for the Third Party Claim, except to the extent it can demonstrate that such delay or failure materially adversely
affects the ability of the Indemnifying Party to defend the Third Person Claim, to cure the breach (if applicable) giving rise
to such Third Person Claim, or minimize the applicable Loss. The Indemnified Party shall also furnish promptly to the Indemnifying
Party copies of all papers and official documents received in respect of the Third Party Claim.

 

    Page 23 of 37

    CONFIDENTIAL

    

(b)Assumption
of Defense. At its option, the Indemnifying Party may assume the defense of the Third Party Claim by giving written notice
to the Indemnified Party within thirty (30) days after receipt of the Indemnification Claim Notice (an “Assumption Notice”).
Such assumption shall not be construed as an acknowledgement of liability or a waiver of any defenses by the Indemnifying Party
(and the Indemnifying Party shall be reimbursed by the Indemnified Party in the case in which the Indemnified Party is not liable
under this Article 7). 

 

(c)Control
of Defense by the Indemnifying Party. Upon giving a timely Assumption Notice to the Indemnified Party, the Indemnifying Party:

 

		(i)	has the exclusive right, at its own expense and by counsel of
its choosing (but who is reasonably satisfactory to the Indemnified Party), conduct and control the defense and the disposition
or, subject to Subsection (d) below, settlement of the Third Party Claim (including all decisions relative to litigation, appeal,
and settlement);

 

		(ii)	will conduct the defense and, if applicable, settlement of such
Third Person Claim in a reasonable and diligent manner;
	 	 	 
	 	(iii)	will
keep the Indemnified Party informed on a reasonable and timely basis as to the status of such Third Party Claim to the extent the
Indemnified Party is not participating in the defense;
	 	 	
	 	(iv)	is
not liable for the fees or expenses of counsel hired by the Indemnified Party in connection with the defense of the Third Party
Claim (except in the case where the interests of the Indemnified Party and Indemnifying Party are sufficiently adverse to prohibit
the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles); and
	 	 	 
	 	(v)	is
not liable for any other expenses subsequently incurred by the Indemnified Party in connection with such defense, other than the
Indemnified Party’s reasonable out-of-pocket costs incurred in cooperating with the Indemnifying Party per Subsection (e)
below.

 

(d)Settlement
by the Indemnifying Party. If an Indemnifying Party has assumed the defense of a Third Party Claim under Subsection (b) above,
the Indemnifying Party may not settle or compromise a Third Party Claim without the prior written consent of the Indemnified Party
(not to be unreasonably withheld, conditioned, or delayed) unless such settlement or compromise (i) involves no payment (whether
by cash, securities or other instrument), assignment, obligation, granting of a license, or admission of fault or wrongdoing by,
or injunctive or other equitable relief against, the Indemnified Party and (ii) the Indemnified Party receives a comprehensive
general release of all claims from the applicable Third Party. In no event will an Indemnifying Party, without the written consent
of the other Party, be entitled to settle any Third Party Claim by granting a license or covenant not to sue under or with respect
to the Patents or other intellectual property rights owned by the other Party. Furthermore, in the case of a Novvi LLC Third Party
Claim under Section 7.1(v), Novvi LLC agrees that, if Amyris has assumed the defense of such Third Party Claim under Subsection
(b) above, Novvi LLC will work together with Amyris in good faith should Amyris reasonably determine that settling such matter
and/or the Parties avoiding additional such Third Party Claims is to modify the BioFene manufacturing process that is both licensed
to Novvi LLC and used by Amyris for its own BioFene manufacturing. 

 

(e)Indemnified
Party’s Cooperation. If an Indemnifying Party has assumed the defense of a Third Party Claim under Subsection (b), the
Indemnified Party shall, and shall cause each of its Novvi

 

    Page 24 of 37

    CONFIDENTIAL

    

LLC
Indemnitees or Amyris Indemnitees (as applicable), to reasonably cooperate with the Indemnifying Party, mitigate potential Losses,
and furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings,
hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during
normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information
that are reasonably relevant to such Third Party Claim and making the Indemnified Party and its Novvi LLC Indemnitees or Amyris
Indemnitees (as applicable) available on a mutually convenient basis to provide additional information and explanation of any records
or information provided. In addition, if an Indemnifying Party has assumed the defense of a Third Party Claim under Subsection
(b), the Indemnified Party may employ separate counsel to participate in the defense of such Third Party Claim, but such counsel
will be at the Indemnified Party’s sole expense.    

 

(f)Expenses.
Any reasonable and verifiable costs and expenses incurred by the Indemnified Party in connection with a Third Party Claim and reimbursable
as set forth this Article 7 shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the
event the Indemnifying Party is ultimately held not to be obligated to defend, indemnify, or hold harmless the Indemnified Party
under this Article 7.

 

(g)
Breach by the Indemnifying Party of its Article 7 Obligations. If the Indemnifying Party denies its obligations under
this Article 7, fails to timely provide an Assumption Notice with regard to a Third Party Claim, or fails to diligently defend,
indemnify, and hold harmless such Third Party Claim throughout the period that such claim exists, then its right to defend that
Third Party Claim shall immediately terminate upon written notice from the Indemnified Party, and the Indemnified Party may assume
the defense of, and settle, such claim with counsel of its own choice and on such terms as it deems reasonably appropriate, with
written notice to the Indemnifying Party but without any obligation to obtain the consent of the Indemnifying Party. The Indemnifying
Party will be obligated to indemnify and hold harmless the Indemnified Party for the costs of such defense and settlement if it
is determined that the Indemnifying Party breached its obligations under this Article 7 with regard to such Third Party Claim and
that the Third Party Claim is subject to the indemnification provisions of this Article 7.  

 

7.4Disclaimer
of Consequential Damages. EXCEPT FOR WILLFUL MISCONDUCT, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL,
CONSEQUENTIAL, EXEMPLARY OR PUNITIVE OR SPECIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH THIS LICENSE AGREEMENT,
INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING
NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), EVEN IF SUCH PARTY WAS ADVISED OR OTHERWISE AWARE OF THE LIKELIHOOD OF SUCH DAMAGES
AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THE FOREGOING DISCLAIMER
DOES NOT APPLY TO OR LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 7 WITH REGARD TO THIRD PERSON CLAIMS.

 

7.5Insurance.
While a Party’s license(s) under this License Agreement are in effect and for three (3) years thereafter, such Party
shall have and maintain such type and amounts of liability insurance covering its activities under this License Agreement as is
normal and customary in such Party’s industry for parties similarly situated, and such Party shall upon request provide the
other Party a certificate confirming such insurance is in place.

 

 

ARTICLE 8

    Page 25 of 37

    CONFIDENTIAL

    

DISPUTE RESOLUTION

 

8.1Governing
Law. This License Agreement shall be governed by and construed, interpreted and enforced in accordance with the laws of the
State of New York, without giving effect to the principles of conflicts of law or of choice of law thereof (other than Sections
5-1401 and 5-1402 of the New York General Obligations Law, which shall apply to this License Agreement).
The Parties agree to exclude the application to this License
Agreement of the United
Nations Convention on Contracts for the International Sale
of Goods.

 

8.2Binding
Arbitration.

 

(a)Informal
Resolution. In the event of any dispute between the Parties involving this License Agreement, such dispute shall be governed
by and resolved subject to this Article 8. Notwithstanding anything contained in this License Agreement, the Parties undertake
to use their reasonable efforts to amicably resolve by mutual negotiation of their chief executive officers (or their designees)
any disputes between themselves involving this License Agreement. 

 

(b)Submit
to AAA Arbitration. In case such mutual agreement is not reached under Subsection (a) above within thirty (30) days after submission
of the dispute to the Parties’ chief executive officers (or their designees), either Party, subject to Subsection (i) below
with regard to Patent disputes, may refer the dispute to binding arbitration under the then-existing rules (“Arbitration
Rules”) of the American Arbitration Association (“Arbitration Chamber”), which will exclusively and
finally settle such dispute. The Arbitration Rules are deemed to be incorporated by reference into this License Agreement, except
as such Arbitration Rules may be modified herein or by subsequent mutual agreement by the Parties. The arbitration proceedings
filed based on this License Agreement shall be administered by the Arbitration Chamber. Any such arbitration shall be conducted
in accordance with, and subject in all respect to, the following: For the avoidance of doubt, this Article 8 equally binds all
Parties to this License Agreement, and such Parties hereby agree to submit to and comply with all the terms and conditions of this
Article 8, which shall be in full force and effect irrevocably, and subject to specific performance. Unless otherwise agreed in
writing, the Parties shall continue to diligently perform their respective duties and obligations under this License Agreement
while an arbitral proceeding is pending.

 

(c)Selection
of the Arbitral Tribunal. Each arbitration under this Article 8 will be settled by a panel of three (3) arbitrators. Each Party
shall nominate one arbitrator in accordance with the Arbitration Rules, and the two arbitrators so nominated shall nominate jointly
a third arbitrator, who shall serve as the chair of the arbitral tribunal (“Arbitral Tribunal”), within fifteen
(15) days from the receipt of a communication from the Arbitration Chamber by the two previously nominated arbitrators. If any
arbitrator has not been nominated within the time limits specified herein and/or in the Arbitration Rules, as applicable, such
appointment shall be made by the Arbitration Chamber upon the written request of either Party within fifteen (15) days of such
request. If at any time a vacancy occurs in the Arbitral Tribunal, the vacancy shall be filled in the same manner and subject to
the same requirements as provided for the original appointment to that position.

 

(d)Location
of the Arbitration. The place of arbitrations shall be the city of New York, New York, U.S.A., where the award(s) shall be
rendered, and all arbitrations shall be conducted in English.

 

(e)Arbitration
Decision. An arbitration award shall be final, unappealable and binding on the Parties, their successors and assignees, who
agree to comply with it and spontaneously and expressly

    Page 26 of 37

    CONFIDENTIAL

    

waive
any form of appeal, except for the request for fraud, correction of material error or clarification of uncertainty, doubt, contradiction
or omission of the arbitration award. If necessary, an arbitration award may be performed in any court that has jurisdiction or
authority over a Party or its assets. The arbitration award will include the distribution of costs, including reasonable attorney’s
fees and reasonable expenses as the Arbitral Tribunal sees fit.

 

(f)Exclusive
Dispute Resolution Process; Exceptions. The Parties are fully aware of all terms and effects of the arbitration provisions
herein agreed upon and irrevocably agree that arbitration hereunder is the only form of resolution of any disputes arising between
themselves involving this License Agreement, except as expressly set forth to the contrary in this Section 8.2. Without prejudice
to the validity of these arbitration provisions, either Party may seek judicial assistance and/or relief, if and when necessary,
for the sole purposes of:

 

		(i)	executing obligations that admit, forthwith, specific performance;

 

		(ii)	obtaining coercive or precautionary measures or procedures of
a preventive, provisional or permanent nature, as security for the arbitration to be commenced or already in course between the
Parties and/or to ensure the existence and efficacy of the arbitration proceeding; or 

 

		(iii)	fraud, correction of material error or clarification of uncertainty,
doubt, contradiction or omission of the arbitration award; or

 

		(iv)	obtaining measures of a mandatory and specific nature; 

 

it being
understood that, upon accomplishment of the mandatory or specific enforcement procedures sought, the dispute shall be returned
to the Arbitral Tribunal to be established or already established, as applicable, full and exclusive authority to decide on all
and any issues, whether related to procedure or merit, which has caused the mandatory or specific enforcement claim, with the respective
judicial proceeding being interrupted until the partial or final decision of the Arbitral Tribunal. The Parties agree that irreparable
damage would occur in the event any provision of this License Agreement was not performed in accordance with the terms hereof and
that the Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity.

 

For the
measures indicated in (i) through (iv) above, the Parties elect any state or U.S. federal court located in the city of New York,
New York, U.S.A., to the exclusion of any other courts, and the Parties hereby irrevocably submit to the exclusive jurisdiction
of any state or U.S. federal court located within the City of New York, New York, U.S.A. over any such action. The Parties hereby
irrevocably waive, to the fullest extent permitted by Applicable Law, any objection which they may now or hereafter have to the
laying of venue of any such action brought in such court or any defense of inconvenient forum for the maintenance of such action.
The filing of any measure under this Subsection (f) does not entail any waiver to the arbitration under this Article 8 or to the
full jurisdiction of the Arbitral Tribunal.

 

(g)Confidentiality.
The Parties and their respective Representatives, the witnesses, the Arbitral Tribunal, the Arbitration Chamber and its secretariat
agree to treat the existence, content, awards and decisions relating to an arbitration proceeding hereunder, together with all
the materials, information and testimony used therein or created for the purposes thereof, as well as other documents produced
or disclosed by each Party during the arbitration proceeding, as Confidential Information of the other Party, subject to the obligations
and exceptions in Section 5.10.

    Page 27 of 37

    CONFIDENTIAL

    

(h)Consolidation
with Second Amended and Restated Operating Agreement Arbitrations. In order to facilitate the comprehensive resolution of related
disputes between the Parties under this License Agreement and the Second Amended and Restated Operating Agreement, any or all such
disputes may be brought in a single arbitration under the following circumstances and conditions: If one or more arbitrations are
already pending between the Parties hereunder or under the Second Amended and Restated Operating Agreement and a new dispute arises
between the Parties under any of said agreements or a subsequently filed arbitration is brought between the Parties under any said
agreements, then a Party may request that such new dispute or any subsequently filed arbitration be consolidated into any prior
pending arbitration. Within twenty (20) days of a request to consolidate, the Parties shall select one of the prior pending arbitrations
into which the new dispute or subsequently filed arbitration may be consolidated (“Selected Arbitration”). If
the Parties are unable to agree on the Selected Arbitration within such twenty (20) day period, then the Arbitration Chamber shall
indicate the Selected Arbitration within twenty (20) days of a written request by a Party. If the Arbitration Chamber fails to
indicate the Selected Arbitration within the 20-day time limit indicated above, the arbitration first initiated shall be considered
the Selected Arbitration. The new dispute or subsequently filed arbitration shall be so consolidated, provided that the Arbitral
Tribunal for the Selected Arbitration determines that: (i) the new dispute or subsequently filed arbitration presents significant
issues of law or fact common with those in the Selected Arbitration; (ii) neither Party would be unduly harmed in the new dispute
or in the Selected Arbitration; and (iii) consolidation under these circumstances would not result in undue delay for the Selected
Arbitration. Any such order of consolidation issued by the Arbitral Tribunal shall be final and binding upon the Parties. The Parties
waive any right they may have to appeal or to seek interpretation, revision or annulment of such order of consolidation under the
Arbitration Rules and/or the Applicable Law in any court. The Arbitral Tribunal for the Selected Arbitration into which
a new dispute or subsequently filed arbitration is consolidated shall serve as the Arbitral Tribunal for the consolidated arbitration.

 

(i)Exception
for Patent-related Disputes. In the event that a dispute arises with respect to the inventorship, scope, ownership, validity,
enforceability, revocation or infringement of a Patent and such dispute cannot be resolved by the Parties in accordance with Subsection (a)
above, then, unless otherwise agreed by the Parties in writing, such dispute will not be submitted to arbitration under this Section
8.2, and either Party may initiate litigation solely in a court of competent jurisdiction in the country of issuance of the Patent
that is the subject of the dispute.

 

8.3Service
of Process. Each Party agrees that, in any dispute, claim, action, suit or proceeding between the Parties in connection with
this License Agreement that, per this License Agreement or Applicable Law, may be brought in a court, process may be served on
a Party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each
Party agrees that service of process on such Party at the location, and as provided, in Section 10.10 shall be deemed effective
service of process on such Party. Nothing herein shall affect the right of either Party to serve legal process in any other manner
permitted by Applicable Law or at equity. 

 

8.4Waiver
of Jury Trial. WITH RESPECT TO ANY DISPUTE, CLAIM, ACTION, SUIT OR PROCEEDING BETWEEN THE PARTIES IN CONNECTION WITH THIS LICENSE
AGREEMENT THAT, PER THIS LICENSE AGREEMENT OR APPLICABLE LAW, MAY BE BROUGHT IN A COURT, EACH OF THE PARTIES HEREBY IRREVOCABLY
WAIVES AND RELEASES TO THE OTHER ITS RIGHT TO A TRIAL BY JURY AND AGREES THAT IT WILL NOT SEEK A TRIAL BY JURY IN ANY SUCH DISPUTE,
CLAIM, ACTION, SUIT OR PROCEEDING.

 

 

ARTICLE 9

    Page 28 of 37

    CONFIDENTIAL

    

TERM AND TERMINATION

 

9.1Term of the
License Agreement. The term of this License Agreement shall commence on the Effective Date and shall continue in full force
and effect until the expiration or termination of all licenses granted pursuant to Sections 2.1, 2.2, and 2.3.

 

9.2Initial Term
of the Licenses.

 

(a)Novvi LLC’s
Licenses in Section 2.1. The licenses granted to Novvi LLC in Section 2.1 will be effective as of the Effective Date and will
continue, unless earlier terminated per this Article 9, until (i) with respect to any Know-How in the Amyris Base Technology, the
twentieth (20th) anniversary of the Effective Date and (ii) with respect to each Patent in the Amyris Base Technology,
the twentieth (20th) anniversary of the Effective Date or the expiration or invalidation of the applicable Patent, whichever
is sooner.

 

(b)Novvi LLC’s
License under Section 2.3. If Amyris grants Novvi LLC a license under Section 2.3, then such license will be effective upon
the date Amyris grants it per the terms of Section 2.3 and will continue, unless earlier terminated per this Article 9, until (i)
with respect to any Know-How in the Amyris BioFene Manufacturing Technology, the twentieth (20th) anniversary of the
Effective Date and (ii) with respect to each Patent in the Amyris BioFene Manufacturing Technology, the twentieth (20th)
anniversary of the Effective Date or the expiration or invalidation of the applicable Patent, whichever is sooner.

 

(c)Amyris’s
License in Section 2.2. The license granted to Amyris in Section 2.2 will be effective as of the Effective Date and will continue,
unless earlier terminated per this Article 9, until (i) with respect to any Know-How in the Novvi LLC BioFene Transformation Technology,
the twentieth (20th) anniversary of the Effective Date and (ii) with respect to each Patent in the Novvi LLC BioFene
Transformation Technology, the twentieth (20th) anniversary of the Effective Date or the expiration or invalidation
of the applicable Patent, whichever is sooner.

 

9.3Extend the
Term of Licenses. If a license granted to Novvi LLC in Section 2.1 or under Section 2.3, or to Amyris under Section 2.2, has
not been earlier terminated under this Article 9, the Parties agree to decide, no later than the eighteenth (18th) anniversary
of the Effective Date, whether or not to extend the term of such license(s) set forth in Section 9.2(a)-(c) beyond the twentieth
(20th) anniversary of the Effective Date. If the Parties agree to extend the term of such licenses to Novvi LLC and/or
Amyris, such extension shall be set forth in writing signed by both Parties, but such licenses will still be subject to earlier
termination under this Article 9.

 

9.4Expiration
of a Novvi LLC License. Upon the expiration of the term (as may be extended per Section 9.3) of a license granted to Novvi
LLC in Section 2.1 or under Section 2.3 if such license was not earlier terminated,

 

	 	(i)	such expired
license will immediately cease;
	 	 	 
		(ii)	Novvi LLC will have no rights to or under any intellectual property or Confidential Information
of Amyris, unless, at the time, it continues to have another unexpired and un-terminated license(s) under this License Agreement,
in which case such unexpired and un-terminated license(s) of Novvi LLC will continue unaffected, as will this License Agreement
with regard to such unexpired and un-terminated license(s);

 

    Page 29 of 37

    CONFIDENTIAL

    

		(iii)	any sublicense Novvi LLC may have granted an Affiliate or Third Party under the expired license
automatically terminates;

 

		(iv)	Section 2.1 or 2.3 (whichever is applicable to the expired license) and Article 3 (if the expired
license had been granted under Section 2.1) automatically terminate;

 

		(v)	Novvi LLC, if upon such expiration it has no more licenses under this License Agreement, will remain
obligated to perform its obligations in Articles 5, 7, 8, and 10; and

 

		(vi)	Amyris’s license under Section 2.2 will continue unaffected, as will this License Agreement
with regard to such license.

 

9.5Expiration
of Amyris License. Upon the expiration of the term (as may be extended per Section 9.3) of the license granted to Amyris in
Section 2.2,

 

	 	(i)	such expired
license will immediately cease;
	 	 	 
		(ii)	Amyris will have no rights to or under any intellectual property or Confidential Information of
Novvi LLC;

 

		(iii)	any sublicense Amyris may have granted an Affiliate or Third Party under the expired license automatically
terminates;

 

		(iv)	Section 2.2 automatically terminates;

 

		(v)	Amyris will remain obligated to perform its obligations pursuant to this License Agreement; and

 

		(vi)	Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected, as will this License
Agreement with regard to such licenses.

 

9.6Uncured Material
Breach by Novvi LLC. If Novvi LLC materially breaches this License Agreement and does not cure such breach within sixty (60)
days after receiving written notice from Amyris of such breach, Amyris may, with another written notice to Novvi LLC, immediately
terminate all of the licenses granted to Novvi LLC under this License Agreement. If, per this Section, Amyris terminates Novvi
LLC’s licenses under this License Agreement, then, upon such termination,:

 

		(i)	Novvi LLC will have no rights to or under any intellectual property or Confidential Information
of Amyris;

 

		(ii)	any sublicense Novvi LLC may have granted an Affiliate or Third Party automatically terminates;

 

		(iii)	Sections 2.1 and 2.3 and Article 3 automatically terminate;

 

		(iv)	Novvi LLC will remain obligated to perform its obligations in Articles 5, 7, 8, and 10; and

 

		(v)	Amyris’s license under Section 2.2 will continue unaffected, as will this License

    Page 30 of 37

    CONFIDENTIAL

    

Agreement
with regard to such license.

 

Termination under this Section is not Amyris’s
exclusive remedy for a Novvi LLC breach but is in addition to any other rights or remedies Amyris may have under this License Agreement
or Applicable Law for such breach.

 

9.7Uncured Material
Breach by Amyris. If Amyris materially breaches this License Agreement and does not cure such breach within sixty (60) days
after receiving written notice from Novvi LLC of such breach, Novvi LLC may, with another written notice to Amyris, immediately
terminate the license granted to Amyris under this License Agreement. If, per this Section, Novvi LLC terminates Amyris’s
license under this License Agreement, then, upon such termination,:

 

		(i)	Amyris will have no rights to or under any intellectual property or Confidential Information of
Novvi LLC;

 

		(ii)	any sublicense Amyris may have granted an Affiliate or Third Party under the license automatically
terminates;

 

		(iii)	Section 2.2 automatically terminates;

 

		(iv)	Amyris will remain obligated to perform its obligations in Articles 5, 7, 8, and 10; and

 

		(v)	Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected, as will this License
Agreement with regard to such licenses.

 

9.8Event of
Dissolution of Novvi LLC. Upon the occurrence of an event described in Section 11.03 of the Second Amended and Restated Operating
Agreement that triggers dissolution of Novvi LLC and Novvi LLC is dissolved and wound up:

 

		(i)	all of the licenses granted to Novvi LLC under this License Agreement, if not previously expired
or terminated, will automatically terminate;

 

		(ii)	Novvi LLC will have no rights to or under any intellectual property or Confidential Information
of Amyris;

 

		(iii)	any sublicense Novvi LLC may have granted an Affiliate or Third Party automatically terminates;
and

 

		(iv)	Sections 2.1 and 2.3 and Article 3 automatically terminate (if not previously terminated).

 

9.9Insolvency
Event for Novvi LLC. Upon the occurrence of an Insolvency Event for Novvi LLC:

 

		(i)	all of the licenses granted to Novvi LLC under this License Agreement, if not previously expired
or terminated, will automatically terminate;

 

		(ii)	Novvi LLC will have no rights to or under any intellectual property or Confidential Information
of Amyris;

    Page 31 of 37

    CONFIDENTIAL

    

		(iii)	any sublicense Novvi LLC may have granted an Affiliate or Third Party automatically terminates;

 

		(iv)	Sections 2.1 and 2.3 and Article 3 automatically terminate (if not previously terminated or expired);

 

		(v)	Novvi LLC will remain obligated to perform its obligations in Articles 5, 7, 8, and 10; and

 

		(vi)	Amyris’s license under Section 2.2 will continue unaffected per Section 2.6, as will this
License Agreement with regard to such license.

 

9.10Insolvency
Event for Amyris. Upon the occurrence of an Insolvency Event for Amyris:

 

		(i)	the license granted to Amyris under this License Agreement, if not previously expired or terminated,
will automatically terminate;

 

		(ii)	Amyris will have no rights to or under any intellectual property or Confidential Information of
Novvi LLC;

 

		(iii)	any sublicense Amyris may have granted an Affiliate or Third Party under the license automatically
terminates;

 

		(iv)	Section 2.2 automatically terminates (if not previously terminated or expired);

 

		(v)	Amyris will remain obligated to perform its obligations in Articles 5, 7, 8, and 10; and

 

		(vi)	Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected per Section 2.6,
as will this License Agreement with regard to such licenses.

 

9.11Surviving
Provisions. Notwithstanding anything to the contrary, in the event that this License Agreement expires or is terminated, the
following provisions, and the Parties’ respective rights and obligations under them, will survive such circumstances: Article
1, Sections 5.1, 5.2, 5.3, 5.4, 5.8, and 5.10 (for the time period set forth in Section 5.10), Article 7, Article 8, and Article
10, and this Section.

 

 

ARTICLE 10

 

MISCELLANEOUS

 

10.1Compliance
with Law. With respect to the performance of this License Agreement and the activities contemplated by this License Agreement,
each Party shall comply with all Applicable Laws.

 

10.2No Conflicting
Rights. Neither Party will grant any license, right, or encumbrance to any Affiliate or Third Party that would conflict with
the licenses or rights granted hereunder or enter into any agreement that would impair such Party’s ability to perform its
obligations under this License Agreement.

    Page 32 of 37

    CONFIDENTIAL

    

10.3Further
Assurances.  After the Effective Date, each of the Parties shall execute and deliver such additional documents, certificates,
and instruments and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out the
purposes and intent and all of the provisions of this License Agreement and to consummate all of the transactions contemplated
by this License Agreement.

 

10.4Expenses. 
Each Party shall be responsible for and bear all of its own costs and expenses (including but not limited to any attorneys’
fees, accountants’ fees, or financial advisors’ fees or any prior commitment in respect thereof) with regard to the
negotiation and consummation of the transactions contemplated by this License Agreement. 

 

10.5Relationship
of the Parties.  Each Party is an independent contractor relative to the other Party under this License Agreement. This
License Agreement is not a partnership agreement, and nothing in this License Agreement shall be construed to establish a relationship
of co-partners or joint venturers between the Parties.  No employee or representative of a Party, per this License Agreement,
shall have any authority to bind or obligate the other Party or to create or impose any contractual or other liability on the other
Party.

 

10.6No
Third Party Beneficiaries. Except with regard
to the Novvi LLC Indemnitees and Amyris Indemnitees under Article 7 and Total with regard to Section 4.1, all rights, benefits,
and remedies under this Licensee Agreement are solely intended for the benefit of the Parties and their respective permitted successors
and assigns. No Third Party (except Novvi LLC Indemnitees and Amyris Indemnitees with regard to their rights, benefits and remedies
Article 7 and Total with regard to Section 4.1) shall have any rights whatsoever to enforce any obligation contained this License
Agreement, seek a benefit or remedy for any breach, or take any other action relating to this License Agreement under any legal
or equitable theory.

 

10.7Amendments
and Waivers. This License Agreement may be
amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by all Parties
or, in the case of a waiver, by the Party against whom the waiver is to be effective. No failure or delay by any Party in exercising
any right, power or privilege hereunder (other than a failure or delay beyond a period of time specified herein) shall operate
as a waiver thereof; nor shall any waiver by a Party of any term or condition of this License Agreement in any one or more instances,
be deemed to be or construed as a waiver of the same or any other term or condition of this License Agreement on any future occasion.

 

10.8Assignment.
Other than its sublicensing rights under Section 2.1 and potentially under Section 2.3, Novvi LLC may not assign or delegate,
in whole or in part, this License Agreement or any of its rights or obligations under this License Agreement without the prior
written consent of Amyris, such consent not to be unreasonably withheld. In addition to its sublicense rights under Section 2.2,
Amyris may, without Novvi LLC’s consent, assign or delegate, in whole or in part, this License Agreement or any of its rights
or obligations under this License Agreement to (i) an Affiliate but only while such Affiliate remains an Affiliate and if Amyris
remains responsible for such Affiliate’s performance of the License Agreement, (ii) a buyer of all or substantially all
of Amyris’s assets as long as such buyer delivers a writing expressly agreeing to assume such performance, or (iii) a surviving
entity with whom Amyris is merged as long as such surviving entity delivers a writing expressly agreeing to assume such performance.
Any assignment or delegation or attempted assignment or delegation not in accordance with this Section 10.8 shall be null and
void. This License Agreement shall be binding upon and inure solely to the benefit of the Parties and their permitted successors
and assigns.

 

10.9Severability. 
If any provision of this License Agreement should be held invalid, illegal

    Page 33 of 37

    CONFIDENTIAL

    

or unenforceable
in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly
reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction
and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible. Such invalidity,
illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.
Nothing in this License Agreement shall be interpreted so as to require a Party to violate any Applicable Law.

 

10.10Notices. 
All notices, consents, claims, waivers, requests and other communications hereunder shall be in writing and shall be delivered
in person, sent by overnight courier (e.g., Federal Express), facsimile transmission or posted by registered or certified mail,
return receipt requested, with postage prepaid, to the following address of each Party:

 

If
to Amyris:

 

Amyris,
Inc.

5885
Hollis Street, Suite 100

Emeryville,
CA 94608

Attn:
General Counsel

 

If
to Novvi LLC:

 

Novvi
LLC

5885
Hollis Street

Emeryville,
CA 94608

Attn:
President

 

with
a copy to, but only for such time as Cosan US remains a member of Novvi LLC, (but which shall not constitute notice):

 

Cosan
US, Inc.

2711
Centerville Road, Suite 400

Wilmington,
Delaware 19808

Attn:
President

 

Cosan
Lubrificantes e Especialidades S.A.

Rua
Victor Civita, 77 – Edifício 6 / Bloco 1 – 4o andar

Barra
da Tijuca – Rio de Janeiro – RJ

CEP
22775-905 Brazil

Attn:
Chief Executive Officer

 

or
to such other address or addresses as each Party may from time-to-time designate by notice as provided herein.  Any such notice
shall be deemed given (i) when actually received when so delivered personally or by overnight courier or (ii) if mailed, other
than during a period of general discontinuance or disruption of postal service due to strike, lockout or otherwise, on the fifth
(5th) day after its postmarked date thereof or (iii) if sent by facsimile transmission on the date sent if such day
is a business day or the next following business day if such day is not a business day.  

 

10.11Entire
Agreement.  This License Agreement sets forth all the covenants, promises, agreements, warranties, representations, conditions
and understandings between the Parties and supersedes and terminates all prior agreements and understandings between the Parties
relating to the

    Page 34 of 37

    CONFIDENTIAL

    

subject
matter hereof.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either
oral or written, between the Parties other than as set forth in this License Agreement that relate to the subject matter hereof. 

 

10.12Interpretation. 
When a reference is made in this License Agreement to Articles, Sections, or Subsections, such reference shall be to an Article,
Section, or Subsection to this License Agreement unless otherwise indicated.  The words “include,” “includes,”
and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”
and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately
following it.  The headings and captions in this License Agreement are for convenience and reference purposes only and shall
not be considered a part of or affect the construction or interpretation of any provision of this License Agreement.  Words
of any gender include the other gender, and words using the singular or plural number also include the plural or singular number,
respectively.  Each Party acknowledges and agrees it has had the opportunity to draft, review and edit the language of this
License Agreement and that no presumption for or against any Party arising out of drafting all or any part of this License Agreement
will be applied in any controversy, claim or dispute relating to, in connection with or involving this License Agreement. Accordingly,
the Parties hereby waive the benefit of any rule of Applicable Law, including California Civil Code Section 1654 and any successor
or amended statute, or any legal decision that would require that in cases of uncertainty, the language of a contract should be
interpreted most strongly against the party who drafted such language. 

 

10.13Counterparts. 
This License Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This License Agreement may be executed by facsimile or other electronic
signatures (including exchange of emailed pdf), and such signatures shall be deemed to bind each Party as if they were original
signatures.

 

THIS LICENSE AGREEMENT is hereby executed
effective as of the Effective Date by the authorized representatives of the Parties.

 

	AMYRIS, INC.	 	NOVVI LLC	 
	 	 	 	 	 	 
	/s/ R. Asadorian	 	 	 	 
	 	 	 	 	 
	By:	R. Asadorian	 	By:	 	 
	 	 	 	 	 	 
	Title:	CFO	 	Title:	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	By:	 	 
	 	 	 	 	 	 
	 	 	 	Title:	 	 

 

 

    Page 35 of 37

    CONFIDENTIAL

    

subject
matter hereof.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either
oral or written, between the Parties other than as set forth in this License Agreement that relate to the subject matter hereof. 

 

10.12Interpretation. 
When a reference is made in this License Agreement to Articles, Sections, or Subsections, such reference shall be to an Article,
Section, or Subsection to this License Agreement unless otherwise indicated.  The words “include,” “includes,”
and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”
and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately
following it.  The headings and captions in this License Agreement are for convenience and reference purposes only and shall
not be considered a part of or affect the construction or interpretation of any provision of this License Agreement.  Words
of any gender include the other gender, and words using the singular or plural number also include the plural or singular number,
respectively.  Each Party acknowledges and agrees it has had the opportunity to draft, review and edit the language of this
License Agreement and that no presumption for or against any Party arising out of drafting all or any part of this License Agreement
will be applied in any controversy, claim or dispute relating to, in connection with or involving this License Agreement. Accordingly,
the Parties hereby waive the benefit of any rule of Applicable Law, including California Civil Code Section 1654 and any successor
or amended statute, or any legal decision that would require that in cases of uncertainty, the language of a contract should be
interpreted most strongly against the party who drafted such language. 

 

10.13Counterparts. 
This License Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This License Agreement may be executed by facsimile or other electronic
signatures (including exchange of emailed pdf), and such signatures shall be deemed to bind each Party as if they were original
signatures.

 

THIS LICENSE AGREEMENT is hereby executed
effective as of the Effective Date by the authorized representatives of the Parties.

 

	AMYRIS, INC.	 	NOVVI LLC	 
	 	 	 	 	 	 
	 	 	/s/ Jeffrey Brown	 
	 	 	 	 	 
	By:	 	 	By:	Jeffrey
Brown	 
	 	 	 	 	 	 
	Title:	 	 	Title:	President
& CEO	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	/s/ Jason R. Wells	 
	 	 	 	 	 	 
	 	 	 	By:	Jason R. Wells	 
	 	 	 	 	 	 
	 	 	 	Title:	CTO	 

 

 

 

    Page 36 of 37

    CONFIDENTIAL

    

Exhibit A

 

Definition of European Union

 

 

 

		1.	Austria

		2.	Belgium

		3.	Bulgaria

		4.	Croatia

		5.	Cyprus

		6.	Czech Republic

		7.	Denmark

		8.	Estonia

		9.	Finland

		10.	France

		11.	Germany

		12.	Greece

		13.	Hungary

		14.	Ireland

		15.	Italy

		16.	Latvia

		17.	Lithuania

		18.	Luxembourg

		19.	Malta

		20.	Netherlands

		21.	Poland

		22.	Portugal

		23.	Romania

		24.	Slovakia

		25.	Slovenia

		26.	Spain

		27.	Sweden

		28.	United Kingdom

 

Page 37 of
37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]